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Abstract
Studies on mitochondrial dysfunction in HIV-infected adults exposed to 
anti-retroviral therapy
A significant proportion of HIV-infected patients who require anti-retroviral 
therapy are or have been exposed to nucleoside analogue reverse 
transcriptase inhibitors (NRTIs). It has been consistently suggested that most 
of the NRTI-attributed adverse drug reactions (ADR) are due to mitochondrial 
dysfunction.
In a sub-analysis of a large randomised clinical trial (Delta) the incidence of 
peripheral neuropathy (PN) was constant over time in all study arms, which 
does not support the hypothesis of cumulative toxicity previously proposed for 
NRTI-induced ADR. Patients taking zidovudine (AZT)/zalcitabine (ddC) 
combination were more likely to develop PN than patients on AZT 
monotherapy (RH= 2.30; 95% CI= 1.62 -  3.28). The incidence of PN among 
patients exposed to zidovudine/didanosine (AZT/ddl) combination was not 
different from that observed in patients on AZT.
In a multi-centre case-control study including 110 cases of lactic acidosis (LA) 
or severe hyperlactataemia (HL) patients with < 200 CD4 cell/pl were more 
likely to develop HULA than patients with higher levels of CD4 cells (OR=3.44; 
95%CI= 1.64 -  7.22). Female patients were found to be at higher risk for 
HULA than men (OR= 4.75; 95%CI= 1.96 -  11.53). Patients exposed to either 
d4T, ddl or the combination of these two were four to six times more likely to 
develop HULA than patients taking other NRTIs based combinations. 
Interestingly, cases of HULA were exposed to d4T for shorter periods of time 
than controls.
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Almost 10 % of the cases included in the study were asymptomatic at the time 
of diagnosis. All these symptom-free cases had blood lactate ranging between 
5 and 7 mmol/l. Therefore, case definitions for HL or LA based on clinical 
presentation may underestimate the magnitude of the problem.
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CHAPTER 1
Introduction
The aim of this thesis was to study clinical and epidemiological factors 
associated with nucleoside analogue reverse transcriptase inhibitors (NRTIs) 
associated adverse drug reactions (ADR) in HIV-infected patients. Particularly 
to identify risk factors for such toxic effects using two models: peripheral 
neuropathy (PN) and lactic acidosis -  severe hyperlactataemia (LA/HL).
Most of the long-term or serious NRTI-associated ADR have been proposed 
to be due to mitochondrial dysfunction induced by these drugs. Evidence 
supporting the hypothesis of mitochondrial impairment as the explanation for 
NRTI-induced ADR has been presented. However, the exact mechanism for 
such mitochondrial harm is still controversial.
Chapter 2 offers background information relevant for the thesis content 
including basic information on mitochondrial structure and function as well as 
medical conditions associated with mitochondrial impairment. In addition, 
background information on NRTIs structure and pharmacology is presented in 
light of potential mechanisms of toxic effects. Finally, the effect of HIV itself on 
mitochondrial function is briefly discussed.
It has been proposed that long-term NRTI-associated ADR depend on a 
cumulative dose of the drug. In chapter 3 the question of cumulative toxicity of 
NRTIs is assessed using PN as a model for NRTI-induced mitochondrial 
dysfunction. A brief introduction on NRTI-associated and HIV-induced PN is 
presented as well as previous research suggesting a cumulative toxicity of 
NRTIs. The analysis presented was performed using data previously collected 
for a large randomised clinical trial and therefore the clinical trial is briefly 
described. The incidence of PN and its association with specific drugs is also 
analysed.
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Lactic acidosis has been proposed as a “proof of concept” for NRTI-induced 
mitochondrial dysfunction. Chapter 4 describes a systematic review on 
published cases of LA with the objective of identifying potential risk factors for 
such a complication. The implications of the findings are analysed in the 
context of further research needs.
A multi-national case-control study on LA and HL was planned and performed 
and is described in chapters 5 and 6. Justification for the study and its design 
are presented and discussed in light of a pilot study performed in advance. 
Results of this multi-centre study are presented including a descriptive 
analysis of the cases together with identification for risk factors associated 
with the study outcome and with mortality. Descriptive analysis of the data 
collected on cases is presented. This is the largest case-series compiled on 
HL/LA to date.
Chapter 7 discusses the results presented in chapter 6 analysing not only risk 
factors for the combined outcome (i.e. HL/LA) but also comparing factors 
associated with each outcome considered individually. Risk factors for 
mortality are also analysed.
In chapter 8 a conclusive discussion is presented where the role of 
dideoxynucleosides in PN and HL/LA is analysed in light of the results 
presented in chapters 3 and 6. The concept of a special susceptibility for 
NRTI-induced mitochondrial dysfunction is discussed.
Finally, chapter 8 includes a short discussion on implications and possible 
consequences of safety issues related to anti-retroviral therapy (ART) on 
HIV/AIDS control programs, particularly in the developing world. 
Recommendations for further research are also presented.
18
CHAPTER 2
Background to the Project
Mitochondria are critically important intra-cellular organelles which perform a 
variety of biological functions. They are also very peculiar not only because of 
their unique origin and genetics but also because they impact on almost every 
cellular function. Mitochondria are present in all nucleated human cells and 
therefore any impairment in function may generate a significant variety of 
clinical conditions depending on the organ or tissue affected.
Over the last few decades the importance of mitochondrial biology on human 
medicine has been increasingly recognised and a significant and still growing 
list of diseases has been attributed to mitochondrial dysfunctions of different 
aetiologies (DiMauro & Schon 2003; White 2001). In that context, 
mitochondrial dysfunctions have been suggested as the common pathway of 
several proposed adverse drug reactions (ADR) attributed to antiretroviral 
agents used to treat HIV infection.
2.1 Adverse effects associated with anti-retro viral therapy for HIV 
infection
The introduction of highly active anti-retroviral therapy (HAART) as standard 
of care for HIV-infected patients has transformed HIV disease to a chronic 
condition inducing a significant reduction in both AIDS-related morbidity and 
mortality (Palella, Jr. et al. 1998). Long-term remission of HIV replication is 
now an achievable goal. Unfortunately, currently available therapeutic options 
are not capable of eradicating the virus and therefore patients must receive 
anti-retroviral therapy (ART) for long periods, probably life long, to achieve the 
goals of HAART.
The last assertion means that patients are now exposed to both therapeutic 
and toxic effects of ART drugs for long periods of time. Furthermore, because
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a combination of ART drugs is the standard of care, patients are now exposed 
to toxic effects of several drug classes at the same time.
2.1.1 Toxicity as a limiting factor for ART success
The long-term success of HAART has been reported to be challenged by 
several factors such as virological or immunological failure and toxicity. 
Observational studies have shown that about 20 -  25 % of those patients who 
start ART discontinue therapy because of either treatment failure or toxicity 
during the first eight months of exposure to their initial regimen (Montessori et 
al. 2004).
Interestingly, most of the patients stopping or modifying ART regimens do so 
because of toxicity. Among 862 treatment naive patients who started ART, 21 
% had to stop therapy because of toxicity whereas the proportion of people 
doing so because of either virological or immunological failure was 5 % over a 
median follow-up period of 45 weeks (d’Arminio et al. 2000). Similarly, an 
analysis of a cohort including 556 patients has shown that 64 % of those 
patients who modified their first ART regimen did so because of patients’ 
choice, poor compliance or toxicity (Mocroft etal. 2001).
Furthermore, full adherence has been shown as crucially important to reduce 
the risk of virological failure (Yeni et al. 2004). Therefore, any factor 
associated with poor adherence is actively favouring the emergence of HIV 
resistant variations. Importantly, ART-related adverse effects have been 
shown as a major cause of intentional non-adherence to ART in several 
studies (Heath et al. 2002). Therefore, ART-associated adverse effects may 
have a negative impact on HAART long-term benefits in at least two different 
ways, directly causing necessary treatment interruptions or indirectly, 
facilitating sub-optimal adherence to ART and subsequently promoting viral 
resistance.
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Currently licensed ART drugs include four major classes: a) nucleoside 
analogues reverse transcriptase inhibitors (NRTIs), which might include 
nucleotide analogues as well, b) non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), c) protease inhibitors (PI) and d) fusion inhibitors. Virtually 
ail ART drugs can induce adverse effects, some of which are class effects, 
and therefore have been described in patients exposed to all or almost all of 
available drugs from a specific class. On the other hand, some adverse effects 
are drug specific.
Two or more NRTIs are often used as backbone of many HAART 
combinations and therefore an important proportion of HIV-infected patients 
world-wide are or have been exposed to NRTI-associated adverse effects. 
Most of NRTI-induced long-term adverse or toxic effects have been proposed 
to be a consequence of mitochondrial dysfunction.
As NRTIs is the drug class most frequently used to treat HIV disease, 
understanding the nature of the proposed NRTI-induced mitochondrial toxicity 
as well as the risk factors for specific NRTI-associated adverse effects are 
critically important for more appropriate and safer management of HIV 
infection.
2.2 Mitochondria
Mitochondria are the legacy eukaryotic cells received a billion years ago, 
when aerobic bacteria colonised their primitive ancestors. Primitive eukaryotic 
cells were unable to use oxygen metabolically, so the parasites offered to their 
host a more efficient way to produce energy and eventually evolved into 
mitochondria (Finsterer 2004). Mitochondria are present in all human 
nucleated cells, so erythrocytes are the only cell type which does not have 
mitochondria.
Energy production in the form of adenosine triphosphate (ATP) is probably the
most relevant of the functions mitochondria perform. However, this organelle
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is involved in many other biological processes including pyruvate oxidation, 
the Krebs cycle, the metabolism of amino acids, fatty acids and steroids and 
furthermore, mitochondria are likely to be implicated in the process of 
apoptosis (Newmeyer & Ferguson-Miller 2003).
2.2.1 Mitochondrial morphology and function
It has been observed that there are several hundred or even a thousand 
mitochondria in each eukaryotic cell (Fig. 2.1). These organelles increase the 
cell capacity of energy production significantly. The process of anaerobic 
glycolysis, which transforms glucose to pyruvate in the cytoplasm, is 
completed in the mitochondria, where pyruvate is oxidised by O2 to produce 
C 0 2 and H20 . This mitochondrial aerobic glycolysis produces 15 times more 
adenosine tri-phosphate (ATP) than the anaerobic cytoplasmic process (Fig 
2.2).
Fig. 2.1 Mitochondrial morphology
Source: Modified from http://www.science-art.corrVimage.asp?id-2205&m«24
Mitochondria are mobile and plastic structures, which are constantly moving in
the cytoplasm and changing their shape. Mitochondria are formed by two
membranes, which define two different internal compartments. Between the
outer and the inner membranes is the inter-membrane space. As explained
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later in this chapter, most of the mitochondrial proteins are assembled in the 
cytoplasm and imported by the mitochondria. Consequently, there are many 
copies of transport systems in the outer membrane and the inter-membrane 
space is occupied by a wide variety of proteins.
Modified from End Rev.
Fig. 2.2 Aerobic and anaerobic glycolysis 
2004: 25<5): 807-30
By contrast, the matrix, which is the compartment defined by the inner 
membrane, has a more selected content. The inner membrane is highly 
specialised, having a structure which makes it “impermeable" to ions and 
contains more specialised transport systems than the outer membrane. These 
two elements, the inner membrane and the matrix, are the metabolically active 
components of the mitochondrion.
As mentioned before, glucose is transformed to pyruvate in the cytoplasm and 
can be subsequently transported into the mitochondria. Once in the 
mitochondrial matrix, pyruvate is transformed to Acetyl-CoA in a process
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catalysed by the pyruvate dehydrogenase enzymatic complex. In addition to 
that, Acetyl-CoA might also be synthesised “de novo” as a product of the fatty 
acid p-oxidation process that is also performed in the mitochondrial matrix. 
Long-chain fatty acids enter the mitochondria in a process facilitated by 
carnitine.
Acetyl-CoA is incorporated in the tricarboxylic acid cycle (also known as the 
citric acid or Krebs cycle) which generates reduced nicotinamide adenine 
dinucleotide (NADH) and reduced flavin adenine dinucleotide (FADH2). In 
addition, FADH2 is also a product of the fatty acid p-oxidation process. These 
two molecules (i.e. NADH and FADH2) are carriers of high-energy electrons, 
which are transferred to the respiratory chain located in the inner membrane.
The respiratory chain is a highly specialised system of five multimeric protein 
complexes that have the function of generating ATP. NADH donates high- 
energy electrons to complex I (NADH-ubiquinone-oxidoreductase or NADH 
dehydrogenase) whereas FADH2 does so to complex II (succinate-ubiquinone 
reductase or succinate dehydrogenase). The process of oxidative 
phosphorylation implies that electrons transferred to the respiratory chain 
eventually are combined with molecular oxygen (0 2) to form water. The 
transport of electrons through the respiratory chain complexes also generates 
an electrochemical proton gradient across the inner membrane. This gradient 
is a consequence of the active pumping of H+ to the inter-membrane space. 
(Fig 2.3)
The final step in the oxidative phosphorylation process is the synthesis of 
ATP. The gradient of protons generated across the inner membrane as a 
consequence of electron transport through the respiratory chain drives H+ 
back into the matrix. The protons can cross the inner membrane using a 
hydrophilic channel formed by a membrane-bounded enzymatic complex. This 
multimeric protein is named ATP synthase because as protons pass through 
its channel, adenosine diphosphate (ADP) is phosphorylated to ATP using 
inorganic phosphate.
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2.2.2 Mitochondrial respiratory chain
The mitochondrial respiratory chain, as mentioned before, is an electron 
transport system located in the inner mitochondrial membrane. The chain is 
formed by more than 80 peptides distributed in five different complexes. 
Complexes I, III and IV are proton pumps which generate the gradient of 
protons used by ATP synthase (often called complex V) to generate ATP.
Fig. 2.3 Mitochondrial respiratory chain
Modified from: Diabetes, 2005; 54: 1619
Complex I is the largest component of the respiratory chain and is the 
acceptor of high-energy electrons from NADH produced by the Krebs cycle. 
The other entry point to the respiratory chain is complex II, which is the 
smallest component of the chain and accomplishes the oxidation of FADH2 
also derived from the Krebs cycle. Complex III generates cytochrome c, which 
is used for the reduction of 0 2 to two molecules of H20  in a reaction catalysed 
by cytochrome c oxidase (complex IV).
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The reduction of 0 2 by cytochrome c oxidase, NADH dehydrogenase and 
some other enzymes involved in the process may be considered as very 
efficient. Nevertheless, about 12 % of the oxygen consumed during the 
respiration process is not fully reduced to water but to superoxide anion ( 0 2 “ )> 
hydrogen peroxide (H20 2) and some other moieties. These reactive oxygen 
intermediates are usually named reactive oxygen species (ROS) (Di Donato
2000).
ROS can induce oxidative damage to any component of the respiratory chain 
and therefore induce impairment in the oxidative phosphorylation process. 
However, in physiological conditions several enzymatic proteins can protect 
cellular structures from oxidative damage. These enzymes include superoxide 
dismutase, catalase and glutathione peroxidase which can catalyse the 
transformation of H20 2 into water and molecular oxygen. In addition, 
antioxidant vitamins E and C can help in defending cells from oxidative 
damage (Droge 2002).
2.2.3 Mitochondrial genetics
As explained before, mitochondria may have been the result of the evolution 
of previously independent bacteria. Mitochondria contain several copies of 
circular double stranded DNA molecules: the mitochondrial DNA (mtDNA). 
This mtDNA is the sole extra-nuclear DNA in human cells. In addition to that, 
mitochondria also have their own systems for transcription, translation and 
protein-assembly (Finsterer 2004).
Human mtDNA has 37 genes and is formed by 16,569 base pairs (Fig. 2.4).
Only 13 of the mtDNA genes encode for components of the respiratory chain
enzymatic complexes. Seven sub-units of complex I (NADH dehydrogenase),
one sub-unit of complex III (ubiquinone c reductase), three sub-units of
complex IV (cytochrome oxidase) and two sub-units of complex V (ATP
synthase) are encoded by mtDNA genes. Interestingly, none of the five
complexes of the respiratory chain is fully encoded by mtDNA, whereas
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nuclear DNA (nDNA) encodes completely the complex II (succinate
dehydrogenase). In fact, mtDNA encoded products represent a significant
minority of the mitochondrial proteins. Furthermore, not only structural proteins 
of both mitochondrial membrane and respiratory chain complexes but also 
those peptides responsible for the tricarboxylic acid cycle and even more 
critical proteins involved in mitochondrial replication are encoded by nDNA.
Nevertheless, peptides encoded by mtDNA are crucially important for
mitochondrial function because they represent functional sub-units of the 
respiratory chain complexes (Stacpoole 1997).
Fig. 2.4 Mitochondrial DNA map
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Because of several peculiar characteristics of the mitochondrial dynamic, 
mtDNA is more prone to suffer mutations than nDNA (see below). Some but 
not all of the thousands molecules of mtDNA coexisting in a single cell might 
be pathogenic mutants. Furthermore, different variants of mtDNA molecules 
may be present in a single mitochondrion. This characteristic of the 
mitochondrial genetic is called heteroplasmy (DiMauro & Schon 2003; White
2001).
The coexistence of normal and abnormal mtDNA copies in a single cell has an 
impact in the function of mitochondria. When the normal population of mtDNA 
outnumbers the amount of variant or mutant copies, the cell is capable of 
showing normal function. As the proportion of mutant mtDNA copies 
increases, the cell is likely to express some degree of mitochondrial 
dysfunction. However, a threshold effect has been described: cells containing 
mtDNA mutant copies develop mitochondrial dysfunction when the 
concentration of these abnormal copies is higher than a certain level. That 
critical level might vary depending on the affected tissue, but it is generally 
accepted that a single cell requires a high population of aberrant mtDNA 
copies to develop functional impairment. For inherited mitochondrial diseases 
it has been estimated that the proportion of mutant mtDNA molecules might 
be around 70 - 80 % of the total mtDNA content to affect the normal function 
of the affected cell (Stacpoole 1997). Nevertheless, it is important to highlight 
that the threshold for cellular dysfunction can be considerably lower in tissues 
which are highly dependent on oxidative phosphorylation such as brain, heart, 
skeletal muscle, retina, renal tubules and endocrine glands (DiMauro & Schon 
2003).
Because of the replicative or mitotic segregation, the proportion of aberrant 
variants of mtDNA might differ after cell replication. The distribution of 
mitochondria in the cell before starting the mitotic process is probably almost 
at random. As a consequence of that, the proportion of aberrant mtDNA 
present in the daughter cells can be different from the proportion noted in the 
mother cell and between the daughter cells. This peculiar characteristic of the
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mitochondrial genome might explain the unequal distribution of aberrant 
mtDNA copies in a given tissue and even more, the heterogeneity of 
mitochondrial function in this given tissue (White 2001).
Mitochondrial DNA is believed to be almost exclusively maternally inherited. 
The content of mitochondria in sperm cells is relatively small in comparison 
with the amount of mitochondria in the ovum. Even more, the segment of the 
spermatozoa that contains most of the mitochondria apparently is lost during 
fertilisation (Stacpoole 1997). In consequence, virtually all mitochondria in the 
zygote are from maternal origin. Nonetheless, a case of paternally inherited 
mitochondrial myopathy has recently been published. Schwartz and Vissing 
determined that 90 % of this patient’s muscle mtDNA had the mutation 
responsible for the myopathy. According to the authors, this mutation was 
paternally inherited (Schwartz & Vissing 2002).
2.2.4 Polymerase gamma
In eukaryotic cells the process of DNA replication is catalysed by a family of 
enzymes called DNA polymerases. There are five DNA polymerases that have 
been described in mammalian cells. DNA polymerases a, p, 5 and e are 
responsible not only for DNA replication but also for repairing DNA strands. All 
these four DNA polymerases are located in the cellular nucleus.
The other DNA polymerase that has been identified in mammalian cells is 
located in mitochondria and is called DNA polymerase y. This polymerase y is 
the sole enzyme responsible for mtDNA replication. In addition, some studies 
have suggested that polymerase y may also be involved in mtDNA repair 
(Lecrenier & Foury 2000). Although some DNA repair capacity has been 
demonstrated in the mitochondria, it has been proposed that this capacity is 
limited and much less efficient that the capacity observed in the nucleus.
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DNA polymerase y contains two sub-units. The largest sub-unit shows both 
polymerase and exonuclease activities whereas the smallest or accessory unit 
provides strong and tight binding to the DNA template, allowing high 
processivity1 in mtDNA synthesis. It has therefore been proposed that mtDNA 
deletions might be replicated more efficiently than the normal variant. The 
proposed preferential replication of abnormal mtDNA copies might accelerate 
the accumulation of mutant mtDNA copies and therefore, the achievement of 
the necessary threshold for cellular dysfunction (Lewis etal. 2001).
High rate of mtDNA replication has been demonstrated not only during cellular 
division but also during electrical stimulation of muscular cells and normal 
physical muscular systematic training (Lecrenier & Foury 2000). Similarly, it 
has been demonstrated that oxidative stress induced by H20 2 promotes an 
increase in both mitochondrial mass and mtDNA (Lee et al. 2000). However, 
DNA polymerase y must be encoded by nDNA as this enzyme can be 
expressed in the absence of mtDNA (Davis et al. 1996). That suggests that 
mitochondrial function is regulated at nuclear level as both synthesis of critical 
functional and structural mitochondrial proteins and mtDNA replication are 
controlled by nDNA (Shoubridge 2001).
There are several factors that make mtDNA more prone to suffer mutations. 
DNA polymerase y has been proposed to have limited capacity to repair 
mismatching errors during the replication process (Feng et al. 2001). In 
addition, the mtDNA replication rate is much greater than the rate of nDNA 
replication. Furthermore, mtDNA is constantly exposed to factors capable of 
inducing oxidative damage on its structure such as ROS (Lecrenier & Foury 
2000). In addition to that, mtDNA is not protected by histones. Finally, in 
addition to its special susceptibility to mutation, mtDNA is much more likely 
than nDNA to express each mutation. Almost all mtDNA genes are translated 
whereas nDNA has many silent genes.
1 Processivity: in DNA replication when the replication complex assembles at the origin (s) of 
replication and then performs template-directed synthesis of DNA over virtually the entire 
genome without dissociation (Reddy MK et al. J Biol Chem 1992, 267 (20): 14157 - 166).
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2.3 Mitochondrial dysfunction associated syndromes
Mitochondrial dysfunction has been associated with a variety of clinical 
syndromes. The most frequent causes of mitochondrial dysfunction in the 
general population are inherited disorders from both nDNA and mtDNA. 
Mutations directly affecting the respiratory chain are classified as primary 
genetic disorders whereas those conditions affecting nuclear encoded 
proteins are considered secondary defects of the respiratory chain.
2.3.1 Inherited mitochondrial syndromes
About one hundred mtDNA mutations have been associated with human 
disease (Schapira 2002). These primary defects of the mitochondrial 
respiratory chain have been presented as rare conditions. However, as their 
estimated prevalence might be in the range of 10 to 15 cases per 100,000 
people (DiMauro & Schon 2003), one could assume that they may be 
considered as uncommon rather than rare. Primary mitochondrial diseases 
are usually diagnosed during infancy, but late onset expression of disease has 
been reported (Schapira 2002).
All mitochondrial diseases described to date (Table 2.1) share some important 
characteristics, the most important being clinical heterogeneity. This group of 
disorders can affect a single organ or can induce systemic disease. 
Furthermore, there is no clear relationship between the site or type of mutation 
and its clinical expression: A given mutation might cause different clinical 
presentations while a specific clinical syndrome might be consequence of 
several different mutations (Leonard & Schapira 2000a). There are however, 
some important exceptions to this rule. Patients with MERRF (myoclonus 
epilepsy with ragged-red fibres) and Leber’s optic neuropathy have specific 
mutations always associated with each condition (DiMauro & Schon 2003).
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Table 2.1 Inherited mitochondrial diseases: clinical classification
Modified from European Journal of Neurology 2004. 11: 163 - 86
Despite the previously mentioned variability, almost all mtDNA disorders 
usually develop lactic acidosis (DiMauro & Schon 2003). Furthermore, 
impairment of the central nervous system is frequently seen and might be the 
main feature of many mitochondrial syndromes such as MELAS (myopathy, 
encephalopathy, lactic acidosis, and stroke-like episodes) or MERRF. Leber’s 
hereditary optic neuropathy (LHON) is the most common cause of blindness in 
healthy young men. It is important to highlight that a significant proportion of 
asymptomatic people can show mutations in mitochondrial ND genes 
suggesting that additional factors might contribute to the expression of LHON 
(DiMauro & Schon 2003; Leonard & Schapira 2000a).
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Mitochondrial function may also be affected by defects in processes not 
directly linked with the respiratory chain. Conditions such as Friederich’s 
ataxia, hereditary spastic paraparesis, Wilson’s disease, Parkinson’s disease, 
Hungtington’s disease and even Alzheimer’s disease have all been proposed 
as showing some degree of impairment in mitochondrial function as a 
consequence of nuclear genetic defects (Leonard & Schapira 2000b).
2.3.2 Acquired mitochondrial dysfunction
Ischemia can induce mitochondrial dysfunction. However, the most frequent 
cause of acquired mitochondrial dysfunction is toxicity. Several chemicals can 
induce mitochondrial impairment by different mechanisms.
Ethanol is probably the most frequent inducer of acquired mitochondrial 
disease. It has been shown that ethanol can accelerate oxidative damage of 
mtDNA and can also induce a significant reduction in some critical 
mitochondrial enzymatic activities affecting the respiratory chain (Fromenty & 
Pessayre 1997; Sebastian & Setty 1999). Nevertheless, other chemicals have 
also been shown to be mitochondrial toxins including drugs such as 
amiodarone, anthracyclines, aspirin, chloramphenicol, hydroxyurea, 
tetracycline, valproic acid and nucleoside analogues of the HIV reverse 
transcriptase (Moyle 2000).
Although a direct effect on mitochondrial function and/or structure has been 
demonstrated in in-vitro studies with most of the drugs associated with 
mitochondrial dysfunction, it has also been suggested that at least some of 
them might be mild toxins. It has been proposed therefore that these drugs 
are capable of unmasking sub-clinical inherited mitochondrial dysfunction 
(Moyle 2005a; Cherry & Wesselingh 2003).
It has also been proposed that mitochondrial toxins may have an additive
effect, so using two or more of these drugs concomitantly might accelerate the
development of clinical expression of mitochondrial dysfunction (Moyle 2000).
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2.4 Pharmacology of nucleoside reverse transcriptase inhibitors
Nucleoside analogues of the HIV reverse transcriptase (NRTI) were the first 
drug class to be licensed for use in patients with HIV disease. Zidovudine 
(AZT) was licensed in the late eighties to treat patients with AIDS in the US 
and in Europe. Soon after regulatory agencies from the developed world 
granted their approval for human use to other related compounds. 
Furthermore, NRTIs are the backbone of most HAART combinations currently 
in use. Taken together, one can appreciate that a significant proportion of the 
treated HIV-infected population is or has been exposed in the past to NRTIs 
and their adverse effects.
2.4.1 Nucleoside analogues
There are seven NRTIs currently approved for the treatment of HIV infection 
or AIDS: zidovudine (AZT or ZDV), zalcitabine (ddC), didanosine (ddl), 
stavudine (d4T), lamivudine (3TC), emtricitabine (FTC), and abacavir (ABC). 
All this compounds are derivatives of the natural nucleosides adenosine, 
cytosine, guanosine and thymidine. Chemical structures of some of the 
licensed NRTIs are shown in Fig 2.5.
As structural analogues, NRTIs share with natural nucleosides several 
properties and therefore they can act as alternative substrates for both HIV 
reverse transcriptase and human DNA polymerases. It is important to note 
that not all human DNA polymerases show the same level of affinity to NRTIs.
DNA polymerase y and possible DNA polymerase p are the more likely to 
incorporate NRTIs (Wright & Brown 1990). Nevertheless, NRTIs are poorly 
incorporated to the DNA forming chain by human polymerases when 
compared to HIV-reverse transcriptase.
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Fig. 2.5 NRTI structure
Source: htto://en.wikipedia.org'w/index.DhD?title=Main Paae&oldid=98546089 (accessed January 30, 
2007).
The most important structural difference between NRTIs and natural 
nucleosides is the 3’-OH substitution of the deoxyribose sugar. This position is 
responsible for the 3’-5’ union with the next nucleotide leading to elongation of 
the new DNA chain. However, NRTIs show either a lack of the 3 ’-OH 
substitution or a modification of that substitution (AZT) which prevents the 3’-5’ 
bond formation. Therefore NRTIs can induce transcription impairment by at 
least two different mechanisms 1) competition with natural nucleic acids to be 
incorporated in the forming DNA chain and 2) premature termination of DNA 
chain elongation (Kakuda 2000; Anderson etal. 2004).
2.4.2 Pharmacology of NRTIs
Pharmacologically, NRTIs must be considered to be pro-drugs as they need to 
be structurally modified to have pharmacological effects. In a similar way to 
natural nucleosides, NRTIs must be phosphorylated to become substrates for
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either the HIV reverse transcriptase or human DNA polymerases. NRTIs 
phosphorylation is an intracellular process, which requires participation of 
several enzymes. Nevertheless, the final step in this activation process, the 
formation of the triphosphorylated moiety, is probably common to all NRTIs 
and is catalysed by nucleoside diphosphate kinase. Nevertheless, it has been 
proposed that ABC has a unique phosphorylation pathway, and that might at 
least partially explain the differences seen between ABC and other NRTIs 
toxicity profiles. ABC is phosphorylated once before being deaminated (to 
form carbovir-MP) in the cytosol and then is phosphorylated twice to form the 
active moiety (carbovir-TP) (Kakuda 2000).
Intracellular NRTIs phosphorylation has been described as a process 
dependent on the cellular status. In vitro studies have shown that non­
activated or resting cells might phosphorylate more effectively 3TC, ddC and 
ddl, whereas activated cells are more efficient in phosphorylating d4T and 
AZT (Kakuda 2000). However, studies addressed to compare NRTIs 
phosphorylation in resting and activated cells have shown that the actual 
intracellular concentration of ddC, ddl and 3TC triphosphate may be up to 2 -  
4 fold higher in active cells when compared with resting cells (Anderson et al. 
2004). In that context, the effectiveness of NRTIs might depend on cellular 
activation as probably also does toxicity if it is associated with concentration of 
active triphosphate moieties in the intracellular compartment.
Chronic systemic cell activation has been described in patients with HIV 
disease, showing a direct association between the level of cell activation, 
measured as concentration of pro-inflammatory markers, and the severity of 
the disease (Hestdal et al. 1997). Similarly, several studies have proposed 
that severely ill HIV-infected patients have a higher risk of developing NRTI- 
associated adverse events (Joly et al. 2002). Recent clinical studies have 
shown that the intracellular concentration of triphosphorylated AZT and 3TC 
seems to be higher in those individuals with lower CD4 cell counts and also in 
those with a higher baseline HIV viral load (Anderson et al. 2003). In addition, 
similar results were found in female patients when compared with males.
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Finally, Anderson et al. also found that both baseline HIV viral load and female 
sex were the only variables independently associated with time to reach less 
than 50 HIV copies/mm3 after starting ART (Anderson et al. 2003). It does 
seem that cell activation and female gender may be associated with an 
increase in the anti-viral activity of NRTIs. These two variables have also 
been proposed as risk factors for NRTI-associated adverse events (Currier et 
al. 2000), suggesting therefore that triphosphorylated NRTIs are responsible 
for both therapeutic and toxic effects.
2.5 NRTI-associated adverse effects
During pre-licensing clinical trials on NRTIs, several adverse effects were 
identified. Some of them have been described as mild and usually self-limited. 
Examples of these are headache, insomnia and gastrointestinal symptoms 
(nausea, vomiting and diarrhoea) which have been associated with AZT, ddC, 
d4T and even ABC. Nevertheless, serious adverse effects such as peripheral 
neuropathy or anaemia were considered as dose-limiting toxicities in clinical 
trials using AZT, ddC, d4T and ddl.
The long-term adverse events associated with NRTIs show a remarkable 
similarity to the clinical manifestations of mitochondrial diseases (Finsterer 
2004). Furthermore, several studies have demonstrated the presence of 
abnormal mitochondria and/or mtDNA impairment in HIV-infected patients 
who develop complications such as peripheral neuropathy or bone marrow 
suppression. Other proposed NRTI-associated adverse events, such as 
pancreatitis, lactic acidosis and even peripheral lipoatrophy might also be 
attributable to NRTI-induced mitochondrial dysfunction.
2.5.1 The Polymerase gamma hypothesis
Since NRTIs are structurally very similar to natural nucleosides, the potential 
for them inhibiting human DNA polymerases exist. However, as was
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mentioned before, in-vitro studies have shown that nuclear polymerases are 
less likely to incorporate NRTIs than the HIV reverse transcriptase. 
Nevertheless, mitochondrial DNA polymerase y has been shown to be 
particularly susceptible to incorporate NRTIs. Because human polymerase y is 
the sole enzyme responsible for replication and repair of mtDNA, it is logical to 
assume that NRTIs can lead to mtDNA depletion causing eventually 
mitochondrial dysfunction (Brinkman & Kakuda 2000; White 2001).
Several in vitro studies have shown that NRTIs can in fact induce mtDNA 
depletion. Studies using human lymphoblastic cells (Molt-4 and CEM) have 
shown that it is possible to induce mtDNA depletion in cultured cells by 
exposure to NRTIs (Chen et al. 1991; Martin et al. 1994). Nevertheless, it has 
also been highlighted that not all NRTIs have the same capacity of inducing 
mtDNA depletion. In vitro studies have shown ddC as the strongest inducer of 
mtDNA depletion among NRTIs licensed to treat HIV disease. Similarly, 
almost all studies presented to date have noticed that ABC and 3TC are the 
weakest inducers of mtDNA depletion (Birkus et al. 2002; Martin et al. 1994; 
Chen et al. 1991). Other NRTIs such as ddl, d4T and AZT have been 
allocated in different points in the scale by different authors. Nevertheless, 
most of the studies suggest that AZT is a weaker inducer of mtDNA depletion 
when compared with either ddl or d4T. Tenofovir (TDF), a nucleotide reverse 
transcriptase inhibitor, has been shown to be at least as weaker inducer of 
mtDNA depletion as ABC or 3TC (Birkus et at. 2002).
As early as 1991, Arnaudo et al. reported a significant reduction in the content 
of mtDNA in muscle biopsies from nine patients with AZT-induced myopathy 
when compared with AZT naive patients (Arnaudo et al. 1991). More recently, 
Masanes et al. found significant mtDNA depletion (52 %, 74 %, and 56 %  
respectively) in three patients with AZT-induced myopathy when compared 
with controls (Masanes etal. 1998).
MtDNA content has also shown to be reduced in different cell types from 
patients exposed to different NRTIs. Patients co-infected with hepatitis C virus
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(HCV) and HIV have been shown as having a significant reduction of the 
mtDNA : nDNA ratio in hepatocytes only when they are exposed to either d4T, 
ddl or ddC as part of their HAART combination. No difference was found in 
the content of mtDNA in those patients receiving “d drugs” sparing regimens 
when compared with controls (HCV infected patients but HIV negative) 
(Walker et al. 2004). Severe episodes of hyperlactataemia and pancreatitis 
have been described in HIV-HCV co-infected patients on regular 
dideoxynucleoside-based ART when exposed to anti-Hep C medication (i.e. 
ribavirin). It has been suggested that those patients on ddl-based 
combinations are at higher risk of developing clinically evident mitochondrial 
dysfunction when exposed to ribavirin (Bani-Sadr etal. 2005). Interestingly the 
last study failed to demonstrate any increased risk for mitochondrial toxicities 
in patients receiving d4T without concomitant exposure to ddl.
Compared with HIV-infected but ART-naTve patients, individuals receiving 
both AZT and d4T based regimens have been shown to have mtDNA 
depletion in adipocytes. By contrast, those individuals treated with non­
thymidine NRTIs (i.e. other than AZT or d4T) have been reported as having 
similar levels of adipocyte mtDNA compared to ART-naTve controls. 
Nevertheless, the effect of AZT on adipocyte mtDNA is not the same as the 
effect induced by d4T on this cell type. In the same study, patients treated with 
d4T showed more severe mtDNA depletion than AZT treated patients. 
Furthermore, after switching from d4T to either ABC or even AZT, patients 
showed a significant recovery in the level of their mtDNA in adipocytes over 1 
to 24 months (Hammond et al. 2004).
Peripheral blood mononuclear cells (PBMC) have been proposed as a 
suitable target to assess mitochondrial function in patients exposed to NRTIs 
(Henry et al. 2002; McComsey et al. 2002). Comparing patients on AZT/3TC 
with patients on d4T/3TC or ART-naTve, Lopez et al. have reported that those 
individuals receiving d4T containing combinations showed not only a 
significant reduction in their mtDNA content but also significant decrease in 
the activity of respiratory chain complexes III and IV (Lopez et al. 2002).
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Previously, Cote et al. had presented data showing that HIV-infected patients 
exposed to NRTIs showed a significant reduction in the mtDNA content of 
PBMC (from buffy coat) when compared with healthy volunteers. Interestingly, 
that study also showed a significant recovery in mtDNA content after stopping 
ART, suggesting reversibility of the toxic effect caused by NRTIs on 
mitochondria (Cote et al. 2002). It is important to mention that all NRTI- 
exposed patients in Cote’s study had symptomatic hyperlactataemia at the 
time of being tested and all of them were receiving d4T based regimens.
However, it has been proposed that NRTI-induced mitochondrial toxicity may 
be tissue specific and therefore, evidence of mitochondrial dysfunction such 
as mtDNA depletion may not be found in every cell type in a given patient. A 
study designed to quantify mtDNA in subcutaneous adipose tissue from lower 
limb biopsies in HIV-infected adults has shown that those patients receiving at 
least one dideoxynucleoside (“d-drug”) had significant reduction in the content 
of mtDNA when compared with patients off treatment. The same study failed 
to show any association between the level of mtDNA in PBMC and exposure 
to NRTIs (Cherry et al. 2002).
Similarly, a case of fatal lactic acidosis with massive hepatic steatosis in a 
patient receiving AZT monotherapy was published in the early 90’s. The liver 
histology of that patient showed abnormal mitochondria without viral 
inclusions. Interestingly, ultra-structural studies of skeletal muscle sample did 
not show any mitochondrial abnormality (Olano et al. 1995).
According to the DNA polymerase y hypothesis (Lewis & Dalakas 1995), 
NRTIs can induce impairment of mitochondrial function primarily by inhibiting 
polymerase y which eventually leads to mtDNA depletion and energy 
deprivation to the affected cell. However, some recent evidence suggests that 
mtDNA depletion might not be the only or even the main mechanism 
responsible for NRTI-associated mitochondrial dysfunction.
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A case of lactic acidosis in a patient exposed to AZT/ddl combination therapy 
was recently published. The interesting point of this particular case is the 
absence of any mtDNA depletion in muscle cells but the evidence of a 
significant impairment of the respiratory chain activity (Miller et al. 2003). 
Similarly, Walker et al. have presented in-vitro data suggesting that AZT and 
AZT/3TC combination in cultured cells can induce a rise in lactate without 
affecting the actual mtDNA content (Walker et al. 2001). Furthermore, a recent 
study has shown that patients with either peripheral lipoatrophy or peripheral 
neuropathy had a significant reduction in the mtDNA : nDNA ratio when 
compared with either HIV-infected patients who did not have any ART- 
associated ADR or to controls (Rabing et al. 2004). Interestingly, in Rabing’s 
study those patients treated with d4T containing combinations had 
significantly lower mtDNA : nDNA ratio than those patients exposed to AZT 
based combinations Similarly, it has recently been shown that patients 
exposed to either AZT/ddl or AZT/ddC combination therapies had more 
pronounced mtDNA depletion in PBMC when compared to patients receiving 
AZT monotherapy after 48 weeks (Reiss et al. 2004).
2.5.2 Other possible mechanisms
A few years after introducing the polymerase y hypothesis, Lewis et al. have 
now proposed a new multi-factorial hypothesis as an explanation for the NRTI- 
induced mitochondrial dysfunction. According to this new proposition NRTIs 
may induce three different pathological processes which eventually leads to 
mitochondrial dysfunction. These three mechanisms are: 1) Energy 
deprivation due to mtDNA depletion, 2) Mitochondrial oxidative stress, and 3) 
mtDNA mutations (Lewis et al. 2001). Although this integrated hypothesis 
includes another two mechanisms, the authors still consider mtDNA depletion 
as the first step in the process.
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Mitochondrial sub-units and therefore mtDNA are particularly susceptible to 
oxidative stress2. MtDNA is constantly exposed to the highly oxidative 
mitochondrial environment. In fact, mitochondrial generation of super-oxide 
anion radical (0 2 ~) represents the major intracellular source of oxygen 
radicals under physiological conditions. Because of that, the steady state 
concentration of O 2 ~  in the mitochondrial matrix is between 5 to 10 fold higher 
than in the cytosol and the nucleous (Cadenas & Davies 2000). In that 
context, ROS are more likely to induce impairment not only of mtDNA but also 
mitochondrial structural and functional proteins than to other cellular 
structures.
Most of the oxygen available for cell respiration or oxidative phosphorylation is 
reduced in a process catalysed by cytochrome oxidase (Complex IV) to
produce water (0 2 + 4e‘ + 4H+ __ ^ 2H20 ). Cytochrome oxidase is the final
electron acceptor in the respiratory chain, so in order to allow electrons to flow 
through the chain it needs to give up its electrons by reducing 0 2 (Cadenas & 
Davies 2000). Although mitochondria represent a highly efficient system, 
between 2 -  4 % of the total of electrons transported by the respiratory chain 
results in the reduction of 0 2 to H20 2 instead of water under physiological 
conditions (Lewis et al. 2001). Obviously, alterations in the electron flow 
through the respiratory chain by any cause can increase ROS production 
substantially.
Several components of complexes I, II and III have the capacity of inducing 
the generation of 0 2 — (Fig. 2.6). In addition, the monoamine oxidase located 
in the outer mitochondrial membrane catalyses the formation of H20 2, which is 
mainly responsible for increasing the concentration of ROS within both the 
mitochondrial matrix and the cytosol. The proximity of mtDNA to sites of ROS 
production and the lack of histones make it very vulnerable to oxidative 
damage. In fact, the level of oxidised bases in mtDNA is generally 10 to 20 
fold higher than in nDNA (Cadenas & Davies 2000).
2 Oxidative Stress: A disturbance in the balance between the production of reactive oxygen 
species (free radicals) and anti-oxidant defences.
(Betteridge DJ. W hat is oxidative stress? Metabolism  2000; 49 (Suppl 2): 3 - 8 )
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Fig. 2.6 Respiratory chain showing potential sites of superoxide anion formation
Source: Lab Invest 2001: 81 (6): 781
It has been proposed that AZT or its metabolites have an inhibitory effect on 
the mitochondrial oxidative energy production that might not be associated 
only with mtDNA depletion. It has been demonstrated that short-term 
exposure of rats to AZT increases ROS production in heart cells, leading also 
to a significant increase in lipid peroxidation and protein oxidation without any 
evidence of mtDNA depletion (Szabados et al. 1999). Furthermore, the last 
study found some increase in the amount of mtDNA in heart cells of AZT 
exposed animals. Similarly, in vitro data using lymphoid cells (U937 and 
MOLT4) cultured with AZT showed significant inhibition of various 
mitochondrial enzymes including ADP/ATP translocator, adenylate kinase, 
NADH-cytochrome c reductase and those of NADH-linked respiration. As 
consequence of that, a rapid decrease in ATP production has been noted in 
human cells exposed to AZT potentially leading to overproduction of ROS 
(Yamaguchi et al. 2002). In both, animal models and cultured human cells 
(lung fibroblasts MRC-5) exposed to AZT it has been noticed that mtDNA 
increases as consequence of oxidative stress (Lee et al. 2000; Szabados et 
al. 1999). This initial rise in mtDNA might be a compensatory mechanism and 
suggest that mtDNA depletion might not be the first step in the NRTI-induced 
mitochondrial dysfunction. Similarly, mtDNA content increases with ageing in
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normal cells and it has been proposed to be associated with oxidative damage 
as well.
In addition, oxidative damage caused by ROS may induce single strand DNA 
breaks, lipid peroxidation and protein oxidation (Szabados et al. 1999). These 
three mechanisms may play significant roles in the development of 
mitochondrial dysfunction associated with NRTIs exposure. MtDNA deletions 
may be detected as early as 12 to 15 days after exposure of human lymphoid 
cells to AZT (Yamaguchi et al. 2002). Finally, ROS may also induce DNA 
base modification. In that context, it has been proposed that those random 
mtDNA mutations are likely to induce complex I inactivation because a large 
proportion of its components are mtDNA encoded (Lewis et al. 2001). Even 
more, inhibition of complex I of the respiratory chain may promote an increase 
in the oxidative stress completing a vicious circle.
In summary, the new hypothesis proposed by Lewis et al. suggests that NRTI- 
induced mitochondrial dysfunction may be consequence of three different and 
complementary mechanisms. These mechanisms include mtDNA depletion 
secondary to polymerase y inhibition that leads to energy deprivation, 
concomitant mitochondrial oxidative stress which lead to lipid, protein and 
DNA oxidative damage and finally mtDNA mutation which can be 
consequence of either oxidative damage, impaired mtDNA replication or 
transcription (Lewis etal. 2003).
Finally, a recent report has shown that short term (two weeks) exposure to 
either AZT/3TC or d4T/3TC combinations may induce a significant reduction 
in mitochondrial gene expression (COX1, COX3 and Cyt b) in adipocytes from 
healthy volunteers (Mallon et al. 2004b). The same group has also presented 
some evidence suggesting that NRTIs can induce inhibition of mtRNA 
transcription by mechanisms other than mtDNA depletion in both adipocytes 
and monocytes (Mallon et al. 2004a). In addition, they have proposed that the 
same NRTIs combinations may also induce a decreased nuclear gene 
expression of some genes implicated in lipid metabolism (PPAR y) suggesting
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the presence of feedback mechanisms between mitochondria and the nucleus 
which may be relevant in the pathogenesis of lipoatrophy associated with 
NRTIs (Mallon et al. 2005). In summary, one could speculate that NRTIs may 
induce selective gene expression reduction in both mitochondria and nucleus, 
which may play a significant role in the pathogenesis of lipoatrophy and 
possibly other NRTI-associated adverse events, independently of polymerase 
y inhibition and irrespective of any effect induced by HIV itself.
In addition, Miro et al have recently reported that asymptomatic HIV-infected 
patients (N = 17) exposed to d4T/ddl had significant mtDNA depletion 
compared with controls (ART naive). Interestingly, despite having significantly 
reduced mtDNA content in PBMC, patients treated with d4T/ddl showed 
normal mitochondrial function, suggesting that transcriptional or post- 
transcriptional mechanisms may compensate, at least initially, in NRTI- 
induced mtDNA depletion (Miro etal. 2004b).
2.5.3 Clinical aspects of NRTI-induced mitochondrial toxicity
As has been mentioned before, there are striking similarities between NRTI- 
associated adverse events and mitochondrial diseases. In fact, most of the 
long-term or serious NRTI-associated adverse effects could be explained by 
mitochondrial dysfunction. Lactic acidosis is the best example.
Bone marrow suppression, myopathy, cardiomyopathy, peripheral neuropathy, 
pancreatitis, hyperlactataemia and lactic acidosis, hepatic steatosis and 
peripheral lipoatrophy have all been associated with NRTI-induced 
mitochondrial dysfunction. The level of evidence supporting the association 
between mitochondrial dysfunction and each of these complications varies. 
However, in all cases in vitro and in vivo data suggest that NRTIs may play a 
significant role in pathogenesis, even when other factors such as HIV infection 
itself may also be determinant in the clinical expression of them.
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Distal symmetrical peripheral neuropathy was identified as the main dose 
limiting factor during early phase I/ll clinical trials of ddC, d4T and ddl. 
Although NRTI-associated peripheral neuropathy (PN) is clinically 
indistinguishable from HIV-induced PN, NRTI-related PN has been described 
as more likely to be painful and to have a more acute course, with an abrupt 
onset and progressing more rapidly when compared with HIV-induced PN 
(White 2001). In addition, it has been suggested that high level of blood 
lactate may be a marker of toxic PN, suggesting that mitochondrial 
dysfunction is the underlying mechanism (Brew etal. 2003).
In vitro studies have shown that nerve cells exhibit mtDNA depletion, 
alterations in mitochondrial structure and shape and an increase in 
intracellular lactate levels when they are exposed to ddC and ddl (Keilbaugh 
et al. 1991). Furthermore, in vitro studies using the same cell line (PC-12) 
have confirmed mtDNA depletion in cells exposed to both ddC and ddl, but 
not in cells cultured with AZT, 3TC or d4T. Interestingly, AZT and 3TC were 
found not to be associated with any toxic change in the PC-12 model but d4T 
was. Authors have suggested that additional mechanisms, other than mtDNA 
depletion, may be involved in d4T-induced PN (Cui etal. 1997).
As has been highlighted above, there is evidence to support an association 
between mitochondrial dysfunction and PN potentially caused by NRTIs. 
However, multiple other mechanisms and variables may play significant roles 
in inducing clinically evident PN in HIV-infected patients. In fact HIV infection 
itself can be critically important in this regard. Both low CD4 lymphocyte count 
and high HIV viral load have been identified as risk factors for PN (Moyle & 
Sadler 1998; Simpson et al. 2002). In fact, according to Simpson et al. 
aggressive control of HIV replication may be beneficial to patients in order to 
control the severity of symptoms. Furthermore, they found that at least for 
mild cases of PN, the use of “dd drugs” does not necessarily increase the 
clinical expression of PN.
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As with PN, many other NRTI-associated ADR have been proposed to be due 
to mitochondrial dysfunction but the possibility of other mechanisms playing 
significant roles in their clinical expression cannot be excluded. However, as 
serum levels of lactate at rest or after exercise have been used to suggest 
cellular oxidative impairment, lactic acidosis and hyperlactataemia are 
conditions which can be considered markers of mitochondrial dysfunction and 
therefore, are arguably the best model to assess the effects of NRTIs on 
mitochondrial function.
Episodes of lactic acidosis have been reported among HIV-infected patients 
exposed to NRTIs since the early 1990’s. This complication has been 
identified in patients receiving monotherapy with NRTIs, mainly AZT or 
combination of at least two NRTIs. Nevertheless, in vitro and animal models 
have also supported the concept of NRTIs causing raised levels of lactate as 
evidence for mitochondrial dysfunction. Cultured human and rodent cells show 
significant increase in lactate production when exposed to either ddl or ddC 
(Keilbaugh etal. 1997; Tsai et al. 1994). Similarly mice and monkeys exposed 
to either AZT/3TC or d4T have been documented to have a two to eight-fold 
rise in blood lactate (Dagan etal. 2002).
Mitochondrial dysfunction would be expected to lead to an increase in 
endogenous lactate production. Leclerq et al. have demonstrated a marked 
increase in endogenous lactate production even in patients with a moderate 
increase in serum lactate (Leclercq et al. 2001). However, even extreme 
elevations of lactate after exercise can be rapidly re-equilibrated as a result of 
lactate clearance. HIV-infected patients with lipodystrophy exposed to 
exhaustive exercise, showed a similar pattern of lactate decline during resting 
time compared to healthy controls (Roge et al. 2002). By contrast, a recent 
study has shown that HIV-infected patients with hyperlactataemia, exposed to 
sub-maximal exercise, have a reduced lactate clearance capacity. The decline 
in the lactate levels in patients on ART was considerately slower in patients 
with raised levels of lactate at baseline compared to patients with normal 
baseline levels (Bauer et al. 2004). One could speculate that hyperlactataemia
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and probably lactic acidosis in HIV-infected patients exposed to NRTIs might 
be a consequence of both an increased lactate production rate and a reduced 
lactate clearance capacity.
NRTIs have also been demonstrated to induce mitochondrial dysfunction and 
hyperlactataemia in the absence of HIV infection. Five out of eight HIV- 
uninfected children were reported as having persistently elevated blood 
lactate levels after perinatal exposure to AZT in a study published by Blanche 
et al. (Blanche et al. 1999). A more recent study has also found significant 
mtDNA depletion in infants exposed perinatally to AZT/3TC (N = 10) 
compared with children born to HIV-uninfected women (Divi et al. 2004). 
Similarly, in a prospective study, HIV-uninfected children exposed to AZT as 
prophylaxis for mother to child transmission showed significant mtDNA 
depletion at birth and at one and two years of age when compared with 
children never exposed to AZT (Poirier et al. 2003). Nevertheless, authors of 
that report have highlighted that most of the AZT-exposed HIV-uninfected 
children are asymptomatic even when they show significant mtDNA depletion.
2.6 HIV and mitochondrial function
HIV-RNA has been identified in the mitochondria of infected cells. In addition,
mitochondrial alterations can be found in patients with the acute HIV
syndrome and with chronic infection (White 2001). However, information about
mtDNA content or the function of respiratory chain enzymatic complexes in
HIV-infected patients who have never received ART is scanty. Miura et al.
have recently reported that treatment naive HIV-infected patients have a
decreased content of mtDNA in PBMC compared with healthy controls.
Furthermore, individuals treated with AZT/3TC or d4T/3TC combinations, but
not with AZT/ddC combination, showed a significant recovery of the content of
mtDNA in PBMC. The study reported by Miura, although involving a small
number of patients (N = 46, of which 13 were ART naive patients) concludes
that the cellular content of mtDNA depends on HIV-disease progression as
they found a significant positive association between CD4 cell count and
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mtDNA content. In addition, the same study showed an inverse association 
between HIV viral load and mtDNA content in PBMC (Miura et al. 2003).
Similarly, a sub-analysis of the Gilead 903 study has shown that ART naive 
HIV-infected individuals (N = 227) had significant reduction in their mtDNA 
content in PBMC when compared with healthy controls (N = 49). In addition, 
the same study has shown that those patients treated with a TDF/3TC  
combination (N = 113) had a significant recovery of their mtDNA content after 
48 weeks of therapy. The study failed to demonstrate any mtDNA recovery in 
the group of patients treated with d4T/3TC combination (Gallant et al. 2002).
Nevertheless, HIV has also been proposed to impair mitochondrial function 
independently of any effect on mtDNA content. A recently published study has 
shown that PBMC from HIV-infected but treatment naive patients (N = 25) had 
a significant reduction in the activity of respiratory chain complexes III and IV 
when compared with healthy volunteers (N = 25). Furthermore, HIV-infected 
patients also had a significant reduction in the activity of complex II, which is 
exclusively encoded by nuclear DNA, concomitant with mtDNA depletion. The 
authors suggest that mtDNA depletion in HIV-infected but treatment naive 
patients may be interpreted as consequence of generalised mitochondrial 
damage rather than any direct effect on polymerase activity (Miro et al. 
2004a).
However, it has not been clearly elucidated whether the effect of HIV on
mitochondrial function is mostly caused directly by the virus itself or is a
consequence of inflammatory mediators released in response to HIV infection.
Furthermore, as HIV cannot infect several cell types which have been
reported as affected in HIV-infected patients, its effect may be mediated by
cytokines at least in neurons, myocytes and adipocytes (Moyle 2005a).
Tumour necrosis factor (TNF)-a has been found to induce heart failure
associated with mitochondrial impairment in a mouse model. Cardiac muscle
cells showed not only a significant reduction in mtDNA when compared with
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control animals but also a reduction in the respiratory chain activity and 
structural abnormalities in mitochondria (Li et al. 2001). Similarly, interferon 
(Inf)-y has been shown, at least in vitro, to be an inducer of mitochondrial 
dysfunction in smooth muscle cells. The study published by Geng et al. shows 
that Inf-y induces autocrine secretion of nitric oxide which blocks mitochondrial 
respiration (Geng et al. 1992).
In summary, one could assume that HIV-infected patients might have an HIV- 
induced sub-clinical mitochondrial dysfunction, which can be exacerbated by 
the toxic effect of NRTIs. Furthermore, this “double hit” hypothesis on 
mitochondrial dysfunction in HIV-infected patients is consistent with the finding 
of advanced HIV disease as a risk factor for both HIV and NRTI-induced 
complications such as peripheral neuropathy.
In addition, HIV has been shown as an inducer, either directly or indirectly, of 
intracellular oxidative stress. As described before, NRTIs can also induce 
oxidative stress and therefore exacerbate the effects induced by HIV infection. 
It has been described that chronic AZT exposure in murine models can lead to 
cardiomyopathy in a NADH oxidase-dependent mechanism. That process has 
been shown to be ameliorated by vitamin C supplementation (Papparella 
2007). The effect of antioxidants on NRTI-induced mitochondrial dysfunction 
has been also studied in-vitro showing that supplementation with acetyl-l- 
carnitine may either protect from the intracellular increase of H20 2 (d4T- 
exposed cells) or reduce the content of H20 2 in ddl-treated cells (Ferraresi 
2006). Furthermore, N-acetylcysteine, the recognised treatment of choice for 
paracetamol intoxication, has been able to reverse the oxidative stress 
induced in a cellular model by HIV antigens (gp 120 and Tat). Therefore, it has 
been suggested that N-acetylcysteine (Aitio 2005) or perhaps other 
antioxidants could be used in conjunction with ART to reduce the deleterious 
effect of both HIV and NRTIs on mitochondrial function. That hypothesis 
should be tested in a proper way.
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CHAPTER 3
Peripheral neuropathy associated with NRTIs
The peripheral nervous system is frequently affected in patients with HIV 
infection. Different conditions have been described affecting peripheral 
nerves in the context of HIV disease, some of them are the consequence of 
opportunistic infections but others have been attributed to the effect of the HIV 
itself (Table 3.1). Special consideration should be given to the impairment of 
peripheral nerve function that has been attributed to exposure to NRTIs. This 
toxic variety of peripheral neuropathy seen in HIV-infected patients, as has 
been previously mentioned (See chapter 2), has been suggested to be 
consequence of mitochondrial dysfunction and because of that a study of it 
has been included in this thesis.
Table 3.1 Peripheral nervous system (PNS) involvement in HIV infection
Modified from Keswani et al. AIDS 2002. 16(16): 2106
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3.1 Cumulative toxicity of NRTIs
Several authors have proposed that NRTI-associated ADR attributable to 
mitochondrial dysfunction are due to a cumulative toxic effect of these drugs, 
implying an increasing incidence with longer exposure. A large prospective 
study assessing subcutaneous fat wasting as a marker of the lipoatrophy 
syndrome described in HIV-infected patients, has shown that both duration of 
dual NRTIs therapy before starting HAART and cumulative time on d4T were 
independently associated with subcutaneous fat loss (Mallal et al. 2000). This 
study showed, in a time-to-event analysis, that the risk of subcutaneous fat 
wasting was primarily dependent on cumulative exposure to NRTIs. In 
addition, a few studies on hyperlactataemia in HIV-infected patients treated 
with NRTIs have suggested that cumulative exposure to NRTIs, particularly to 
d4T and ddl, may lead to accumulation of mtDNA mutations (Manfredi et al. 
2003; Coghlan etal. 2001).
Early clinical trials for dideoxynucleosides reported data suggesting 
cumulative toxicity of these drugs. PN was proposed to be a cumulative dose 
dependent toxicity in phase I clinical trials of ddl and ddC but not d4T. 
However, the number of patients in these studies was small. All had relatively 
advanced HIV disease and therefore they might have been at a higher risk of 
developing PN than most patients currently offered ART (Lambert et al. 1990; 
Petersen et al. 1995; Yarchoan et al. 1988). In addition, a recently published 
prospective study on risk factors for PN in HIV-infected people has shown 
anti-retroviral therapy, particularly dideoxynucleoside exposure, is a predictive 
factor for PN after a year follow-up. Based on their findings, the authors 
conclude that it is possible that there may be a threshold of HIV disease after 
which patients become more susceptible to the toxic effect of drugs and 
therefore, express clinical evidence of PN. The authors also suggest that such 
a threshold might be consequence of either duration of the exposure or 
cumulative dose of ART (Lopez etal. 2004).
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3.2 Peripheral neuropathy in HIV-infected patients
As mentioned earlier, individuals infected with HIV may present with several 
types of peripheral nerve impairment. Both opportunistic infections such as 
CMV and HIV-related processes are mainly seen in patients with advanced 
HIV disease. By contrast, inflammatory demyelinating polyneuropathies and 
NRTI-induced neuropathy might be seen at any stage in the course of the HIV 
disease (Table 3.1).
Although the spectrum of neuropathies described in HIV-infected patients is 
quite large, the vast majority of patients affected by them present with either 
HIV-induced distal sensory polyneuropathy or toxic peripheral neuropathy 
induced by NRTIs (Luciano et al. 2003). Interestingly, both conditions are 
sensory neuropathies and are very similar to each other from a clinical point of 
view. Given the difficulty of making a differential diagnosis based on clinical 
information, the temporal association between the initiation of NRTIs therapy 
and the onset or worsening of symptoms has been claimed to be the most 
useful distinguishing feature (Keswani etal. 2002).
3.2.1 HIV-induced peripheral neuropathy
Peripheral neuropathy (PN) has been shown to be the most frequent 
neurological complication affecting HIV-infected patients, particularly after the 
introduction of HAART combinations when the incidence of most opportunistic 
neurological infections has decreased significantly (Keswani et al. 2002; Manji 
& Miller 2004).
Distal sensory polyneuropathy is usually described as a progressive,
symmetrical condition affecting initially the limbs in a centripetal fashion.
Patients usually complain of pain or dysesthesia of gradual onset, which might
be described as aching, numbness or a burning sensation. This condition is
usually more severe on the soles of feet and is particularly distressing at night.
On physical examination no evidence of muscular power or tone impairment is
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found in the vast majority of cases, the reduction or absence of ankle reflexes 
being the most evident clinical sign (Keswani etal. 2002; Verma 2001).
In the pre-HAART era, distal sensory polyneuropathy was seen in about 35 % 
of HIV-infected patients, but some autopsy series have shown evidence of 
peripheral nerve involvement in almost 100 % of cases (Luciano et al. 2003; 
Manji & Miller 2004). In fact, during the period between 1992 and 1995 the 
incidence of sensory PN increased from 10 to 25 cases per 100 person-years. 
However, the incidence of PN has decreased gradually since 1996, reaching 
values around 5 cases/100 person-years (Lichtenstein et al. 2005; 
Lichtenstein et al. 2005). Interestingly, the beginning of the rise in the 
incidence of PN was coincident with the time when NRTIs other than AZT, 
particularly dideoxynucleosides, were licensed to treat HIV-infected patients 
(Keswani et al. 2002). Nevertheless, the beginning of the subsequent drop in 
the incidence of PN was evident when HAART combinations were introduced 
for the treatment of HIV-infected patients (Lichtenstein et al. 2005).These data 
suggest that sensory PN is closely related to both HIV replication and disease 
status and the toxic effect of dideoxynucleosides.
The exact mechanism by which HIV induces distal sensory polyneuropathy 
still remains elusive. Nevertheless, a significant association between the 
probability of developing distal sensory polyneuropathy and progression of 
HIV disease has been demonstrated (Simpson et al. 2002; Childs et al. 1999). 
More immunosuppressed patients are more likely to develop distal sensory 
polyneuropathy and therefore several factors such as direct HIV effect or 
indirect damage to peripheral nerves induced by cytokine cascade and even 
vitamin B12 deficiency, have been proposed as possible causes of distal 
sensory polyneuropathy (Verma 2001). Pathological studies have shown 
almost universal peripheral nerve damage in cases with HIV-related death that 
underwent autopsy.
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There is a gradual onset of symptoms in most cases of distal sensory 
polyneuropathy. These data suggest that the pathology develops gradually 
and that sub-clinical peripheral nerve impairment might be present in many 
HIV-infected patients for an undetermined period of time before any symptoms 
appear (Cherry et al. 2003). This is supported by studies showing sub-clinical 
peripheral nerve dysfunction assessed by both thermal threshold 
determination and quantitative sensory testing in patients with advanced HIV 
disease (Tagliati etal. 1999; Gulevich etal. 1992).
3.2.2 Evidence for NRTI-associated peripheral neuropathy
Phase I clinical trials of ddl, ddC, and d4T demonstrated a clear relationship 
between dose and the incidence of PN (Yarchoan et al. 1988; Browne et al. 
1993; Lambert et al. 1990). In fact, PN was the most important dose-limiting 
adverse event identified in phase I clinical trials of dideoxynucleosides. In 
addition, Moore et al. have found a synergistic neurotoxic effect when ddl and 
d4T are given in combination. Moore et al. included just over 1,000 patients 
who were on treatment with either ddl, d4T or a combination of these two 
NRTIs with or without hydroxyurea. The authors found that those patients 
exposed to a d4T/ddl combination were 3.5 times more likely to develop PN 
when compared with those receiving ddl monotherapy. In addition, the 
combination of d4T/ddl plus hydroxyurea was found to be associated with a 
hazard ratio of 7.8 for PN compared with ddl monotherapy (95 % Cl = 3.92 -  
15.5) (Moore et al. 2000).
As has been noticed for most NRTI-induced long-term adverse effects, not all 
dideoxynucleosides have the same capacity for inducing PN. In fact, ddC has 
been shown as the strongest inducer of PN in clinical studies, followed by d4T 
and according to some authors, ddl. The incidence of PN in patients receiving 
ddC at a dosage of 0.75 mg three times a day over a period longer than nine 
months has been reported to be around 25 %. On the other hand, 17 and 23
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% of patients taking d4T at 20 mg and 40 mg twice a day respectively 
developed PN at week 24 in a large clinical trial (Moyle & Sadler 1998).
Mitochondria have been shown as the target for NRTI-induced toxicities 
including PN. Dalakas et al. have found a much higher proportion of abnormal 
mitochondria in axons and Schwann cells of sural nerve biopsies from HIV- 
infected patients treated with ddC when compared with patients with HIV- 
induced PN or non HIV-infected patients with other causes of PN. In addition, 
this also showed a significant reduction in the content of mtDNA in the nerve 
samples of ddC exposed patients compared with controls (Dalakas et al. 
2001; Cui etal. 1997).
In vitro experiments have shown that human neurones (PC-12) exposed to 
either ddC or ddl concentrations that did not affect cell growth develop mtDNA 
depletion (Cui et al. 1997). Interestingly, the same experiment failed to 
demonstrate any reduction in the content of mtDNA in neurones exposed to 
d4T, even at concentrations leading to inhibition of neurite regeneration.
In summary, both clinical and epidemiological data support the association of 
NRTIs, mainly dideoxynucleosides, and the development of PN. In addition, 
some in vitro and in vivo studies have demonstrated mitochondrial impairment 
in patients exposed to dideoxynucleosides.
Assessing ADR in clinical trials is an approach which can generate important 
information regarding associated clinical and epidemiological factors. 
However, clinical trials of HIV therapy have been mostly focussed on efficacy 
rather than safety. Therefore, ADR are usually poorly reported (see section 
3.3.3). Nevertheless, clinical trials are considered as the gold standard to 
assess almost any question in clinical medicine, including those related to 
safety issues (Bisson etal. 2003).
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3.3 Delta trial: description and justification
3.3.1 Delta trial
Delta was a large, randomised, double blind, international clinical trial aiming 
to compare monotherapy against dual combination therapy in HIV-infected 
individuals (1996). Patients enrolled in Delta were randomised to receive AZT 
alone or in combination with either ddl or ddC. Patients included in Delta were 
ART-naTve (Delta 1) or patients previously exposed to AZT (Delta 2). All 
patients were treated with AZT at 600 mg/day (200 mg three times a day). 
Those patients randomised to receive ddl were given 400 mg/day (200 mg 
twice a day), whereas those to be treated with ddC received 2.25 mg/day 
(0.75 mg three times a day) in addition to their AZT therapy.
Delta was designed with primary endpoints of mortality and AIDS defining 
illnesses. Nevertheless, safety was also considered and serious adverse 
events were also defined as secondary endpoints. In that context, peripheral 
neuropathy was included in the list of expected adverse events and the 
frequency of PN grade 2 or worse (Table 3.2) was included in the original 
report published in 1996. Therefore one could expect that PN would be 
reported consistently through the study period.
A total of 3,207 HIV-infected individuals older than 15 years were recruited for 
Delta. Overall, 85 % of the participants were male and the mean of age at 
entry was 36.5 years (SD = 9.3). About 50 % of the study population had 200 
or less CD4 cells/pl at entry. The median follow-up was 30 months whereas 
the total follow-up in the study was 7,638 person-years.
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3.3.2 Study on peripheral neuropathy in Delta
W e performed a sub-analysis of the Delta trial (1996) to further understand the 
nature of NRTI-associated PN. In particular, the objective of our study was to 
assess whether the Delta data on PN supported or refuted the hypothesis that 
NRTI-associated PN, as a marker of NRTI-induced mitochondrial dysfunction, 
is a cumulative toxic process. In addition, the sub-analysis was also 
addressed to compare the effects of ddl and ddC.
According to the Delta protocol, assessment of each participant was carried 
out 4-weekly until week 24 after trial entry and 8-weekly subsequently. At each 
visit, the case record form elicited whether the patient had developed PN and, 
if so, the grade of severity on a 4-point scale (Table 3.2). The diagnosis and 
subsequent classification of PN was primarily based on symptoms suggestive 
of that condition.
Previous PN was an exclusion criterion for Delta, so none of the included 
participants in either Delta 1 or 2 had had episodes of PN before being 
exposed to the study drugs. Regarding other ADR, patients included in Delta 2 
should have been exposed to AZT for at least three months before their 
enrolment in Delta and they should not have developed any major ADR during 
that previous exposure to AZT to become eligible.
3.3.3 Justification of the sub-analysis
During the first two decades of the HIV epidemic, the main priority in clinical 
research was to identify therapeutic approaches to treat HIV disease as 
effectively as possible. Clinical trials therefore have been designed focussing 
mainly on efficacy rather than safety. In addition, because of the relatively 
short duration of follow-up in more recent trials, they are not suitable for 
assessing ADR over the longer term. In fact, only 50 % of the clinical trials on
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ART published before 1997 and no more than 15 % of those trials published 
between 1998 and 2001 presented results after week 48 of follow-up 
(loannidis & Lau 2001). In this context, observational studies may provide the 
next best level of evidence for longer-term adverse events (Bisson et al. 
2003).
Nevertheless, HIV-infected individuals are frequently exposed to multiple 
treatments mainly because combination therapy is the standard of care for 
HIV disease control and multiple co-morbidities exist. Clinical trials in which 
randomisation allows blinded administration of pre-determ ined drug 
combinations to two or more comparable groups are a valuable source of 
information on ADR (Bisson etal. 2003).
Finally, it has been proposed that the “intention to treat, missing equals failure” 
(ITT) approach, which is the standard for analysing clinical trials data, might 
overestimate the tolerability of the drug being tested. ITT analysis usually 
does not consider changes in the backbone of a given HAART combination 
neither does it take into account the possibility of patients receiving additional 
treatment for ART-associated ADR (Carr 2002). Therefore, for clinical trials to 
address safety questions they must record all relevant information regarding 
ADR, even if such events do not result in stopping or switching the study 
medication. It has also been proposed that time-to-event analysis of safety 
data, through Kaplan Meier plots for instance, might help in adjusting for 
changes over time in the number of individuals at risk of developing any ADR. 
In addition, statistical methods such as multivariate Cox regression models 
might be valuable in adjusting the analysis of risk for a given ADR by potential 
confounding variables (Bisson etal. 2003).
In summary therefore the Delta trial might be considered as an ideal resource
to study aspects of NRTI-associated toxicities for a number of reasons. It was
a large randomised multi-centre clinical trial with a very long follow-up. In
addition, Delta was a double-blind trial so the diagnosis of any ADR was not
influenced by the knowledge of which drugs the patients were taking. Finally,
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a time-to-event analysis of such a long lasting trial might offer important 
information on ADR, particularly PN as it was included in the list of the 
expected ADR in Delta. Therefore, there was the opportunity for participant 
clinicians to report directly and in a standardised way the occurrence of PN.
3.4 Materials and methods
The primary outcome of this sub-analysis was time from trial entry to first 
diagnosis of PN, regardless of grade of severity. In this analysis, time was 
measured from the date of randomisation. All grades of severity were 
included to allow for the possibility that an initial low grade PN could progress 
to a higher grade PN and modification of treatment at the initial diagnosis 
might avoid progression to more severe toxicity (see section 3.5). The median 
time between randomisation and trial drug prescription was 14 days.
In Delta, there was a high rate of switching from the allocated regimen and 
data were therefore censored at first change in ART (with a 4-week lag period 
to allow for any residual drug effect), or at the end of follow-up. Kaplan-Meier 
methods were used to estimate the cumulative incidence of PN in each of the 
3 treatment arms. Nested parametric (exponential and Weibull) survival 
models were then fitted and likelihood ratio tests used to assess whether the 
incidence of PN over time was constant. In addition, the effect of the allocated 
drug regimen on the risk of developing PN using a multivariable Cox model 
was also assessed, adjusting for updated (most recent) CD4 lymphocyte 
count, sex, and age at randomisation.
If the association of NRTIs with PN was independent of the effect of HIV on 
peripheral nerves, one could hypothesise that associations between drug 
regimen and the risk of PN could be more marked at higher CD4 counts due 
to a lesser influence of HIV-associated PN. This was investigated by refitting
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the multivariable Cox model and including an interaction term between CD4 
lymphocyte count (categorised) and allocated drug regimen.
3.5 Results
Of the 3,207 participants recruited in Delta, 12 individuals were excluded from 
the present analysis (9 never started their allocated treatment regimen, and 3 
had no anti-retroviral treatment information recorded). The remaining 3,195 
participants had the following baseline characteristics: 1,079 (34 %) were 
previously treated with AZT for a median duration of 17 months (2 -  72), 85%  
were male, mean age 36.5 years (SD = 9.3), mean CD4 lymphocyte count 
205 cells/mm3 (SD = 114), and 13 % had a previous diagnosis of an AIDS 
defining illnesses.
After initial randomisation, 1,051 patients were allocated to receive AZT 
monotherapy whereas 1,076 individuals were randomised to receive dual 
therapy with AZT and ddl, and 1,068 participants to have dual therapy with 
AZT and ddC.
Table 3.2 Grade of severity of PN and indication for changing anti-retroviral therapy
Grade Definition Resulted in change of therapy
No Yes Net known
Total (%)
1 Mild symptoms*, 
no treatment required
55 37 18 110 (62)
2 Moderate symptoms, 
analgesia required
5 36 5 46 (26)
3 Severe symptoms, 
narcotic analgesia required
0 7 0 7 (4 )
4 Intolerable discomfort, unable 
to walk despite narcotic analgesia
0 0 0 0 (0 )
Not known 9 4 1 14(8)
Total (%) 69 (39) 84 (47) 24 (14) 177(100)
* Symptoms: Paresthesiae, pain or numbness
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Incidence estimates are based on a total of 4,593 person-years follow-up, a 
median of 15 months (inter-quartile range -IQ R -=  6-28 months) per individual. 
Overall, 177 initial diagnoses of PN were recorded (Table 3.2), which 
represent an incidence of 38.5 cases per 1,000 person-years (Table 3.3). 
These diagnoses were most commonly grade 1 (110, 62%) or grade 2 (46, 
26%), of which 37 (34%) and 36 (78%) respectively resulted in a modification 
of ART. All seven cases of grade 3 PN led to ART modification and 
interestingly, there was no cases of PN grade 4 recorded in Delta. In addition, 
47 out of 177 (27%) patients with PN had one or more subsequent diagnoses 
of PN after their initial diagnosis.
Table 3.3 Incidence of Peripheral Neuropathy by Study Arms
Study Arm N Events P-years Incidence
(per 1000 p-years)
95 % Cl
AZT 1,051 46 1,516 30.3 22.7 - 40.5
AZT/ddl 1,076 33 1,497 22.0 15.7-31.0
AZT/ddC 1,068 98 1,579 62.1 50.9 - 75.7
TOTAL 3,195 177 4,593 38.5 33.3 - 44.7
Stratifying results by drug regimen received (Table 3.3), PN incidence was 
substantially higher in patients taking AZT/ddC compared with those on AZT 
monotherapy (62.1 versus 30.3 cases respectively per 1,000 person-years). 
By contrast, PN incidence in the AZT/ddl group was slightly lower than that 
observed among patients on AZT alone (22.0 versus 30.3 cases respectively 
per 1,000 person-years). However, because confidence intervals overlap the 
apparent difference between patients treated with AZT monotherapy and 
AZT/ddl combination may not be real.
In a time-to-event analysis, the incidence of PN appeared to be approximately 
constant over time for all three study arms (Fig. 3.1). This visual impression 
was confirmed by significance testing using nested parametric survival models 
(P = 0.43, 0.27 and 0.19 in the AZT, AZT/ddl and AZT/ddC arms respectively).
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Broadly similar results were found in analyses limited to PN diagnoses of 
grade 2 or higher (results not shown).
Multivariable Cox models were fitted to assess the extent to which 
comparative differences between drug regimens were mediated by their 
immunological effects and to explore other risk factors (Table 3.4). After 
adjusting for current CD4 count, age at randomisation, and sex, the hazard of 
developing PN was 2.30 times higher in those patients taking AZT/ddC 
compared with those on AZT monotherapy (95% Cl = 1.62 -  3.28, p<0.0001).
Figure 3.1 -  Survival to a PN diagnosis by treatment arm
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There was no significant difference in the risk of developing PN in patients 
taking AZT/ddl when compared with patients on AZT alone (RR = 0.80, 95%
Cl = 0.51 -  1.26, p = 0.34) (Table 3.4). It is important to notice that 23 
individuals were excluded from this part of the analysis as no data on CD4 
count were available.
After adjusting for other factors, a low CD4 count and older age were both
strongly associated with an increased risk of PN (Table 3.4). Individuals with a
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CD4 count of <150 cells/mm3 had a relative risk of developing PN of 2.27 
compared with those with CD4 >350 cells/mm3 (95% Cl 1.55-3.34). Patients 
entering the trial aged 35 years or over had a greater than 2-fold risk of PN 
compared with younger individuals, but there was no evidence of an effect of 
gender.
Table 3.4 Relative risk for Peripheral Neuropathy 
(Cox regression model)
Variable RH 95 % Cl
Allocated regimen
AZT 1.00
AZT / ddl 0.80 0.51 - 3.28
AZT / ddC 2.30 1 .6 2 -3 .2 8
Gender
Male 1.00
Female 1.15 0.72 - 1.83
Age at randomisation (years)
< 3 0 1.00
3 0 - 3 4 1.13 0 .65 -1 .94
3 5 - 4 4 2.35 1 .46-3 .80
45 + 2.47 1.49-4.11
Current CD4 group
0 -149 2.27 1 .55 -3 .34
1 5 0 -3 4 9 0.99 0 .66 -1 .50
350 + 1.00
An interaction term between CD4 group and treatment arm was added to the 
model to examine whether the risk of developing PN in patients exposed to 
either of the study drug combinations was affected by the current (most 
recent) count of CD4 lymphocytes. The intention behind this was to assess 
whether CD4 count was an effect modifier for the association between study 
drug exposure and the risk of developing PN. However, this indicated that the 
effect of NRTIs therapy on the risk of PN was similar across CD4 strata 
(Figure 3.2, P-interaction = 0.44), meaning no significant differences were
found in the association between study drugs exposure and the development 
of PN when controlled by the effect of CD4 count. Therefore, the increased 
risk of PN in patients taking AZT/ddC compared with those taking AZT alone 
was consistent in this analysis, regardless of their CD4 count. Similarly, the 
decreased risk of PN associated with AZT/ddl exposure was also consistent.
Figure 3.2 -  Effect of treatment arm on PN risk by CD4 level
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3.6 Discussion
In the present study participants who were both naive (Delta-1) and those with 
prior AZT exposure (Delta-2) were included to increase the power of the 
study. This was considered justifiable since AZT monotherapy has not been 
shown to be associated with an increased risk of PN in several placebo- 
controlled trials (1994;Hamilton et al. 1992; Volberding et al. 1990; Richman 
et al. 1987) and no patients in Delta had PN prior to entry.
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3.6.1 Evidence for cumulative toxicity
In this study, the incidence of PN was approximately constant over time for all 
three treatment groups. This observation does not support the concept of a 
cumulative toxic effect of NRTIs, where one could expect an increase in the 
incidence of the effect once the cumulative dose reaches a specific threshold. 
Kelleher et al. also failed to find any apparent association between the 
cumulative ddl dose and incidence of PN in early trials in which the doses 
used were higher than these currently in use in clinical practice (750 mg/d) 
and also higher than the doses used in Delta (Kelleher et al. 1999). Similarly, 
in a sub-analysis of the ACTG 175 study Simpson et al. present a Kaplan- 
Meier plot where the incidence of PN also appeared to be constant over time 
for all study groups (i.e. AZT, ddl, AZT/ddl and AZT/ddC) (Simpson et al.
1998). Of interest, the analysis of PN incidence over time included in 
Simpson’s study, which enrolled a smaller number of patients than Delta, 
included only cases of PN grade 2 or higher. Unfortunately, the precise 
estimation of follow-up was not reported in the paper, but it was mentioned 
that patients were followed for about three years. Nevertheless, authors of the 
last study did not comment on the pattern of incidence of PN over time, but 
the shape of the presented Kaplan-Meier plot is in agreement with our 
findings. On the contrary, a time to event analysis presented by Moore et al. 
comparing incidence of PN between patients exposed to ddl monotherapy, 
d4T monotherapy and a combination of these two NRTIs with or without 
hydroxyurea (HU), shows a different shape. Although incidence of PN in 
patients treated with either ddl or d4T monotherapy appear to be constant 
over time, it is not the case for patients exposed to ddl/d4T or 
ddl/d4T/Hydroxyurea combinations (Moore et al. 2000). Although the authors 
did not make any comments on it, from the Kaplan-Meier plot one could 
assume that the probability of developing PN rises abruptly after 10 or 20 
months of exposure to ddl/d4T/HU or ddl/d4T respectively.
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3.6.2 Incidence of PN by study arms
Our analysis found that the incidence of PN among patients exposed to the 
AZT/ddl combination was comparable to or slightly lower than the incidence 
among patients on AZT alone. In Simpson’s sub-analysis of the ACTG 175 
study, the incidence of PN among those exposed to AZT/ddl and AZT 
monotherapy was also shown not to be significantly different: 9 % of patients 
on AZT developed PN compared to 8 % among those on AZT/ddl. 
Nevertheless, even though this study included similar drug combinations to 
those used in Delta, the incidence of PN was slightly lower for all of the study 
arms (i.e. only 11 % of those patients on AZT/ddC developed PN), probably 
because the study population was different to the population included in Delta. 
Simpson’s study included mainly asymptomatic patients with CD4 counts 
between 200 and 500 cells/mm3 (Simpson et al. 1998).
In our study the incidence of PN of any grade was significantly higher in those 
patients exposed to AZT/ddC combination therapy compared with those 
individuals treated with AZT monotherapy, also in agreement with data 
presented by Simpson et al (Simpson et al. 1998). Nevertheless, Kelleher et 
al., combining data of four randomised phase ll/lll clinical trials, did not find 
any difference in the incidence of PN among patients taking ddl, AZT, AZT/ddl 
and AZT/ddC. However this observation might be confounded by the high 
dose of ddl used in the trials included in Kelleher’s review (600 -  750 mg/day) 
(Simpson et al. 1998; Keswani etal. 2002). Interestingly, a pilot study recently 
published showed that after 48 weeks none of the 24 treatment naive HIV- 
infected patients exposed to a combination therapy including AZT/ddC twice a 
day developed PN (Antunes et al. 2004). It is important to highlight that this 
small group of patients probably had a low risk of developing PN any way 
because all of them had CD4 lymphocyte count > 200 cells/mm3 and pre­
existing PN was an exclusion criterion for that study. In addition, patients 
enrolled in the Antunes study were also receiving a protease inhibitor and 
therefore they achieved a better immune response than patients included in 
Delta.
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In Delta, there was some evidence of better clinical response to AZT/ddl than 
to AZT/ddC. Patients on AZT/ddl had better survival, particularly among those 
with AIDS at entry in Delta 2 and a longer delay in developing AIDS defining 
clinical conditions in those without AIDS at entry in Delta 1 compared with 
similar patients taking AZT/ddC. Survival was also better among those treated 
with AZT/ddl compared with patients on AZT/ddC in Delta 1 (1996). ART may 
improve peripheral nerve sensory function in HIV-infected patients (Martin et 
al. 2000). Quantitative assessments of thermal perception thresholds were 
performed in a group of 49 HIV-infected individuals exposed to ART. The 
majority of those patients who responded to ART showed improved nerve 
function during the study period (P<0.05). Those patients, whose thermal 
perception returned to normal, had higher CD4 counts at entry. Furthermore, 
individuals with better immune function, induced by ART might be at lower risk 
of developing PN. One could speculate that in Delta, patients taking AZT/ddl 
had a lower incidence of PN not only because ddC is a stronger inducer of 
mitochondrial dysfunction than ddl (Martin et al. 1994), but also because 
patients taking AZT/ddl combination had a better immune response than 
those taking AZT/ddC.
In a cohort study including over 7,000 HIV-infected patients followed since 
1992, the incidence of PN was shown to be inversely correlated with the 
proportion of patients receiving HAART over time. After 1996, when HAART 
combinations were introduced, the incidence of PN has decreased steadily. 
Furthermore, although HAART combinations including drugs such as ddl and 
low dose (< 30 mg twice a day) d4T were associated with PN during the first 
year of treatment, after a year of exposure any treatment with these drugs 
became negatively associated with PN (Lichtenstein et al. 2005). The last 
observation suggests that after a lag period immune reconstitution and control 
of HIV replication induced by ART may reduce significantly the risk of 
developing PN, even when potential neurotoxic drugs are included in the 
HAART combination in use.
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PN was associated with both dose and duration of ddC and ddl treatment 
during the phase I clinical trials but not in the expanded access programs with 
ddl (Lambert et al. 1990; Schindzielorz et al. 1994; Yarchoan et al. 1988). In 
fact, patients enrolled in expanded access programs with ddl having a history 
of PN in the past were more likely to develop PN while exposed to ddl when 
compared with those patients without previous episodes of PN (P < 0.001) 
(Schindzielorz et al. 1994). In addition, patients included in both early clinical 
trials and expanded access programs for NRTIs were usually severely 
immunosuppressed and this might have implications in patients’ susceptibility 
for developing toxic effects to ART.
3.6.3 Other risk factors for PN
Severity of HIV disease, age and pre-existing neuropathies from any cause 
have been proposed as risk factors for NRTI-induced PN (Schifitto et al. 2002; 
Chaudhry et al. 2003). In almost all studies presented to date, patients with 
low CD4 lymphocyte count have been found to be at higher risk for the 
development PN compared with those with less advanced HIV disease (Childs 
et al. 1999; Schifitto et al. 2002). In this study we found that the risk for PN 
appears to increase markedly at CD4 counts below 150 cells/mm3. It has been 
proposed that NRTIs might be mild neurotoxins capable of unmasking sub- 
clinical HIV-induced peripheral nerve dysfunction. In a comprehensive review 
on PN Cherry et al. argued that NRTIs cannot induce PN in the absence of an 
HIV infection background or pre-existing peripheral nerve impairment of any 
cause (Cherry et al. 2003). According to the authors, the absence of reports of 
PN among individuals exposed to post-exposure prophylaxis (PEP) with 
dideoxynucleosides might support their point. Nevertheless, the duration of 
standard PEP regimens (four weeks) might be too short for any toxic effect on 
peripheral nerves to be expressed. However, in contexts other than HIV 
infection, toxic PN associated with some chemotherapeutic drugs such as 
taxol, vincristine and cisplatin has been proposed to be more aggressive in 
patients with pre-existing PN of any cause (Chaudhry etal. 2003).
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It has been proposed that HIV-1 envelope glyco-protein 120 (gp120) may 
induce neuropatic pain and pain hypersensitivity (Oh et al. 2001). In addition, 
inflammatory mediators, such as chemokines (e.g. TNF a produced by 
activated macrophages) can also induce peripheral nerve dysfunction. This 
process has been proposed to be Schwann cell mediated and this might 
explain the axonal degeneration pattern, which has been observed in cases of 
HIV-induced PN (Keswani et al. 2003). HIV-induced distal sensory 
polyneuropathy, even if sub-clinical, might be a necessary prerequisite for 
toxic PN associated with dideoxynucleosides.
In a recent large cohort study, HIV-infected patients older than 50 years were 
more likely to report PN than those individuals younger than 50 years 
(Zingmond et al. 2003). In this study it was found that individuals older than 
35 years were 2.35 times more likely to develop PN than individuals younger 
than 30 years, so the age effect may be broader than has been previously 
proposed. Age is also a risk factor for other causes of PN such as diabetes 
mellitus or alcohol abuse (Tapp et al. 2003; Ammendola et al. 2001). Finally, 
pre-existing PN has been associated with an increased risk of developing 
NRTI-associated PN. Even inherited conditions such as hereditary motor and 
sensory neuropathy or Leber’s optic neuropathy can be exacerbated by NRTIs 
exposure in HIV-infected patients (Miller et al. 2002; Shaikh et al. 2001; 
Luzhansky et al. 2001). In Delta pre-existing PN was an exclusion criterion, 
so in this context if previously HIV induced peripheral nerve dysfunction 
played a part in the development of NRTI-induced PN, this dysfunction had to 
be sub-clinical.
There was no association between gender and the risk for PN in our study, 
consistent with previous reports (Lopez et al. 2004). However, women appear 
to be at higher risk of developing other NRTI-associated adverse effects that 
are believed to be also due to mitochondrial toxicity such as lactic acidosis 
(Arenas-Pinto etal. 2003). Nevertheless, not only in Delta but also in the study 
published by Lopez et al. the proportion of female patients included was low
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(about 15 % for both). NRTI-induced mitochondrial dysfunction has been 
proposed to be organ and drug specific, so it is likely that even when the 
underlying mechanism is the same, other factors might be crucial in the 
development of any specific mitochondrial toxicity.
3.6.4 Limitations of this study
Studies on adverse events are usually based on severity scales designed for 
each complication, which have in common general important limitations. 
Grade three or four complications (the highest grades in most scales currently 
in use) do not necessarily predict clinical outcomes and might not have 
equivalent implications for ART continuation. For instance, nausea grade 
three normally results in some form of ART modification whereas grade three 
hypercholesterolemia usually does not imply any acute treatment intervention 
despite its potential implications for cardiovascular disease (Carr 2002).
Problems related to severity scales are more important when they are 
exclusively based on clinical information such as the PN gradation scale used 
in Delta. Furthermore, the assessment of PN-associated symptoms was made 
by local clinicians without any specialised neurological confirmation of the 
diagnosis made or involvement in its classification. A consistent degree of 
discordance between neurologists and HIV doctors regarding PN diagnosis or 
classification has been observed (Moore et al. 2000; Simpson et al. 1998). 
Similarly, physiologic studies on peripheral nerve conduction have 
demonstrated both the presence of peripheral nerve function impairment in 
the absence of any clinical symptoms suggestive of PN and normal function of 
peripheral nerves in patients complaining of neuropatic pain (Tagliati et al.
1999).
In summary, one must acknowledge the consequent limitations of the present 
study. Diagnosis and classification of PN in Delta was made based on a scale 
of severity including only information regarding symptoms. Furthermore,
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clinical signs such as ankle reflex or assessment of sensation were not 
recorded and no studies on peripheral nerve function were performed. In that 
context, the reported incidence of PN might not be completely accurate. 
Severity scales for PN which combine symptoms and signs with or without 
physiological peripheral nerve function tests might offer a more accurate 
classification of PN.
In addition, the study records show some variability regarding the 
classification of the PN diagnosed in a given patient. Some patients with 
diagnosis of PN were classified as having a high-grade complication at certain 
point in time and in following visits the classification of the impairment was 
reduced without switching ART. One possible explanation for this is the 
possibility of interventions other than analgesia being used to control 
symptoms, which would not have been recorded. However, we cannot rule out 
the possibility of changes in the severity classification as a consequence of a 
different clinician evaluating the patient in subsequent visits or changes in the 
patient’s perception of the severity of symptoms.
Nevertheless, despite the limitations described in the above paragraphs, 
results of this study are in agreement with previous studies which used more 
comprehensive case definitions and severity scales (Kelleher etal. 1999).
Neither monotherapy nor dual therapy with NRTIs is currently recommended 
to treat HIV-infected patients any more. However, as has been mentioned 
before, Delta might be considered as an important tool to assess 
dideoxynucleoside-associated ADR as it was a large clinical trial with a very 
long follow-up. In addition, NRTIs, some times including dideoxynucleosides, 
are currently included in most HAART combinations in use. However, PN has 
been shown to be significantly associated with the severity of HIV disease. 
Therefore patients included in Delta might have been more likely to develop 
PN than patients treated to day as Delta patients had more advanced HIV 
disease when starting ART and because they could not achieve the level of 
viral suppression patients on HAART can reach.
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3.6.5 Implications for the study on mitochondrial toxicity
PN is a common complication affecting HIV-infected patients and it may be 
associated with serious disability. Although PN might be induced by NRTIs, in 
a time to event analysis we did not find any evidence to support the 
hypothesis of cumulative toxicity. It has also been suggested that NRTI- 
associated ADR are tissue and drug specific and therefore, pharmacological 
variables such as drug penetration into specific cells and tissues might affect 
the likelihood of development of any specific complication after exposure to a 
given combination therapy including NRTIs.
As described earlier (see Chap. 2), HIV might affect mitochondrial function in 
treatment naive patients. Furthermore, ART might result in an improvement in 
mitochondrial function by controlling HIV replication even when 
dideoxynucleosides are used in combination with other anti-retrovirals to treat 
these patients (Miura et al. 2003; Casula et al. 2004). These observations 
have been made mainly in PBMC, but taken together with the evidence of 
peripheral nerve function improvement seen in patients with PN at the 
beginning of their ART, may suggest a similar positive effect of ART on 
mitochondrial function in other tissues. Nevertheless, in contrast to other 
proposed mitochondrial toxicities, clinically evident PN is a common condition 
in HIV-infected patients. Therefore, if the authors that suggest NRTIs might be 
mild neurotoxins are right, one could speculate that PN is probably not the 
best model to assess NRTI-induced mitochondrial toxicity, particularly 
because of its strong dependency on HIV disease severity.
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CHAPTER 4
Systematic review on lactic acidosis in HIV-infected patients
In August 2001 a systematic review of published cases of lactic acidosis in 
HIV-infected patients was submitted in partial fulfilment as a requirement of 
the University of London for the award degree of Master of Science in 
Infection and Health in the Tropics. The project report submitted for the MSc 
degree also included a proposal for a case-control study on the subject and 
was conceived as the initial approach to develop a proper research plan for a 
PhD.
In this chapter I present a summary of what was previously submitted for my 
MSc followed by a subsequent analysis of the data collected and further 
preparatory work which was performed at the beginning of the PhD period 
prior to the final publication. For the analysis of potential risk factors 
associated with lactic acidosis, such as gender, NRTI exposure allowing for 
the examination of drug combinations and viral hepatitis co-infection, the 
original reports were revisited and additional information was collected after 
submission of the MSc dissertation. The database of the study was 
redesigned to allow further analysis and the study proforma was amended to 
be used in the case-control study described in chapters 5 to 7.
4.1 Lactic acidosis and hyperlactataemia
Lactic acidosis (LA) is one of the acid-base disorders included in the category 
of metabolic acidosis. It may be caused by either excessive production of 
lactate, diminished clearance capacity of blood lactate or a combination of 
these two mechanisms. LA has been classified into two different categories:
Type A is the most frequent form of LA and is caused by inadequate oxygen 
delivery, as in shock or cardiac arrest. The consequence of this condition is an
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increase in lactic acid production, but also a reduction in the liver clearance 
capacity because of reduced hepatic perfusion. Type A LA has been 
frequently seen among HIV-infected patients, especially associated with septic 
complications of opportunistic infections.
Type B LA is associated with processes in which tissue hypoxia can not be 
demonstrated and has been reported in patients with different types of cancer 
such as lymphoma and leukaemia but also in patients with severe liver failure.
This second type of LA has also been associated with drug-toxicity. Ethanol 
can produce an increase in the blood lactate level, but is only capable of 
inducing severe type B LA in the presence of previous hepatic dysfunction. 
However, other toxic products like salicylates have been identified as a cause 
of LA (Tantisiriwat etal. 2001).
4.1.1 LA and mitochondrial dysfunction
As has been mentioned before (see Chapter 2), most mitochondrial diseases 
induce LA. This has been seen not only in cases of primary but also in those 
patients with secondary mitochondrial impairment. Different mechanisms have 
been identified in the development of LA ranging from genetic alterations 
leading to aberrant respiratory chain peptides to increased oxidative stress 
inducing damage to both respiratory chain complexes and mtDNA. Chapter 2 
includes a comprehensive review of mechanisms leading to LA in 
mitochondrial impairment.
4.1.2 Lactic acidosis and hyperiactataemia in HIV-infected patients
Asymptomatic elevated blood lactate concentration has been proposed as a 
relatively frequent finding in HIV-infected individuals regardless of their 
exposure to NRTIs or any other ART medication (Vrouenraets et al. 2000). In 
fact, a study on biochemical abnormalities including 1,152 HIV-infected
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patients showed that 9 % of them had raised lactate levels (Datta et al. 2001). 
Nevertheless, it has been also demonstrated that the accuracy of the 
determination of blood lactate is strongly affected by the conditions under 
which blood samples are obtained and processed, suggesting that at least 
some mild to moderate cases of hyperiactataemia may be spurious (Andersen 
et al. 2003).
Nonetheless, almost all studies and case-series presented to date suggest 
that NRTIs, especially d4T, may be significantly associated with the 
development of severe LA (Tantisiriwat et al. 2001; John et al. 2001; Gerard et 
al. 2000). In a large study on symptomatic hyperiactataemia it was possible to 
identify an incidence rate of 0.8% per year of symptomatic cases among 
patients taking ART (Gerard et al. 2000). Interestingly, the incidence of LA 
increases to 1.2 % per year when only patients exposed to regimens including 
d4T were considered. However, long-term exposure to NRTIs has been 
proposed as an important factor for developing both hyperiactataemia (HL) 
and severe LA (ter Hofstede et al. 2000) and d4T has been showed as a 
marker of long exposure to NRTIs. In fact, Carr et al. have reported that most 
of their cases of LA were on d4T at the time of the event but had received AZT 
previously. Based on this, they suggested that additive toxicity might increase 
the risk of developing LA. In contrast John et al. established no difference in 
incidence of LA episodes between AZT-treated and AZT- naive individuals 
among patients taking d4T. In John’s study, the increased risk attributable to 
d4T was not confounded by the longer history of NRTIs use (Carr et al. 2000; 
John etal. 2001).
The association between HL and LA remain less clear. It has been suggested 
that symptomatic hyperiactataemia could be an early clinical evidence of 
progression to LA (Gerard et al. 2000). However, LA is reported as a rare 
complication whereas hyperiactataemia appears to be not an infrequent 
condition. John et al. reported only five cases of severe HL in 516 patients- 
years of routine lactate measurement (John et al. 2001). Nevertheless, of 
these five patients with blood lactate levels higher than 5 mmol/l only two were
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receiving ART at the time of the event and both of them developed LA and 
eventually died. The calculated incidence rate of NRTI-induced LA in the study 
presented by John et al. was 3.9 cases per 1000 person-years. Nevertheless, 
a previous study had reported an incidence rate of 1.3 cases per 1000 person- 
years but this just included exposed individuals (Fortgang et al. 1995). 
Discrepancies on the incidence of LA among HIV-infected individuals exposed 
to ART are more pronounced if other studies are also considered. For 
instance, Lonergan et al. reported 20.9 cases of symptomatic HL per 1000 
person-years on ART. The last study also found that seven out of 10 patients 
they identified with raised blood lactate levels actually had some evidence of 
metabolic acidosis (i.e. low blood bicarbonate or high anion-gap) (Lonergan et 
al. 2000).
The incidence of HL or LA may vary depending on the frequency of use of 
specific NRTIs more likely to induce such complications. However, one 
additional possible explanation for such discrepancies might be differences in 
the case definition used by the authors of each report. Unfortunately, there is 
not a universally accepted classification scale for disorders of lactate 
metabolism in HIV-infected individuals. Therefore, variations in the cut-off 
values used to make a diagnosis of HL or the inclusion of clinical data such as 
symptoms to define a case may make any comparison between studies 
impossible. In addition, the contribution of other conditions to the development 
of HL or LA has not been properly assessed. In fact, a study on HIV-infected 
patients admitted to hospital has reported a prevalence rate of HL about 3 %. 
Interestingly, the vast majority of these hyperlactataemic patients fulfilled the 
criteria for LA but most of them were septic at the time and only 15 % of these 
27 cases of LA had exposure to NRTIs as the most likely cause of the episode 
(Tantisiriwat et al. 2001). Additionally, in a more recent study all four patients 
who developed LA had concomitant infectious diseases (i.e. respiratory or 
urinary tract infections) at the time of the event (Moyle et al. 2002). In the last 
study, the incidence rate of severe HL (Lact > 5mmol/l) and LA was 7.3 and
3.2 per 1000 person-years on ART.
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Hepatic steatosis3has been frequently described in patients diagnosed with 
LA. In fact, since 1998 there have been frequent reports of cases of “Lactic 
Acidosis - Hepatic Steatosis Syndrome”. Hepatic steatosis associated with LA 
in HIV-infected patients has been described as predominantly macrovesicular, 
but mixed pattern and even microvesicular steatosis as a predominant feature 
have been reported not infrequently (Lonergan et al. 2000; Shaer & Rastegar 
2000). Interestingly, liver involvement is frequently seen in patients with 
severe LA, but not in patients with compensated hyperiactataemia.
Until the first half of 1999 the Food and Drug Administration (FDA), in the US, 
had received notification of about 60 cases of LA. All these cases were on 
dual NRTIs therapy, 69 % had hepatic steatosis and 50 % were obese 
(Revuelta 2000). Other reports have mentioned obesity as a frequent clinical 
observation in patients with LA (Lonergan et al. 2000; Stenzel & Carpenter
2000) but the biggest reviews published recently by Megarbone and 
Tantistiriwat did not include obesity in the list of clinical diagnoses more 
frequently seen in patients with LA (Tantisiriwat et al. 2001; Megarbane et al.
1999).
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of 
abnormal liver function test (LFT) results among adults (Day 2002; Angulo 
2002) affecting about 20 % of the general population in some settings (Falck- 
Ytter et al. 2001; McCullough 2002). Of interest, cases of NAFLD occur more 
frequently in female patients (65 -  83 %) with a high prevalence of obesity (60 
-  95 %) (Falck-Ytter et al. 2001). According to several case-series patients 
with LA are more likely to be women, be overweight and have previous or 
concurrent liver diseases such as viral hepatitis B or C.
Despite the lack of conclusive evidence, it is likely that because lactate 
metabolism is highly dependent on liver function, any severe impairment in 
liver function may facilitate the development of hyperiactataemia.
3 Hepatic steatosis: Slight to moderate enlargement of the liver due to a diffuse accumulation of neutral 
fat (triglycerides) in hepatocytes. (Isselbacher and Podolsky. Infiltrative and metabolic diseases affecting 
the liver. On Harrison's principles of Internal Medicine. 14th Edition. McGraw Hill, New York 1998. pp. 
1718.)
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Finally, a high case fatality rate (CFR) has been attributed to LA in the context 
of HIV infection, and in some published series the CFR is 100 %. However, 
most of these series include a small number of cases and delayed LA 
diagnosis. Stenzel and Carpenter in their review of complications of ART, 
suggest that CFR attributable to LA is around 60% (Stenzel & Carpenter
2000).
4.2 Systematic review on lactic acidosis in HIV-infected patients
LA has been identified as a life threatening complication associated with 
NRTIs therapy. As has been mentioned before, the CFR associated with LA 
has been shown as extraordinary high reaching 100 % in some small case- 
series. Nevertheless, conclusive information regarding this complication is 
lacking.
4.2.1 Justification
Despite being considered as a serious complication, there is limited 
information regarding the risk factors for LA in HIV-infected patients treated 
with anti-retrovirals. Most of the available information regarding this issue has 
been presented in case reports or case-series. In fact, from 1991 to 30th June 
2001 there were 217 published cases of LA in medical and scientific indexed 
journals but 87 of them were presented as part of case series with aggregated 
data without sufficient individual data on potential risk factors. Additionally, 
another 40 cases were reported as part of cohort studies examining outcomes 
other than LA without individual description of cases.
The biggest case-series reported during that period of time included no more 
than 12 cases whereas the largest reviews of published cases before the one 
described in this thesis included no more than 60 cases. Interestingly, neither 
of these two reviews were designed to explore potential risk factors for LA but
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aimed to describe clinical presentation of the included patients and to 
determine factors associated with mortality (Falco et al. 2002; Megarbane et 
al. 1999).
Proper investigation of risk factors associated with any ADR requires an 
appropriately designed study. Nevertheless, the appropriate design of such a 
study must be based on assumptions grounded in the best available level of 
information. Therefore, putting together all published clinical information might 
be the best starting point to assess risk factors for LA in HIV-infected patients.
4.2.2 Materials and methods
An exhaustive search strategy was adopted to identify all published cases of 
LA in HIV-infected patients exposed to ART. To do so, the following electronic 
databases were searched:
1. MEDLINE for the years 1982 -  2000 using the search terms lactic 
acid*, metabolic acid* and HIV infection.
2. AIDSLINE for the years 1982 -  2001 using the search terms lactic 
acidosis, lactic acidaemia, metabolic acidosis, metabolic acidaemia 
and hepatic steatosis.
3. Web of Science v 4.31.
4. The Cochrane Database of Systematic Reviews, Database of 
Abstracts of Reviews of Effectiveness and the Cochrane Clinical 
Trials register in the Cochrane Library, Issue 2, 2001. Oxford: 
Update software.
5. Cab abstracts database.
The abstracts of relevant conferences were reviewed as indexed references at 
AIDSLINE or by checking available abstract books of scientific or medical 
events. Additionally, all references cited in included papers were checked and 
included if pertinent. Selection of reports was not limited by publication source
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or language. In fact, three reports written in Spanish, two in French and one in 
Japanese were included in the review.
Cases were included if they were reported with enough individual description 
to be entered in the study database. The required individual data included 
some demographic variables such as age, gender, specific ART received at 
the time of the event and laboratory values indicating the acid-base 
metabolism impairment. Cases included in small case-series presented with 
aggregated data were not included. Patients younger than 16 years old were 
not included either.
LA was defined using standard criteria: pH < 7.35, serum bicarbonate < 20 
mmol/l, or anion-gap > 12 mmol/l in the presence of blood lactate levels > 1.2 
mmol/l. In absence of specific numeric data, patients were included as cases if 
they were defined as “LA cases” by the author of the original report. Patients 
with diagnosis of clinical conditions potentially leading to LA such as sepsis or 
alcohol intoxication were excluded, as these were exclusion criteria for most of 
the original reports.
Duplicate cases were detected by matching variables such as name of the 
author, hospital where the patient were admitted. Specific variables related to 
each patient were also matched looking for duplicate cases; these variables 
include age, sex and date of the LA episode when available.
Relevant information was extracted from each original report using a 
standardised proforma, which was specifically designed for this review. Data 
collected were transcribed into a database designed in Access® and 
subsequently analysed using Stata® version 6. Continuous variables were 
summarised using the mean and standard deviation if normally distributed or 
median and range (or inter-quartile range) if not. For categorical data, 
variables were presented as proportions.
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4.2.3 Summary of the data presented as MSc dissertation
A total of 90 cases with a mean age of 40.11 years (SD=10.38) were included 
in the review. Of note, 53 % of the cases were female and 6.4 % of them were 
pregnant at the time of the event. All pregnant women developed the episode 
of LA during their last trimester of pregnancy.
Information regarding nutritional status was reported in 26 cases of whom 17 
(65.4 %) were overweight at the time of the event. Nine out of the 17 
overweight patients were female, so there was no gender difference in the 
presence of overweight (P = 0.97).
HIV disease status was not described in 27 cases. Nevertheless, 44/63 
patients were reported as fulfilling the criteria for an AIDS diagnosis according 
to the CDC classification. The median nadir CD4 count was 145 cell/pl (IQR = 
40 to 210 cell/pl) among the 29 cases in whom these data were reported. 
Furthermore, CD4 count at the time of the LA event was reported in 46 cases 
and its median was 231.5 cell/pl (IQR = 129 to 450 cell/pl).
Eleven cases had previous hepatic diseases of which 65 % had viral hepatitis. 
In addition, seven cases had abnormal results in liver function tests (LFT) 
before the LA event according to original reports. Hyperlipidemia was reported 
only in one patient before the event.
Fig. 4.1 Patients on NRTI therapy at the time of the 
LA event (N = 83)
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All 83 patients in whom ART was described at the time of the event were 
taking at least one NRTIs (Table 4.1). Almost 62 % of the patients were 
receiving d4T at the time of the event. The median duration of d4T exposure 
was 8 months (1 -  36 months). Twenty-nine patients (35 %) were taking AZT 
at the time of the event. The median duration of the AZT exposure before the 
event was 8 months (1 -  24). Of note, 26 out of the 29 patients on AZT were 
taking it as monotherapy whereas only two of the 51 patients taking d4T were 
doing so as monotherapy (Fig. 4.1). Similarly, only two out of the 27 patients 
who were receiving ddl were taking it as monotherapy. Median duration of the 
treatment with ddl before the event was 8.5 months (3 -  48). Finally, 27 
patients were taking 3TC always in combination with at least one more NRTIs. 
The median exposure to 3TC before the event was also 8 months (1 -  18). 
Nevertheless, because of the lack of any comparison or control group, this 
descriptive analysis offers little conclusive evidence on possible association 
between ART exposure and LA.
Table 4.1 Anti-retroviral Therapy 
at the time of the LA event
(N = 83)
ART Cases %
Monotherapy 30
ZDV 26 87
ddl 2 7
d4T 2 7
2 Drugs therapy 16
ZDV + ddl 2 13
Z D V + d 4T 1 6
d4T + ddl 6 38
d4T + 3TC 7 44
3 or more drugs 37
d4T + ddl + 3TC 1 3
d4T + ddl + PI 12 32
d4T + 3TC + PI 12 32
d4T + ddl + Nev 4 11
d4T + 3TC + Nev 3 8
d4T + 3TC + Del 1 3
d4T + ddl + Efav 1 3
d4T + ddl + PI + Del 1 3
d4T + 3TC + PI + Nev 1 3
d4T + 2 PI 1 3
PI: protease inhibitors
Very few cases had their previous history of ART recorded. However 14 of the 
17 cases in whom previous exposure to ART was reported had received AZT 
whereas seven of them were treated with ddC. Furthermore, adverse effects 
related to ART were reported in 16/90 patients before the LA event: six cases 
of myelosupression, four of myopathy, four of peripheral neuropathy and one 
case of pancreatitis were reported. Lipodystrophy syndrome was reported as 
a previous complication in two patients.
Symptoms associated with the event of LA were described in 85 cases and 
only two cases were reported as asymptomatic. Non-specific gastrointestinal 
symptoms were the most frequently reported and more than 50 % of the 
cases had either nausea, vomiting or abdominal pain (Table 4.2). Symptoms 
classically associated with metabolic acidosis such as dyspnoea, tachypnoea 
and impairment of consciousness were less frequently described and usually 
were present in more severe cases.
Table 4.2 Symptoms Reported 
at the time of the LA event
Symptom Number of Cases
(N = 85)
Proportion
(%)
Nausea 45 53
Vomiting 44 52
Abdominal pain 38 45
Weight loss 19 22
Weakness 19 22
Dyspnoea 19 22
Anorexia 16 19
Tachypnoea 13 15
Diarrhoea 8 9
Fatigue 7 8
Abdominal distension 5 6
Impairment of consciousness 2 2
Other 8 9
The median level of blood lactate for the 79 cases in whom the value was 
recorded was 10.5 mmol/l (range 2.4 and 168.5 mmol/l) (Table 4.3). Arterial 
blood pH was reported in 52 patients ranging between 7.1 and 7.29 whereas
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median blood bicarbonate level was 8 mmol/l (IQR = 5 - 1 7 ) .  Anion-gap was 
reported in 32 patients with a median value of 25.5 mEq/l (10 -  42). Reported 
abnormalities in LFT and pancreatic enzymes are presented in table 4.4
Table 4.3 Acid-base status of the patients at the time of the event
Test Normal Range N Median IQR
Lactate (mmol/l) 0 .7 -  1.2 79 10.5 7 .0 -1 7 .3
pH 7.35 - 7.45 52 7.2 7.1 - 7.29
Bicarbonate (mmol/l) 2 4 -2 9 51 8 5.0 -17.0
Anion-gap (mEq/l) 8.0 - 12.0 32 25.5 1 8 .5 -3 1 .1 5
Images suggestive of fatty infiltration of the liver were reported in 13 out of the 
20 patients with abdominal ultrasound performed at the time of the event. 
Similarly, images suggestive of hepatic steatosis were described in 31 of the 
32 abdominal CT scan performed at the time of the event. Furthermore, 
histological evidence of hepatic steatosis was reported in 36 out of the 39 
patients who underwent either liver biopsy or autopsy. Microvesicular 
steatosis was reported in 31 % (8/39) of the tissue examinations whereas 41 
% (16/39) of the patients had mixed pattern hepatic steatosis. Twelve patients 
(31 %) had macrovesicular hepatic steatosis whereas the remaining three 
biopsies showed hepatic fibrosis and inflammation as their most important 
abnormality.
Table 4.4 Liver function test and pancreatic enzymesat 
at the time of the lactic acidosis ev ent
Test Times over upper Range
limit of normal *
Alkaline Phosphatase 1.5 1.04 -  6.6
Alanino aminotranferase 2.5 1.04 -  10.7
Aspartate aminotranferase 3.1 1.2 -  10
Lipase 11.6 1.6 -  787.5
Amylase 2 1 .2 -1 6 .9
* median of
A total of 43 patients had a fatal outcome, which represented 47.8 % of the
cases included in this study. Among the 46 non-fatal cases, the median follow-
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up was 3 months (0.24 -  30) after the event. In 13 of these cases (28.3%) 
ART was restarted. Among these patients exposed to a re-challenge with 
ART, 6 were put on regimens including NRTIs whereas the remaining 7 were 
challenged with regimens with anti-retroviral other than NRTIs.
4.2.4 Subsequent analysis of the data: the beginning of the work 
in the thesis period
A second review of the collected data was performed to extract the maximum 
level of information available regarding specific issues considered important in 
the process of generating hypothesis on risk factors for LA and to prepare the 
systematic review for publication. Additional analyses were performed to 
estimate more accurately the effect of some potential risk factors such as 
gender (see bellow).
It was considered important to know where the cases included in the review 
were diagnosed. It was noticed that reports from three countries accounted for 
83 % of the included cases; 56 (62 %) from the United States, 14 (16 %) from 
France and 5 (6 %) from The Netherlands.
Regarding the ART exposure at the time of the event, it was felt important to 
describe in more detail the proportion of patients on combination therapy. 
Thirty cases (36%) were on monotherapy regimens when LA was diagnosed, 
26 of them were on AZT. In addition, 16 (19%) were taking two ART drugs (a 
combination of NRTIs) and 37 (43%) were on combinations of three or more 
drugs, including either a protease inhibitor (PI) or NNRTIs, at the time of the 
LA event. One additional patient was taking 3 NRTIs.
Furthermore, no patient was on ABC or ddC at the time LA was diagnosed but 
among the 17 patients with previous ART regimens reported, 7 had received 
ddC. Thirteen of these 17 cases were on d4T at the time of the LA event, but 
all of them had received AZT therapy in the past.
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Patients on AZT at the time of the LA event had more advanced disease than 
those exposed to other NRTIs. The median CD4 cell count among patients on 
AZT was 79 cell/mm3 (range 18 -  406) (data from 10/29 cases) compared to
282.5 cell/mm3 (range 35 - 1321) (data from 36/61 cases) in those not on AZT.
Regarding past medical history described in 17 patients, who were reported 
as having had previous hepatic diseases, it was possible to determine that 11 
of these were viral hepatitis. Two patients had chronic hepatitis B (HBsAg 
positive), two hepatitis C (HCV RNA positive), four previous acute hepatitis B 
and one past hepatitis A. There was no specific information on the two other 
patients with a history of viral hepatitis. In addition, nine patients were reported 
as receiving concurrent treatment with potentially hepatotoxic drugs such as 
fluconazole, ketoconazole or isoniazid.
In 11 patients mitochondrial morphology or function were examined. In nine 
patients electron microscopy was performed on liver or muscle biopsies or 
both. In four who had only liver biopsies, enlargement, alteration of shape or 
increase mitochondrial density were reported (Carr et al. 2001; Charton-Bain 
et al. 1997; Khouri & Cushing 2000). In three patients who had muscle 
biopsies two showed similar mitochondrial ultra-structural changes (Gopinath 
et al. 1992; Sundar et al. 1997) and one was reported as normal (Shaer & 
Rastegar 2000). In one patient who had both a liver biopsy and muscle 
biopsy, the liver biopsy was abnormal but the muscle biopsy was normal. The 
remaining patient had a normal muscle biopsy (Olano etal. 1995).
Respiratory chain dysfunction was examined in only three cases using 
spectrophotometric determination of enzymatic complex activity. MtDNA 
depletion and particularly low levels of activity of complexes 2, 3 and 4 was 
reported in one case using muscle mitochondria (Roy et al. 1999). Two other 
patients with biochemical evidence of mitochondrial dysfunction were tested 
using hepatic mitochondria and had reduction of complexes 1 and 1, 3, 4 & 5 
respectively (Carr et al. 2001; Brivet et al. 2000). Finally, mtDNA depletion
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was reported in one other patient on muscle and liver biopsy but enzymatic 
complexes were not examined (Chariot etal. 1999).
Regarding the outcome of included cases, in 13/46 (28.3%) non fatal cases it 
was stated that ART was restarted. NRTIs was used in six of these patients, 
but the exact duration of follow-up was reported only in three of these six. 
Three of six patients re-challenged with NRTIs had further episodes of LA. 
Two were females. One male and one female were challenged with AZT as 
monotherapy; both developed a further episode of LA but no other adverse 
effect attributable to NRTIs (Coyle & Abel 1993; Freiman et al. 1993). The 
other female patient was re-challenged with a regimen that was not specified. 
An additional female patient was re-treated with a combination of 3TC and 
nelfinavir and followed for 26 months, with no further LA or other adverse 
event (Shaer & Rastegar 2000). One male patient who developed LA on a 
combination of d4T and ddl did not resume ART. However, 22 months after 
discontinuation he developed fatal portal hypertension, liver failure and 
hepatic mitochondrial dysfunction with normal serum lactate (Carr et al. 2001).
4.2.5 Study limitations
Although this is the largest review of published cases of LA to date, it includes 
only 90 cases and therefore, robust conclusions about the possible risk factors 
associated with LA are not possible. In addition, it was based on original 
reports either published in international scientific or medical journals or 
presented in scientific meetings. Consequently, the review is affected by the 
expected differences in quality among different reports. Furthermore, it is also 
affected by the limitations of any retrospective analysis, where missing data is 
a constant problem, particularly in exercises like this where included cases 
have been diagnosed over a relatively long period of time. The level of 
description of cases varied. More recent cases were described in more detail 
as the level awareness of clinicians was increased by early reports.
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Additionally, as the standard care of HIV disease has dramatically changed 
over a relatively short period of time since the introduction of ART, patients 
diagnosed at the beginning of the therapeutic era might have been exposed to 
a different risk factor profile than those who started ART more recently. 
Patients treated with monotherapy during the late 80’s or the first part of the 
90’s were usually more severely affected by HIV disease and were also less 
likely to achieve significant and long-lasting viral suppression when compared 
to patients treated with HAART combinations. This might be particularly 
important when analysing potential risk factors for NRTI-associated 
mitochondrial toxicities as it has been demonstrated that HIV itself might affect 
mitochondrial function (see Chap. 2). Furthermore, advanced HIV disease has 
been described as an independent risk factor for some NRTI-induced ADR, 
including peripheral neuropathy (see Chap. 3).
The data included in this systematic review on lactic acidosis was extracted 
from the original published reports by the principal investigator. The data was 
entered twice to the database to check for consistency. However, there was 
not any independent verification of the literature reports.
Nonetheless, the results do add some weight to proposed risk factors from the 
individual case reports, case series and other smaller reviews. Megarbane et 
al. described 40 cases published during the 90’s accompanied by a literature 
review of possible causes (Megarbane et al. 1999). Falco et al. reviewed 60 
cases, and performed a multivariate analysis of possible prognostic factors for 
mortality (Falco et al. 2002). Neither of these reviews aimed to identify risk 
factors for LA and their literature review strategies were not described.
Finally, our systematic review of published cases was performed to generate 
hypotheses on potential risk factors for LA. It also aimed to offer the strongest 
possible grounds for designing a case-control study on this subject.
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4.3 Discussion
LA has been recognised as a potentially life threatening complication in HIV- 
infected patients exposed to ART since the beginning of the 90’s. It has been 
proposed that LA is a relatively infrequent condition (see Chap. 2), but it has 
been associated with a high mortality. Previous reviewers have reported high 
CFR associated with LA, of around 60 % (Megarbane et al. 1999; Stenzel & 
Carpenter 2000), but in a more recent study it was 33 % (Falco et al. 2002). In 
our review CFR was 48 % overall. In the first 45 cases, published between 
1991 and 1999, the CFR was 64 %. In contrast, for the second 45 cases, 
published between 2000 and June 2001, it was 33%.
The last paragraph highlights two important issues regarding the complication 
being studied. Fifty percent of the cases included in this review were 
published over a period of nine years whereas the second half of cases, the 
most recent ones, were reported just over a period of 18 months. The lower 
CFR among more recently published cases might be due to a higher level of 
awareness among clinicians about LA and earlier identification of cases. 
Similarly, the increasing level of awareness among clinicians might have 
encouraged practitioners to report the cases they saw. It is also possible that 
physicians were more likely to report fatal cases than those who recovered 
from the event.
4.3.1 Clinical presentation of patients with lactic acidosis
This review highlights that a common presentation of LA is with non-specific
gastrointestinal symptoms. Abdominal pain, nausea and vomiting are present
in around 50 % of the affected patients (Table 4.2). Of note, similar symptoms
have been described in cases of mild to moderate symptomatic
hyperiactataemia even in the absence of acidosis. Some authors have
suggested that symptomatic hyperiactataemia may be the early and very often
non-fatal form of the lactic acidosis-hepatic steatosis syndrome (Penzak &
Chuck 2000; Giaquinto et al. 2001). Nevertheless, non-specific
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gastrointestinal symptoms are quite frequently seen in HIV-infected individuals 
and therefore a high level of suspicion is required if an early diagnosis of LA is 
to be made.
In contrast with the moderate evidence of impairment of liver function 
observed in these patients, hepatomegaly and hepatic steatosis have been 
consistently reported in patients with LA. Among 90 % of the patients included 
in this review in whom abdominal imaging studies were carried out, suggestive 
evidence of liver fatty infiltration was found. Additionally, 36/39 histology 
examinations showed hepatic steatosis as a predominant feature. Data from 
this review suggest that macrovesicular steatosis, even in a mixed 
presentation (i.e. macro and microvesicular steatosis patterns), might be the 
most important histopathologic finding associated with LA in HIV-infected 
patients. Another important characteristic is how uncommon the presence of 
fibrosis or necrosis are in the liver biopsies or autopsy specimens.
Microvesicular steatosis has been associated with drug toxicity, acute liver 
failure of pregnancy, pancreatic disease, Kwashiorkor and Reye’s syndrome 
(Freiman et al. 1993; Sundar et al. 1997). Furthermore, microvesicular 
steatosis is the pattern most frequently seen in patients affected by 
genetically-induced mitochondrial disorders (Chariot et al. 1993). In contrast 
macrovesicular steatosis is more frequently seen in patients with diabetes, 
alcohol abuse and steroid therapy. Macrovesicular steatosis is generally 
associated with low rate of progression to liver failure, but in cases associated 
with NRTIs the progression to hepatic failure is not infrequent (Sundar et al. 
1997).
4.3.2 Risk factors for lactic acidosis
LA has been associated with some potential risk factors, but these factors
have not been consistently supported by all studies. The case is similar for
gender. Some authors have proposed that LA could be more frequently seen
in women than in men (Miller et al. 2000; Olano et al. 1995). However, the
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analysis of our series with 90 cases suggests that there may not be a gender 
difference. 52.8 % of the affected patients were female and the male/female 
ratio was 0.89. This observation must be analysed with caution since the 
included cases are from Western Europe, Australia and US. In fact, 83 % of 
the cases were diagnosed in the US, France and the Netherlands, where the 
vast majority of the HIV-infected people are male, so similarities in the 
absolute number of affected women and men could represent a relatively 
higher proportion of affected women.
Using data on the numbers of HIV-infected individuals receiving care in the 
US (Bozzette et al. 1998), we made a very approximate estimate of the 
denominator of patients receiving ART, from the estimated number of patients 
with less than 500 CD4 cell/mm3. Of the total of 209,756 patients likely to be 
exposed to ART, 44,892 (21 %) were female. Assuming no gender bias in 
publication of cases, if there were no association between gender and LA, 
among the 56 USA cases, the expected number of females would be 11, but 
the observed number was 30. These data suggest that the risk of developing 
LA could be 2.5 times higher in women than in men (Table 4.5).
Although age has also been suggested as a risk factor for LA, cases of LA 
have been reported affecting patients of all age groups, including neonates 
exposed to prophylactic ART (Scalfaro et al. 1998; Blanche et al. 1999). Carr 
et al. suggested that older patients are more susceptible to develop LA 
complications and ter Hofstede proposed that this predisposition could be 
related longer exposure to ART (Carr et al. 2000; ter Hofstede et al. 2000). 
However, in our study considering only episodes diagnosed in adults, the 
range of the age in patients affected by LA is very wide ( 1 6 - 6 9  years of age) 
and no clusters at any age group could be identified. This would suggest that 
age might not be an important factor associated with LA.
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Table 4.5 Relative Risk of developing Lactic Acidosis by sex
Number of Pts* Pts at risk** 
(CD4 < 500)
LA cases 
observed
LA cases 
expected***
RR
Female 52,200 44,892 30 12 2.5
Male 179,200 164,864 26 44
Total 231,400 209,756 56
* From: Bozzette SA et al. The Care of HIV-infected Adults in the United States 
N Engl J Med 1998;339 (26): 1897-1904 
** CD4 < 500 cell/ul (assumed as more likely of receive ART)
*** if risk of LA were the same for men and women
Determining associations between ART exposure and the risk of developing 
episodes of any ADR is complicated. Firstly, combination therapy is not 
randomly allocated and secondly patients switch treatments and have long 
ART exposure histories, which are often poorly recorded. It is therefore 
difficult to estimate the contribution of individual drugs to a specific toxicity 
particularly if the event is the result of cumulative exposure to a drug class 
rather than any individual drug exposure. Nevertheless, a background of HIV 
infection is not required for NRTIs to produce LA, as there are reports of LA in 
HIV-negative neonates exposed to prophylactic AZT (Scalfaro et al. 1998; 
Blanche etal. 1999).
AZT-associated LA events were reported mainly during the monotherapy era 
(Megarbane et al. 1999). In our series, 90 % of those cases on AZT at the 
time of the LA episode were taking it as monotherapy. The cases of LA 
associated with AZT therapy had more advanced disease compared with 
patients exposed to NRTIs other than AZT. Additionally, the CFR among AZT- 
treated patients was 68 %, compared with 37 % for patients not exposed to 
AZT. These differences probably reflect the use of AZT monotherapy in 
patients with more advanced HIV disease in the late 80’s and early 90’s as 
well as the low efficacy of monotherapy compared to combination therapies.
The association between d4T use and hyperiactataemia or LA has been 
highlighted in previous studies (Brivet et al. 2000; Lenzo et al. 1997). For
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instance, Gerard et al. reported a significant increase in the incidence rate of 
symptomatic hyperiactataemia in patients taking d4T in comparison with 
patients on other NRTIs from 0.8% to 1.2 % per year (Gerard et al. 2000). 
However, 51 of the 53 patients on d4T in our review were taking it as part of 
combination therapy, which included at least one additional NRTIs. 
Furthermore, 24 patients were taking d4T in combination with ddl which, in 
contrast with 3TC (the other drug associated with d4T), has been implicated 
as a cause of LA in several reports and has been shown to be an inducer of 
mitochondrial toxicity in in-vitro studies (Lai et al. 1991; Bissuel et al. 1994). 
Cumulative toxicity has been proposed as a risk factor for mitochondrial 
toxicity and therefore total duration of exposure to NRTIs could be important 
(ter Hofstede et al. 2000). The median duration of NRTIs exposure of patients 
included in our review was 8 months, but in most cases this period refers to 
the regimen on which LA occurred and not the total time exposed to NRTIs. If 
cumulative toxicity is relevant some of the association of LA with d4T might be 
confounded by a long duration of NRTIs exposure. Previous ART regimens 
were reported in only 13 of the 52 patients on d4T and all of them had a prior 
history of AZT use. Similarly, Carr et al. found that an important proportion of 
patients on d4T had received previous treatment with AZT (Carr et al. 2000). 
By contrast, John et al. reported that the association between d4T and 
hyperiactataemia was not confounded by previous treatment with AZT (John 
et al. 2001). The contribution of other NRTIs to the development of LA events 
is difficult to evaluate because the majority of patients taking ddl or 3TC (92 
%) were also taking d4T as it was previously mentioned. Lonergan et al. have 
reported improvements in both laboratory abnormalities and clinical symptoms 
when d4T was replaced by either ABC or AZT in symptomatic patients with 
hyperiactataemia (Lonergan etal. 2004).
An additive toxic effect between NRTIs and other hepatotoxic drugs may 
affect the likelihood of developing LA. Olano et al. have suggested that the 
combination of AZT with fluconazole may be a better inductor of LA than AZT 
alone (Olano et al. 1995). In our review nine patients were reported as being 
concomitantly exposed to fluconazole, ketoconazole or isoniazid. The role of
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these drugs has not been evaluated yet, but is not possible to exclude their 
contribution to the development of LA even though only a small proportion of 
the patients were using these
Special susceptibility has also been proposed. In this context, it has been 
proposed that sub-clinical mitochondrial disorders can be unmasked by an 
NRTIs toxic effect. According to this rationale, previous complications 
attributable to mitochondrial toxicity could be a good predictor of LA (ter 
Hofstede et al. 2000). In this review, previous adverse events related to ART 
were reported in only 16/90 cases but all them may be attributable to an 
NRTIs induced mitochondrial toxicity. Nevertheless, from the data collected in 
our review, no firm conclusions can be reached regarding this topic.
Previous reviewers have reported high CFR associated with LA, of around 60 
% (Megarbane et al. 1999; Stenzel & Carpenter 2000), but in a more recent 
study it was 33 % (Falco et al. 2002). In our review the CFR was 48 % overall. 
In the first 45 cases, published between 1991 and 1999, the CFR was 64 %. 
In contrast, for the second 45 cases, published between 2000 and June 2001, 
it was 33%. The lower CFR among more recently published cases might be 
due to a higher level of awareness among clinicians about LA and earlier 
identification of cases.
4.3.3 Evidence of mitochondrial dysfunction
In this review, only a small number of cases had investigation of mitochondrial
morphology or function. At least 43 studies have shown evidence of NRTI-
related mitochondrial toxicity in vitro, and in animal models (Kakuda 2000). As
has been described before (see Chap. 2), the proposed mechanism for LA is
inhibition of mtDNA polymerase y leading to mtDNA depletion. However,
Walker et al. showed that AZT and the combination AZT/3TC can produce
raised lactate levels and cell death without a reduction in or deletions of
mtDNA in an in vitro study (White 2001). In addition, Bartley et al. have
reported multiple hepatic mtDNA deletions in a patient with LA (Bartley et al.
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2001) and recently a case of LA with marked reduction in respiratory chain 
enzyme activity but not mtDNA depletion has been published. Finally, as has 
also mentioned in Chapter 2, direct NRTI-induced toxicity on the respiratory 
chain has also been proposed (Miller etal. 2003; Masini etal. 1999).
In this review both mtDNA depletion and respiratory chain impairment were 
described in patients presenting with LA. Nevertheless, because of the small 
number of cases with mitochondrial studies it is difficult to make any 
conclusion about the mechanisms involved. Nevertheless, it is clear that all 
patients had severe mitochondrial dysfunction at the time of their lactic 
acidosis.
Mitochondrial dysfunction would be expected to lead to an increase in 
endogenous lactate production. Leclercq et al., using an exogenous lactate 
challenge test in 11 symptomatic and 3 asymptomatic patients with 
hyperiactataemia, showed a marked increase in endogenous lactate 
production even in patients with a moderate increase in serum lactate 
(Leclercq et al. 2001). In addition, in the face of this over-production of 
lactate, factors which affect lactate clearance such as hepatic dysfunction 
might also be expected to contribute to hyperiactataemia and lactic acidosis 
(Brinkman 2000). Concomitant use of drugs such as ribavirin with other 
NRTIs, i.e. ddl, has also been proposed as a risk factor for the development of 
mitochondrial dysfunction leading to LA in patients with hepatic dysfunction 
caused by hepatitis C (Lafeuillade etal. 2001).
4.4 Implications of the performed review
4.4.1 Generating hypothesis
LA is likely to be an NRTI-related adverse effect, which affects female patients 
more frequently. Although it is difficult to evaluate the precise role of individual 
NRTIs drugs from case reports, it is possible that d4T, and probably also AZT, 
may be more likely to induce LA when compared with other NRTIs. These
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factors may be considered as the strongest hints the review shows in terms of 
risk factors for LA.
Since the clinical presentation of LA is frequently non-specific and because 
raised levels of lactate occur in asymptomatic patients, a standard case 
definition is required to assess risk factors and prognostic factors accurately. 
In this context, combined case definitions including both biochemical 
laboratory results and clinical data might be confusing as no correlation has 
been shown between severity and even presence of symptoms and the level 
of alteration in biochemical variables. A case definition of LA based 
exclusively on biochemical laboratory data offers at least two main 
advantages. Firstly it would be an objective definition and therefore not subject 
to any inter-observer variation and secondly would offer the possibility of 
making it comparable to other clinical entities i.e. cases of LA caused by 
causes other than NRTIs in populations other than HIV-infected individuals.
There are insufficient data to support the effect of other proposed risk factors 
for LA in this population. Nevertheless, it is possible that factors like 
concurrent liver impairment or genetic factors such as sub-clinical 
mitochondrial dysfunction play important roles in the likelihood of developing 
LA. Furthermore, additive drug toxicity in the setting of a specific sub-group of 
individuals such as co-infected patients with HIV and HCV exposed to both 
anti-HIV and anti-HCV therapy including ribavirin may be important (Fleischer 
etal. 2004).
No conclusive information is available on the subject of acid-base metabolism 
impairment in HIV-infected individuals. Studies are urgently needed to clarify 
issues such as the proposed progression from mild to moderate 
hyperiactataemia to severe and life threatening LA and to establish risk factors 
for that complication.
Hyperiactataemia (HL) and LA may be particularly relevant in the context of an 
increasing access to ART in resource limited settings, where laboratory
97
support for early diagnosis might be much weaker than in developed 
countries. In addition, combination therapies based on NRTIs likely to induce 
LA such as d4T have been increasingly used in developing countries as the 
first line suggestion of the World Health Organization (WHO) (World Health 
Organization 2003). In addition, a significant proportion of patients likely to 
receive ART in developing countries, particularly in Sub-Saharan Africa, are 
women and children and the information available on safety issues in these 
groups is very limited.
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CHAPTER 5
Development of the case-control study on lactic acidosis and 
severe hyperiactataemia in HIV-infected patients 
treated with anti-retroviral therapy
Following the systematic review of published cases of lactic acidosis in HIV- 
infected patients exposed to ART (see Chapter 4), a number of questions on 
risk factors for such a complication became evident. Many variables had been 
proposed as associated with LA, but conclusive evidence of these proposed 
associations were lacking for most of them.
As has been mentioned before, most of the available information regarding LA 
in this type of population has been derived from case reports or case-series, 
which by definition cannot provide definite information on risk factors for any 
suspected drug-induced complication. Therefore, it was critically important to 
design and perform studies addressed to identify risk factors for LA in HIV- 
infected patients.
5.1 Justification for a case-control study
LA has been described as an infrequent complication attributed to ART and 
therefore, identifying risk factors for that using any other epidemiological study 
design would be impractical. Case-control study design has been shown to be 
useful for studying rare or infrequent outcomes, and therefore has been used 
to investigate other rare but serious adverse drug reactions (ADR) (Strom 
2000). Case-control studies on the other hand have been described as not 
appropriate for rare exposures, unless exposure often leads to the outcome of 
interest. Nevertheless, this not the case of many drug adverse events and 
particularly is not the case for LA in this population as the complication has 
been associated with NRTIs exposure and this drug family is by far the most 
frequently used in the treatment of HIV infection.
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In addition, case-control studies allow the simultaneous assessment of 
multiple exposures that are potentially associated with the outcome of interest. 
As has been mentioned before (see chapter 4), several variables and 
exposures have been proposed as risk factors for this complication.
Furthermore, case-control study design is particularly convenient when the 
latency period between exposure and outcome is relatively long. This feature 
is particularly relevant to this study as there is not conclusive evidence of the 
relevance of long exposure to ART and the development of LA. It has been 
suggested, but not proven, that longer exposures are associated with higher 
risk for this and other ART-induced mitochondrial dysfunction among HIV- 
infected individuals (Brinkman etal. 1998). In addition, the case-control design 
may also be convenient to assess the relevance of total ART exposure rather 
than current drug exposure for the event to occur.
No temporal relationships between any exposure and the outcome can be 
derived from case-control studies. Therefore, no causality association can be 
demonstrated but the strength of an association between a specific exposure 
and the outcome can be estimated. Furthermore, associations confirmed in 
any case-control study between exposures or risk factors and the outcome are 
significant as hypothesis generating data. Furthermore, at least some 
exposures may be assumed to be certainly present before the outcome. This 
is particularly the case for studies assessing drug exposures as potential risk 
factors for acute and objectively defined outcomes.
Nevertheless, case-control studies have significant weaknesses which must 
be taken into account. Case-control studies are prone to bias and that is one 
of the most important limitations of this type of epidemiological study. With 
retrospective studies, recall and reporting bias may critically affect the 
accuracy of the results. However, when information for the study is collected 
directly from a source produced at the time of the event rather than from what 
either included participants or health care workers can recall some time after
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the outcome occurred, the likelihood of these types of bias affecting the 
accuracy of the results is much lower.
Other important potential source of errors in designing case-control studies is 
the process of selection of participants. It is critically important to develop a 
clear and unambiguous case definition. Differences in the reported incidence 
of either LA or HL among different studies may be partially explained by the 
use of different case definitions. In addition, presence of symptoms may not 
correlate precisely with the level of blood lactate making it difficult to include 
both laboratory markers and symptoms, potentially associated with the 
complication, in a case definition. The use of objective criteria to define a case 
may prevent getting a definition that is too wide and less specific and this may 
lead to more conclusive and accurate results even if some cases are not 
identified. For metabolic complications such as LA and HL it was assumed 
that using appropriate thresholds for laboratory variables may lead to an 
appropriate case definition. Furthermore, the lack of electronic databases in 
some centres may force one to rely on clinicians’ memories to identify 
potential cases. Such a practice may introduce important bias in the study as 
some specific patients may be more easily remembered; for example, those 
patients more seriously ill or those diagnosed in the context of specific 
conditions such as clinical trials.
Selection of controls is also a critical step in the development of a case-control 
study. Controls are meant to represent the distribution of the exposure of 
interest in the study population where cases are identified. In this context, 
controls must have been likely to have had similar exposure to ART than 
cases or at least controls must be at similar risk of being prescribed the drugs 
prescribed to cases. As prescription patterns have changed over time, 
selection of cases and controls for this study must take into account such a 
variation in exposure likelihood (see section 5.3.4).
In addition, it is important to acknowledge other limitations of retrospective 
studies. The level of awareness of LA and HL as complications of ART has
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also changed over time. Therefore the intensity of monitoring for these 
complications as part of regular care offered to HIV-infected individuals on 
ART has changed as well. In this regard, not only the number of investigations 
performed on patients to diagnose these complications but also the level of 
description of the events and interventions indicated to treat or prevent it may 
have also changed over time. As a result, the level of available information 
about cases recorded in clinical notes may also vary over time. Furthermore, 
monitoring of blood lactate or any other relevant laboratory variable may not 
be a routine practice in all participant centres.
It may be obvious that prospective, randomised clinical trials may be the best 
possible strategy to ensure that all participants are going to be under equal 
diagnostic surveillance and therefore the most likely study design to produce 
clean and conclusive data on risk factors associated with a given outcome. 
Moreover, given the high frequency of co-morbidities seen in HIV-infected 
patients and the increasing offer of available therapeutic options 
randomisation and blinded administration of predefined therapeutic 
combination might be the only way to control for all known and unknown 
confounders. Clinical trials therefore, may be the most appropriate strategy to 
identify associations between ART drugs and long-term adverse events 
(Bisson et al. 2003). Unfortunately, such trials may not be possible for many 
reasons, including logistic complications related to the long follow-up period 
required, associated costs and lack of interest of the pharmaceutical industry. 
In addition to that, it may also have ethical implications as randomisation to 
exposures thought to be more harmful may not be acceptable.
Therefore, observational studies and particularly case-control studies can offer 
a good opportunity of generating valid and conclusive data on risk factors 
associated with drug-related adverse events. In fact, case-control studies 
have been performed in different settings to assess safety questions related to 
many drugs and some of them have impacted clinical practice quite 
significantly. A good example of the potential benefit of this study design in 
assessing drug safety is the study on diethylstilbestrol and vaginal
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adenocarcinoma published by Herbst in 1971 (Herbst et al. 1971). The study 
included only eight patients with clear-cell adenocarcinoma of the vagina who 
were matched to four controls each and it showed a very strong association 
between maternal exposure to estrogens during the first trimester of 
pregnancy and vaginal cancer in their daughters.
5.2 Background
As has been highlighted before (see chapter 4), most of the initial published 
data on LA were based on case reports or case series including few cases, 
the largest one being a series published by Megarbane in 1999 which 
included 40 previously published cases (Megarbane et al. 1999). However, in 
the following years, a few observational and retrospective studies were 
performed addressing several questions on LA in HIV-infected individuals 
exposed to ART.
A few cross-sectional studies have identified and therefore described cases of 
LA. Moyle et al. managed to identify four cases of LA among 108 individuals 
with raised blood lactate levels (Moyle et al. 2002) whereas the Swiss Cohort 
Study has reported only one case of LA among 73 patients with 
hyperlactataemia (Boubaker et al. 2001). A small case-control study 
addressed to identify risk factors for LA has also been published. The study 
published by Bonnet et al. in 2003 included nine cases of LA (Bonnet et al. 
2003). Interestingly, all nine cases reported by Bonnet were severely ill and all 
were admitted to an intensive care unit.
The identification of risk factors for case fatality in HIV-infected patients who 
develop LA was the aim of a study published by Falco et al. The study 
included a series of cases (N=12) diagnosed and managed by authors and a 
group of 60 previously published cases (Falco et al. 2002). That study did not 
address the question of risk factors for LA itself.
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5.2.1 Proposed risk factors for lactic acidosis
All cases of LA included in the systematic review we have performed were 
receiving at least one NRTIs at the time of the event and about 97 % of them 
were on a thymidine analogue (i.e. zidovudine or stavudine) at the time when 
the event was diagnosed (see chapter 4). Similarly, the review published by 
Megarbone also highlights that the vast majority (83 %) of the included cases 
were receiving a thymidine analogue at the time of the event (Megarbane et 
al. 1999). Eleven out of 12 cases of LA reported by Falco were taking d4T 
either as monotherapy or in combination with one or more NRTIs at the time 
of the event.
Nevertheless, in the study published by Moyle et al. in 2002 current exposure 
to ddl was over-represented among patients with either severe HL or LA 
(Moyle et al. 2002). Similarly, the Swiss Cohort Study has also highlighted the 
potential role of ddl exposure as risk factor for HL. Of note, the results 
presented by the Swiss Cohort Study suggest that the higher risk attributable 
to ddl may be more pronounced when this drug is used in combination with 
d4T. The authors found that the risk of developing HL may be significantly 
higher (HR=2.7, 95 % Cl= 1.5 -  4.8) amongst those patients on d4T with or 
without ddl when compared with those patients on AZT based combinations 
(Boubaker et al. 2001).
Furthermore, a matched case-control study (N= 21 cases) addressed to 
evaluate risk factors for HL has reported that d4T exposure is a significant 
independent predictor of sustained HL (adjusted hazard ratio = 4.27, 95% Cl =
1.02 -  17.79) (Datta et al. 2003). Exposure to ddl was one of the matching 
factors. In addition, it is important to mention that the case definition they used 
was based on a blood lactate threshold of 3.5 mmol/l, whereas the cut-off 
used in most studies for severe HL is 5 mmol/l.
As has been discussed in chapter 4, variables other than NRTIs exposure 
have also been proposed as risk factors for LA. It has been suggested for
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instance that female patients are at higher risk of developing LA when 
compared to men. Based on the data we collected in the systematic review 
presented in chapter 4, the risk of developing LA in women exposed to ART 
may be more than twice higher than for men. In fact, the Food and Drugs 
Administration (FDA) in the United States produced a warning letter a few 
years ago highlighting the increased risk seen in women exposed to ddl/d4T 
combination therapy. Similarly, in a study performed in London (which 
included nine cases with blood lactate higher than 5 mmol/l, four of whom 
were acidotic), female gender was overrepresented among the cases group 
(Moyle et al. 2002). Nevertheless, the study published by Moyle et al. failed to 
demonstrate any significant association between female gender and the 
likelihood of developing HL (defined as blood lactate higher than 2.5 mmol/l) 
(Relative Hazard= 1.39; 95% Cl= 0.74 -  2.61).
Previous or concurrent NRTI-induced adverse events have also been 
proposed as risk factors for LA. Previous and sustained mitochondrial 
impairment affecting different tissues or organs has been proposed to 
increase the likelihood of developing life threatening LA (Carr & Cooper 2000; 
Manfredi et al. 2003). Similarly, advanced HIV disease and low CD4 nadir 
have been proposed as risk factors for almost all mitochondrial toxicities 
related to NRTIs, including LA (Bonnet etal. 2003; Anderson etal. 2003).
Liver diseases, including not only viral infections but also other conditions 
such as non alcoholic fatty liver disease have been proposed to be associated 
with an increased risk of developing both symptomatic HL and LA in HIV- 
infected individuals (John etal. 2001;Gerard etal. 2000; Dagan etal. 2002).
5.2.2 Lactic acidosis and severe hyperlactataemia
Over the past few years a few observational studies and case series have
addressed several questions on proposed NRTI-associated mitochondrial
toxicities. These studies have used several models from PN to peripheral
lipoatrophy to assess the impact of specific drug exposures on these
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outcomes. However, as has been mentioned before, several other factors 
apart from NRTI-induced mitochondrial dysfunction may play significant roles 
in almost all proposed mitochondrial toxicities. Nevertheless, hyperlactataemia 
has been recognised as a marker of mitochondrial dysfunction in many clinical 
situations in the general population. Therefore, HL and or LA may be the ideal 
outcome to evaluate the effect of any ART drug on mitochondrial function.
LA is a condition well described in several medical fields and its definition is 
universally accepted. Patients with elevated blood lactate, usually above 2 
mmol/l (or 18 mg/dl), low arterial blood pH (< 7.35) and low blood bicarbonate 
(< 20 mmol/l) are recognized as cases of LA. It is possible however to identify 
patients with high blood lactate and low blood bicarbonate who do not have 
low arterial blood pH. In that condition the bicarbonate buffer is efficient 
enough to keep blood pH in the normal range in the presence of a harmful 
factor leading to an imbalance in the acid-base metabolism. Patients with high 
blood lactate and low blood bicarbonate may be in an earlier stage in the 
process which will eventually lead to LA if the noxious agent is not controlled.
In addition, arterial pH has not been regularly measured in HIV-infected 
patients with abnormal blood lactate who have been included in most of the 
studies published to date. Therefore, a high proportion of the available 
information is on cases of HL. In fact, the management recommendations on 
metabolic complications associated with ART for HIV-1 infection published in 
2002 by the International AIDS Society-USA Panel suggested using the term 
lactic acidemia instead of LA or HL to described HIV-infected patients with 
elevated lactate (Schambelan et al. 2002). Furthermore, it has been proposed 
that even when measurement of arterial pH confirms the diagnosis of LA, it 
may not be necessary in many instances assuming that severe HL is itself a 
diagnostic criterion for lactic acidemia (Schambelan et al. 2002; Carr 2003). 
Following the rationale previously described, a diagnosis of lactic acidemia 
based on the level of blood lactate and regardless of the blood pH may be an 
indication for a medical intervention anyway. This implies a progression from
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HL to LA and therefore assumes that controlling episodes of HL will prevent its 
evolution to LA.
In addition, it has also been suggested that the diagnosis of NRTI-associated 
lactic acidemia requires the exclusion of other known causes of raised blood 
lactate such as dehydration, vigorous exercise, sepsis, hypoxemia, alcohol 
intoxication, renal failure, hyperthyroidism and other drug-induced HL (Carr 
2003).
Although there is not a universally accepted definition of severe NRTI-induced 
lactic acidemia, some diagnostic criteria have been proposed, most of them 
include clinical symptoms in the definitions. The IAS-USA Panel suggested 
that a diagnosis of NRTI-induced lactic acidemia can be made in the presence 
of either 1) a confirmed blood lactate above 5 mmol/l (45 mg/dl) plus new 
“related” symptoms or signs or 2) blood lactate above 10 mmol/l (90 mg/dl) 
regardless of the clinical presentation (Schambelan et al. 2002). Similarly, 
Powderly in a review published in 2002 includes the category of symptomatic 
lactic acidemia but acknowledged that there is a separate category which he 
called LA with hepatic steatosis (Powderly 2002). In addition, Powderly 
includes a separate category for patients with asymptomatic lactic acidemia 
and/or chronic HL, as a condition not including acidosis. As has been 
mentioned before (see Chapter 4), mild to moderate HL may be a relatively 
frequent condition among HIV-infected patients exposed to NRTI-containing 
combinations. Nevertheless, it has also been proposed that these mild 
elevations in blood lactate in asymptomatic patients may be either transient 
and of uncertain clinical significance (Powderly 2002) or may be just spurious 
results as a consequence of several possible mistakes in the process of taking 
or processing blood samples.
To get accurate measurements of blood lactate, patients must be instructed to 
not perform vigorous exercises for 24 hours before the test and must be well 
hydrated at the time of blood sample collection. In addition, samples must be 
collected without use of tourniquet or fist clinching in a pre-chilled fluoride-
107
oxalate tube. The sample must then be transported on ice to the laboratory, 
where it must be processed within four hours of collection (Carr 2003). If 
samples are not taken and processed in the right way, the results may be 
spurious showing an elevation, generally mild, of blood lactate which is not a 
real reflection of the metabolic status of the patient. Therefore, some authors 
have suggested that most if not all cases of asymptomatic mild HL (blood 
lactate between 2.2 and 5 mmol/l) are due to spurious results rather than a 
true effect of any drug on lactate metabolism (Andersen etal. 2003).
Conversely, confirmed blood lactate results above 5 mmol/l (45 mg/dl) are 
likely to correspond to real cases of sustained and severe lactic acidemia, 
even if arterial blood pH is not measured. The latest assertion is based on the 
rationale described in the paragraphs above but has not really been 
demonstrated in the context of HIV infection and NRTIs exposure.
Finally, as has been mentioned before, symptoms claimed to be associated 
with LA and HL are non-specific and difficult to classify. In addition, symptoms 
such as abdominal pain, nausea, fatigue, weakness, etc are frequently seen in 
HIV-infected patients taking ART. Taking both together, it is likely that the 
precision of the description of these symptoms in clinical notes would not be 
very high and therefore, in the context of a retrospective study, it would be 
difficult to assess accurately not only the presence but also the severity and 
duration of the symptoms, making it difficult to use clinical information for the 
case definition. In addition, it has not been demonstrated that there is any 
correlation between presence or severity of any clinical variable and the 
severity or prognosis of the event of either HL or LA (Walmsley et al. 2004).
For the present study it has been considered pertinent to combine HL and LA 
as a single outcome based not only on suggestions and assumptions made by 
experts in the field but also because biological plausibility of the progression 
from HL to LA. In addition, logistical issues were also taken into consideration. 
It was considered that if HL and LA are steps in a continuous process, given 
the low incidence described for LA, combining the two entities would increase
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the probability of collecting a significant number of cases in a relatively short 
period of time. In addition, clinical practice had changed in many centres, by 
the time of our study, and patients were generally switched away from specific 
ART drugs when an episode of HL was diagnosed. This would make it even 
harder to find cases of LA if HL progresses to LA without intervention.
5.3 Study description
5.3.1 Aim of the study
The main motivation for this study was to identify risk factors associated with 
LA and HL in HIV-infected individuals exposed to ART. Particularly interesting 
to us was the proposed association between NRTIs exposure and these 
complications. Therefore, the study was designed to identify and quantify the 
strength of any association between any specific NRTIs or NRTIs combination 
and LA or HL. The study would pay special attention to history of ART 
exposure as well as the drug or drug combination patients were taking at the 
time of the event.
In addition to drug-related variables, other factors would also be tested as 
potential risk factors for LA and HL. Such additional factors would include 
demographic parameters as well as previous medical conditions either related 
or not to HIV infection as is described in section 5.6.4.
Although the study was designed to identify risk factors for LA and HL, it 
would be also the largest case-series ever compiled on the subject and 
because of that, provide a detailed descriptive analysis of epidemiological, 
clinical and biochemical characteristics of cases compared to controls.
Finally, as LA had been described to be associated with a high mortality rate, 
an analysis on risk factors for case fatality would also be possible.
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5.3.2 Study design
A retrospective case-control study was designed to achieve the aims 
described above. Because of the proposed relatively low incidence rate of LA 
among HIV-infected patients exposed to ART (see Chapter 4), an international 
multi-centre study was considered as the best possible option to include a 
sufficient number of cases to reach convincing conclusions in a relatively short 
period of time. The study therefore, was planned to include cases and controls 
regularly seen in specialised centres from Europe, the Americas and Australia.
The study included confirmed HIV-infected adult individuals receiving or 
previously exposed to ART. Cases were to have biochemical evidence of 
either lactic acidosis or severe and sustained hyperlactataemia, whereas 
controls were to be randomly selected from patients attending the same clinics 
or admitted to the same hospital wards as the cases.
5.3.3 Case definition
Following the rationale discussed previously (see section 5.2.2) both cases of 
lactic acidosis and severe and sustained hyperlactataemia were eligible to be 
included in the study. It is important to mention that both entities are defined 
solely in terms of biochemical markers, so no clinical data are considered for 
any of the case definitions.
I. Cases of lactic acidosis: Out or in-patients meeting the following 
criteria were considered eligible for the study. The criteria used in 
this study to define lactic acidosis are in agreement with the 
definition widely used in medical practice.
• Arterial blood pH < 7.35
• Blood bicarbonate < 20 mmol/l (22 mEq/l)
• Blood lactate > 2.2 mmol/l (19.8 mg/dl)
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Patients had to meet all three criteria to be included as cases. 
Nevertheless, discrepancies between the cut-off previously 
mentioned and the reference ranges used by centre laboratories did 
occur. Cases of lactic acidosis in that situation were defined following 
the same principle (i.e. low arterial pH, low blood bicarbonate and 
high blood lactate) but taking the cut-off from the reference normal 
range for each specific laboratory.
II. Cases of severe hyperlactataemia: Irrespective of their acid-base 
metabolic status, patients with at least two consecutive readings of 
blood lactate above 5 mmol/l (45 mg/dl) were considered eligible as 
cases.
III. Controls: HIV-infected patients seen as outpatients or admitted to 
hospital at the same centres as the included cases. Controls, as well 
as cases, were older than 16 years and being exposed to ART, even 
if they were not on treatment at the time of being selected as 
participants in this study.
Two randomly selected individuals, meeting the above-described 
criteria, were selected as controls for each included case.
5.3.4 Matching criteria
Because of the lack of conclusive information regarding variables associated 
with either LA or HL it was assumed that matching, as a strategy to control for 
confounders, might exclude the possibility of detecting important associations. 
One might argue that it would be logical to attempt to design a study where 
controls are randomly selected from the entire study population and not 
matched at all to cases by any variable. It is likely that a simple study design 
like this would produce clean results which may be valid as long as the 
sample size was large enough.
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Nevertheless, apart from the logistic complications which may be associated 
with using the entire study population as a source of controls, there are 
important methodological and scientific reasons to include at least some 
matching variables in this study. First, ART drugs have been developed and 
introduced into clinical practice at different points in time over the last 15 
years, and therefore the probability of being exposed to a given drug or drug 
combination varies with time. Patients who developed the study outcomes 
during the late 90’s were unlikely to be exposed to the same drug 
combinations as individuals who started ART several years later. Therefore, to 
make cases and controls comparable with respect to the likelihood of being 
exposed to specific ART drugs, it was decided to match cases and controls by 
calendar time.
In addition, patterns of ART prescription may vary not only as function of time 
but also according to the centre where patients are regularly treated for their 
HIV infection. Countries and centres have their own guidelines and so specific 
ART drug combinations may be more frequently prescribed in a given centre. 
Therefore, the likelihood of exposure to any specific ART drug combination or 
even the threshold for switching therapy might differ between participant 
centres. As a result it was also decided to match cases and controls by 
centre. So controls were matched to their respective cases by time and place.
The criterion used for matching by time was calendar year. Therefore, controls 
were to be patients receiving regular outpatient care or admitted to hospital 
during the same calendar year when their respective case was diagnosed with 
either LA or HL. Despite the dramatic changes we have seen in prescription 
patterns of ART drugs over the last few years, a calendar year was assumed 
as an appropriate period because changes are usually gradually introduced 
into clinical practice and so it was felt that a shorter time frame would not 
necessarily improve the precision of matching.
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The controls were selected from individuals who had been seen at the same 
clinic at least once or admitted to the same hospital ward during the year 
when their respective case was diagnosed with either LA or HL.
5.4.4 Ethical issues
After a comprehensive discussion with invited researchers, the study protocol 
was submitted to all relevant ethics committees for approval. In the UK the 
protocol was submitted at separate times to two different committees, the 
Local Research Ethics Committee (LREC) of Camden & Islington Community 
Health Services NHS Trust for the pilot study and later to the Multi-Centre 
Research Ethics Committee (MREC) of London for the full study in UK 
centres. Full approval was granted to the study for both entities.
This was to be a retrospective study designed to collect information already 
recorded at each participant clinical notes without requiring any direct contact 
between participants and investigators. However, in the UK individual 
informed consent from each living participant in the UK was required. 
Furthermore, according to the ethics committee’s conditions, each participant 
was to be consented by his or her regular physician, preventing the principal 
investigator from approaching any potential participant directly. Explicit 
permission from each relevant NHS trust Caldicott Guardian4 was required to 
include any deceased patient in the study.
Separate patient information sheets about the study as well as consent forms 
were prepared for cases and controls. All these documents were prepared 
following LREC and MREC guidelines and were approved by the relevant 
body before being used.
4 NHS Caldicott Guardians: Senior staff in the NHS and social services appointed to protect 
patient information (Definition taken from the DH website, available at
www.dh.QOv.uk/PolicvAndGuidance/lnformationPolicv/PatientConfidentialitvAndCaldicottGuar 
dian s /, accessed on 8* June 2006)
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Proformas used to collect the relevant information for the study were 
anonymous, but included a unique identification number. The local 
investigator at each locality was the custodian of a list linking the study 
number and patients’ identification data.
Similarly, ethical approval was obtained from all relevant ethics committees in 
all participant countries. Identification and inclusion of patients in the study in 
each international centre was performed in accordance with the conditions 
imposed by the relevant ethics committees. Not all centres required consent. 
Where individual consent was required local investigators were the custodians 
of the consent forms signed by each participant.
5.5 Pilot study
A pilot study was carried out. The aim of the pilot study was to identify 
potential pitfalls and gaps in the instruments to be used for the case-control 
study such as the proforma and database and to amend such instruments and 
study procedures. The pilot also assessed the time required to consent 
patients, complete proformas and transcribe the data onto the database.
5.5.1 Centres involved
The pilot study was conducted at the Centre for Sexual Health and HIV 
Research, University College London and Camden Primary Care Trust (PCT). 
The study therefore included outpatients regularly seen at the Bloomsbury 
Clinic, Mortimer Market Centre.
Patients admitted to the Patrick Manson Unit at University College Hospital, 
(University College London Hospitals NHS Foundation Trust) were also 
eligible for the study. Finally, patients seen at Archway Sexual Health Clinic, 
also part of Camden PCT were also included in the pilot study if they met the 
inclusion criteria.
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5.5.2 Identification of cases
Cases diagnosed between 1990 and 2003 were identified using different 
methods. First, discharge summaries from the Patrick Manson Unit were 
searched for diagnoses of acidosis, lactic acidosis, and lactic acidemia. In 
addition, those discharge summaries reporting abnormal blood lactate levels 
were also checked. Some patients who met the study case definition among 
those with abnormal lactate reported in their discharge summaries had 
diagnoses such as mitochondrial toxicity, pancreatitis, peripheral neuropathy, 
and sepsis. Consequently, we searched the discharge summaries again to 
assess whether or not patients discharged with those diagnoses met the study 
criteria to be included as cases.
In addition, the Bloomsbury and Archway Clinics database was searched also 
for laboratory results. Specifically, blood lactate and bicarbonate values were 
searched to identify eligible patients for the study. The search on laboratory 
results was made using the threshold values previously defined (see section 
5.3.3). As arterial pH is not recorded in the database, it was not used as a 
searching variable. Nevertheless, pH values were checked in all patients 
identified through the other strategies described.
Finally, all clinicians working at both sites were asked about any potential 
cases they remembered. A few cases were identified using this approach but 
all of them were also caught by the other mechanisms.
5.5.3 Selection of controls
Controls were selected from a list of eligible patients. The list was obtained by
selecting people seen in clinic at any time during the period of interest
according to the diagnosis date of each case. According to the study protocol,
that period corresponded to the calendar year when each case was
diagnosed. However, as people seen in clinic during a year period would be
likely to include all the clinic population and most patients are seen in clinic
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every three or four months, the list of eligible controls for each case was 
limited to a three month period including one month before and one month 
after the month when each case was diagnosed.
Then, each list was filtered by ART exposure. Following the study protocol the 
list was filtered not by current exposure but exposure to ART at any time. 
Therefore, the final list included only patients eligible to become controls for 
the study. The list was later completed adding all those patients who were 
admitted to Patrick Manson Unit over the same period of time but who were 
not seen in clinic as outpatients. Careful cross check was performed to avoid 
duplications and to ensure that every patient in the list was included just once.
Finally, controls were randomly selected from these merged lists. A hand 
calculator was used for random number generation which was used to select 
controls for each identified case.
5.5.4 Findings
Fifteen cases were identified and included. Other five potential cases were 
not included as they did not meet the inclusion criteria in full. Eight out of the 
15 included cases met the criteria for LA whereas the other seven had HL. 
Two of the cases had died but only one as a consequence of the episode of 
LA. Five cases were identified as cases of LA through discharge summaries, 
whereas the other three cases of LA were identified by checking blood lactate 
levels and arterial blood pH in patients with diagnoses such as pancreatitis, 
peripheral neuropathy and bacterial infections such as sinusitis. All the cases 
of HL were identified through a database search for blood lactate results. 
Three out of the seven cases of HL were also picked up from the discharge 
summaries search, where one of them was also classified as a case of 
mitochondrial toxicity.
Once the cases were identified, two controls per case were randomly selected
as previously described (see section 5.5.3). Both cases and controls were
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approached by their regular doctors by post. Each potential participant 
received an invitation letter signed by his or her regular doctor plus a copy of 
the patient information sheet and three copies of the consent form printed in a 
Camden PCT NHS Trust headed paper. The package also included a pre­
paid addressed envelope for patients to return two of the signed consent 
forms if they agreed to take part in the study. The consent form patients 
signed clearly stated that only information already recorded in their medical 
notes or records was going to be used for research.
Over a two month period the response rate was higher than 90 % among 
cases who were alive but it was only 54 % among invited controls. Because of 
the poor response rate among controls it was considered necessary to 
implement a second strategy. A copy of their invitation letter as well as copies 
of the correspondent patient information sheet and the consent form were 
placed in each patient set of notes for patients to be consented during their 
following consultation. The process of getting consent from controls using the 
second approach took five months but led 90 % of the consents not obtained 
by the first method being obtained. Only two potential controls declined to take 
part in the study (7 %). They were replaced by two additional patients who 
were selected in the same way as original controls were. One case was also 
consented using this second approach. The entire time period required to 
consent all participants in the pilot study was seven months.
Relevant information both cases and controls was collected in a standardised 
way using the same proforma. The study proforma was designed on the basis 
of the data collected during the systematic review (see Chapter 4) and divided 
into three sections (as described for the database on section 5.6.2). For cases 
the index date was the date when the diagnosis of either LA or HL was made 
according to the study case definition, regardless of the date of admission if 
the case was an inpatient (or the date when the clinician made the diagnosis). 
For controls the date of the consultation each control had closest in time to the 
date when the respective case was diagnosed, was chosen as the index date. 
Therefore, all information collected for controls is referred to the date of one
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specific consultation held during the calendar year when the respective case 
was diagnosed with either LA or HL.
5.6 Case-control study design
Although the aims of the study remained the same, after analysing the 
experience of the pilot some adjustments were made in the study design to 
facilitate its applicability. Therefore, the following section describes these 
amendments and details the analysis strategy for the case-control study.
5.6.1 Objectives
In the light of both the systematic review (see Chapter 4) and the pilot study 
results it was agreed to focus the case-control study to achieve the following 
objectives:
I. To describe the demographic and clinical characteristics of HIV-infected 
patients with lactic acidosis and severe hyperlactataemia.
II. To describe the biochemical characteristics of these patients at the time of 
diagnosis and their evolution.
III. To identify risk factors associated with lactic acidosis and severe 
hyperlactataemia.
IV. To identify factors associated with case fatality in those patients affected by 
either lactic acidosis or severe hyperlactataemia.
V. To compare risk factors for lactic acidosis and for hyperlactataemia as 
separate outcomes.
118
5.6.2 Sample size calculation
From the systematic review on published cases on lactic acidosis we found 
that treatment with d4T might be more likely to induce LA than other NRTIs 
exposures (see Chapter 4). Therefore treatment with d4T was assumed to be 
the main exposure of interest for this study. Furthermore, using retrospective 
data from the Mortimer Market Centre we estimated that about 40 % of the 
clinic population may have been exposed to d4T over the study period 
(September 1990 to December 2004). We therefore used that figure to 
calculate the sample size we would need for this study assuming that 40 % of 
the control population may have been exposed to d4T over the study period.
Because of the lack of previous information on the study outcome it was 
decided empirically to design a study with a 90% power of achieving 
significance at the 5% level to detect an odds ratio of two or more for the risk 
of LA or HL from the use of d4T.
Applying the formula proposed by Kirkwood for sample size calculations 
(Kirkwood 1988) (Fig. 5.1) it was estimated that the minimum sample size 
required for the study was 135 cases plus 2 controls per case. Therefore, the 
total study population aimed to be recruited was at least 405 participants.
Fig. 5.1 Formula used for the sample size calculation
(u ^ [x ( l - x ) ]  + v^[x0(l  - x j ] j 2
US >
( x - x j 2
5.6.3 Patients and methods
Patients diagnosed between 1990 and 2004 and regularly seen at seven
centres in the UK and 12 international centres were included. UK centres were
mainly located in London (King’s College Hospital, Chelsea & Westminster
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Hospital, North Middlesex Hospital, Northwick Park Hospital) but centres 
located in other regions of the country i.e. Brighton and Manchester were also 
included. Table 5.1 shows a list of all participant centres, including 
international ones.
Table 5.1 Participant centres
Centre Location
King’s College Hospital London, UK
North Middlesex Hospital London, UK
Northwick Park Hospital London, UK
Chelsea & Westminster Hospital London, UK
Mortimer Market Centre, UCL7 Camden PCT London, UK
Brighton General Hospital Brighton, UK
North Manchester General Hospital Manchester, UK
Academic Medical Centre Amsterdam, The Netherlands
University Hospital Zurich, Switzerland
Hospital Clinic Barcelona, Spain
Hospital Carlos III Madrid, Spain
St Jam e’s Hospital Dublin, Ireland
Hvidovre Hospital Copenhagen , Denmark
Righshospitalet Copenhagen , Denmark
Fundacion Huesped Buenos Aires, Argentina
Policlinica Metropolitana Caracas, Venezuela
Washington University, St Louis St Louis, USA
Alfred Hospital Melbourne, Australia
St Vincent’s Hospital Sydney, Australia
Most participant centres had electronic databases which were used to identify 
cases and to select controls. Procedures vary from centre to centre, but the 
basic principles were always observed. Laboratory results were the main 
searching tool, being mostly based on blood lactate and bicarbonate levels 
given the study thresholds. As was described in the section on the pilot study, 
pH values were almost never recorded in databases, so patients’ notes had to
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be checked to assess their eligibility. In those centres where patients had two 
sets of notes, as outpatients and inpatients, both sets were searched.
Controls were selected following the study protocol specifications. Each centre 
produced a list of eligible patients, mostly using electronic databases to do so. 
Where electronic records were not available a list was produced using clinic 
booking records. As these records often did not include information on 
treatment exposure, the clinical notes of each randomly selected patient were 
checked to ensure eligibility.
Different procedures were followed in two specific participant centres. In one 
international centre (St. Vincent’s Hospital, Sydney) all patients booked for 
clinics during a three weeks period were considered as potential controls and 
consented during that specific consultation. Most of the patients seen in clinics 
during that period of time were actually consented. Finally, the number of 
needed controls according to the number of cases identified in that centre was 
randomly selected from that group of pre-consented patients. Nevertheless, 
the index date for matching was consistent with the study design.
The other centre (Fundacion Huesped, Buenos Aires) is mainly a clinical 
research unit and therefore, all patients seen there were involved in at least 
one clinical trial. Furthermore, during specific periods of time the number of 
clinical trials enrolling patients was relatively small. As a consequence of that, 
the population of patients to select controls from was relatively small 
compared to other participant centres. A special procedure was carried out to 
generate a list of eligible patients by combining the available lists of 
participants in each clinical trial. The intention was to not limit the group of 
available potential controls to those patients enrolled in the same trial to avoid 
an indirect matching by ART.
In an attempt to increase consistency of the data and to reduce inter-observer 
variability it was planned that all study forms from centres would be completed 
on site by the principal investigator. Although this was fulfilled in some centres
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(53 % of the included centres), mainly in the UK, it was considered not 
appropriate in some other centres. Legal regulations, administrative 
procedures and in some cases language limitations prevented the principal 
investigator to having access to the actual clinical notes and therefore in such 
centres local investigators were responsible for completing the study 
proformas. In those centres where study proformas were completed by local 
researchers (37 %), the principal investigator carried out an audit-style review 
of the study proformas in situ to check for consistency and to completeness of 
the recorded information. All inconsistencies or missing data identified by the 
principal investigator were immediately reviewed by the local researcher 
against the actual clinical records.
Although the principal investigator was involved directly in the data collection 
at most participant centres, there were two centres, one UK and one 
international, which were not visited by the principal investigator. The UK 
centre was visited by a clinical research fellow from the Centre for Sexual 
Health & HIV Research, who was trained in the procedures followed by the 
principal investigator to either complete or audit study proformas. The 
additional international centre was included in the study after reviewing the 
study proformas, which were completed and brought to London by a local 
investigator. The requested additional information was either obtained from 
additional documents the local researcher brought with them to London or 
sent electronically to the principal investigator a few days after the audit 
meeting.
All collected data were transcribed into a database designed in Access® in a 
systematic way. The accuracy of the transcribed information was assessed by 
three different mechanisms. Firstly, for numeric variables included in the 
database all valid entries were specified using validation rules (e.g. for 
variables coded as 0, land 2, only these figures were allowed as valid 
answers). Secondly, after transcription, the data was randomly audited. 
Fifteen percent of the cases were checked against the information collected in 
the study proformas. During the last process, errors were found in no more
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than seven records and almost all of them were minor discrepancies in dates. 
As a result, the last mechanism to check data accuracy was performed. A 
separate table including demographics and ART drug history variables was 
produced to manually check consistency of the original database.
5.6.4 Analysis strategy
The primary analysis was planned before the data collection phase and it was 
conceived to test specific prior hypotheses which generated during the 
systematic review of published cases of LA (see Chapter 4). Nevertheless, it 
was acknowledged that several secondary analyses would become pertinent 
after completing the primary analysis. In order to pursue these it was decided 
that the database and the study completed proformas will remain at the 
Centre for Sexual Health & HIV Research. Any proposed secondary analysis 
should be approved by the study steering committee, which includes not only 
the principal investigator and researchers from the co-ordinating centre but 
also local investigators involved in the study. This thesis is restricted to the 
primary analysis which is summarised in table 5.2.
Statistical analysis was performed using STATA version 9.1(StataCorp LP,
College Station, Texas USA). Categorical variables are presented as
proportions. Medians and inter-quartile range (IQR) are used to present
continuous variables, as most of them were not normally distributed.
Significance was assessed using likelihood ratio test (LR) for categorical
variables. The same test was performed to the log 10 transformation of
continuous variables. Differences in duration of exposures to NRTIs were
assessed using Mann-Whitney test. Significance testing included in this study
takes into account the matching variables. Conditional logistic regression was
used to identify risk factors associated with the study outcome. A multivariate
model was built using the stepwise forward approach. The criterion used to be
included in the multivariate model was a P < 0.05 in the LR test for the
univariate analysis. Comparisons between LA and HL were done considering
the matching variables. Finally, classical logistic regression was used to
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identify risk factors for case fatality. Again, the model was also built using the 
stepwise forward approach.
For the analysis of factors associated with fatality and the likelihood of 
developing any further episode of HULA categorical variables were presented 
as proportions and significance tested for by using chi2 test. Continuous 
variables were summarised as median and IQR and significance assessed 
with the T test. Logistic regression models were developed to identify factors 
associated with fatal outcome and further episodes of HULA.
5.6.5 Definitions and assumptions for the case-control study
For this study the following definitions were used.
• Base-line: refers to CD4 count or HIV viral load. Before any ART 
exposure.
• Current exposure to ART: Patients receiving drugs at the time of the 
event or at the time of being included in the study. Patients who 
stopped ART because of the symptoms associated with the event 
within a two week period before the diagnosis were also included in this 
category.
• Previous exposure to ART: Any exposure to ART drugs patients may 
have had before the combination they were taking at the time of being 
included in the study.
• Current ART duration: Duration of the exposure to ART drugs patients 
were taking at the time of inclusion in the study.
• Past ART duration: Duration of ART exposures patients may have had 
before the combination therapy taken at the time of their inclusion in the 
study.
• Total ART duration: Duration of all exposure periods to any ART drug 
patients may have had. Generally includes past and current exposures 
to a given drug.
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• Past medical event: Refers to 01 or ADR. Event diagnosed before the 
last regular follow-up consultation each patient had before the event 
was diagnosed in cases or the index date for controls.
• Concurrent medical event: Refers to 01 or ADR. Event diagnosed after 
the last regular follow-up consultation each patient had before the event 
was diagnosed in cases or the index date for controls.
• Chronic hepatitis B or C infection: Patients with HBsAg or AntiHCV 
positive results for at least six months. Patients explicitly described as 
Hep B or Hep C/HIV co-infected in their clinical notes.
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Table 5.2 Variables assessed in the primary analysis
I. Demographics
1.1. Age at the time of inclusion
1.2 Gender
1.3 Ethnic background
1.4 Country of birth
II. HIV disease history
11.1 Time known as HIV positive
11.2 Most likely mode of HIV infection
11.3 Previous AIDS diagnosis
11.4 Nadir CD4 count (previous to ART exposure)
11.5 Peak HIV viral load (previous to ART exposure)
11.6 Previous ART-related adverse drug reactions
11.7 ART exposure complete history
11.7.1 Current exposure to any specific ART drug
11.7.1 Previous exposure to any ART drug
II.7.3 Duration of the exposure to any ART drug
III. Past medical history
III. 1 Chronic hepatic diseases
111.2 Viral hepatitis B and C markers
111.3 Diabetes mellitus
111.4 Cancer (non HIV-related)
111.5 Drug exposure
111.5.1 Including recreational drugs and drugs associated with LA
IV. Event of interest
IV. 1 Symptoms
IV.2 Imaging and other tests performed 
IV.3 Laboratory tests performed 
IV.3.1 Acid-base metabolism 
IV.3.2 White blood cell count and haemoglobin 
IV.3.3 Liver function tests 
IV.3.4 Blood glucose, amylase and lipase 
IV.3.5 Blood urea and creatinine 
IV.3.6 Blood lipids 
IV.4 Concurrent opportunistic infections 
IV.5 Concurrent ART-associated adverse drug reactions 
IV.6 Management 
IV.7 Outcome 
IV.8 Further ART exposure
IV.9 Further episodes of LA or HL
V. Comparison between LA and HL
V.1 Risk factors for LA 
V.2 Risk factors for HL
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CHAPTER 6
Results of the case-control study on 
Severe hyperlactataemia and lactic acidosis
6.1 Introduction
As described in chapter 5, the main objective of this study was to identify risk 
factors for HL/LA. However, because this is the largest case series on HULA 
compiled to date, a descriptive analysis is presented as introduction to this 
chapter. In addition, risk factors for HULA are analysed considering ART 
exposure as the main variable to be assessed. Nevertheless, all other non- 
pharmacological factors associated with the study outcome are analysed as 
well.
6.2 Identification of risk factors for hyperlactataemia and lactic acidosis
6.2.1 Descriptive analysis of included patients
A total of 110 cases and 220 controls were included in the study. The 
geographical distribution of the study participants is shown in table 6.1 but 
briefly, the majority (64%) of included cases were patients regularly seen in 
the European participant clinics. Forty nine of the cases had LA and the 
remaining 61 cases had HL.
The proportion of males included as cases was 63.6 % whereas the 
proportion of male controls was 81.8 %. Cases were significantly older than 
controls (P=0.011). The median age of cases was 42.4 years (IQR=36.01 - 
52.5) whereas for controls it was 40 years (IQR= 35.0 -  47.1). Stratifying age 
at the time of the event by gender, we found that male cases were also 
significantly older than controls (median age 43.1 and 41.5 years respectively; 
P=0.010).
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Table 6.1 Cases included in the study by region
Region LA* HL* TOTAL
United Kindom 16 16 32
Continental Europe 16 23 39
North America 4 8 12
South America 5 4 9
Australia 8 10 18
TOTAL 49 (45%) 61 (55%) 110
* LA= Lactic acidosis; HL= Hyperlactatemia
Table 6.2 shows some additional demographic characteristics of the study 
participants. Female gender was overrepresented in the case group as 36.4 % 
of them were female compared to only 18.2 % of controls (P <0.001). Three 
pregnant women were included in the study, one was a case. The majority of 
the study population (65.3 %) was white (a category which includes white 
Europeans, Americans and Australians). Nevertheless, the proportion of non­
white cases (including black African, black Caribbean, black American, 
Hispanics and Asians) (41.8 %) was significantly higher than among controls 
(30.8 %) (P=0.014). It is important to mention that not all study centres 
document ethnicity in all patients. In fact, a few centres do not record ethnicity 
at all. Furthermore, there is little ethnic variability among the study population; 
most study participants were white or black (89.3 %) meaning that just about 
10 % of the study population belongs to a different ethnic background (i.e. 
Hispanic or Asian). In addition, a significant ethnic homogeneity was noted in 
most of participant centres populations. For instance, in centres such as 
Sydney, Madrid, Barcelona and Caracas all or almost all study participants 
belong to a single ethnic group. Therefore, as all the analyses presented in 
this chapter take into consideration matching variables and because the 
health centre is one of them, given the homogeneity of some centres 
population, matching by centre may be an overmatching by ethnicity.
Cases were more likely to have been infected with HIV through exposures 
other than homosexual contact (P= 0.009). Fifty nine percent of cases were
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likely to be infected either by heterosexual exposure (40 %), intra venous drug 
use (14 %) or blood transfusion (5 %) whereas about 63 % of controls were 
likely to be infected through homosexual exposure. It may be obvious that this 
difference between cases and controls may be confounded by the higher 
proportion of female patients in the case group compared to the controls. 
However, it may also be affected by the differences in the ethnic background 
of study participants, since 70 % of male cases and controls were white, 
whereas 60% of female cases were non-white, compared to 50% of female 
controls (Table 6.3).
Table 6.2 Demographic characteristics of included patients
Variable Cases  
N %
Controls  
N %
P
Demographics
Male* 70 63.6 180 81.8
< 0.001
Female 40 36.4 40 18.2
Mode of infection 
Homosexual* 41 41.0 125 62.8
0.009
Heterosexual 40 40.0 47 23.6
IVDU 14 14.0 23 11.6
Blood transfusion 5 5.0 4 2.0
Ethnicity
White all* 50 58.1 108 69.2
0.014
Black all 22 25.6 36 23.1
Asian 5 5.8 2 1.3
Hispanic 9 10.5 10 6.4
* base-line category
Eleven cases (10 %) had a previous diagnosis of diabetes mellitus (DM) 
compared to two controls (0.9 %) (P< 0.001). Similarly, proportionally more 
cases (22.7 %) than controls (11.4 %) had a diagnosis of high alcohol 
consumption (P= 0.004). Furthermore, cases were also more likely to have
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pre-existent hepatic disorders other than viral hepatitis. Nine cases (8.2 %) 
had either hepatic steatosis (2/9), alcohol related hepatitis or cirrhosis (2/9), 
non-alcohol related cirrhosis (1/9) or hepatitis of unknown aetiology (4/9) 
whereas only 5 controls had any of the previous hepatic conditions mentioned 
before (P= 0.018).
Table 6.3 Ethnic background of study participants
Variable Cases (N:= 86) Controls (N = 157)
Male Female Male Female
N % N % N % N %
White* 36 70.6 14 40.0 92 74.2 16 50.0
Black** 7 13.7 15 42.9 24 19.4 12 37.5
Hispanic 5 9.8 4 11.4 6 4.8 4 12.5
Asian 3 5.6 2 5.7 2 1.6 0 0.0
Other 0 0.0 0 0.0 1 0.8 0 0.0
* Includes white Europeans, Americans and Australians 
** Includes black African, American and Caribbean
6.2.1.1 Severity and markers of HIV disease
Information regarding the date of the first positive HIV serology test was 
available from 107 cases (97 %) and 216 controls (98 %). The median 
duration of the period between the first positive result and the date of inclusion 
in the study was not significantly different between cases and controls, 70.1 
months in cases (IQR= 20.6 -  132.3) and 82.2 months in controls (IQR= 39.2 
-1 3 0 .3 ) (P=0.515).
Nevertheless, cases were more likely to have more advanced HIV disease 
when compared to controls both at baseline (i.e. before any exposure to ART) 
and at the time of the LA/HL event. Almost 54 % of cases had a history of an 
AIDS defining condition compared to only 37.2 % of controls (P= 0.004) (Table 
6.4).
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The median nadir CD4 count (previous to any exposure to ART) among the 
91/110 cases in whom such a value was available was 120 cell/pl (IQR=50 - 
200). The median nadir CD4 count for 188/220 controls was 180 cell/pl (IQR= 
60 -  285) (P= 0.011) (Table 6.5).
Table 6.4 Previous AIDS defining conditions
Cases (N= 110) Controls (N= 220) Overall
N ° Events % N ° Events % %
Candidiasis 15 13.6 24 10.9 11.8
Cryptococosis 8 7.3 3 1.4 3.3
Cryptosporidiosis 1 0.9 5 2.3 1.82
CMV infection 7 6.4 8 3.6 4.6
HIV encephalopathy 4 3.6 2 0.9 1.82
HSV infection 11 10.0 14 6.4 7.6
Histoplasmosis 1 0.9 2 0.9 0.9
Isosporiosis 1 0.9 0 0.0 0.3
Kaposi’s Sarcoma 11 10.0 22 10.0 10.0
Lymphoma 9 8.2 4 1.8 3.9
Mycobacterium non TB 6 5.5 13 5.9 5.8
Tuberculosis 6 5.5 3 1.4 2.7
Pneumocystosis 17 15.5 30 13.6 14.2
PML 1 0.9 0 0.0 0.3
Toxoplasmosis 6 5.5 5 2.3 3.3
Wasting syndrome 4 3.6 6 2.7 3.0
Recurrent pneumonia 2 1.8 4 1.8 1.8
Any AIDS defining condition 59 53.6 82 37.3 42.7
Although there were only a small number of episodes of opportunistic 
infections (Ol) at the time of the event, cases were more likely to have a 
concurrent AIDS defining illness when compared to controls. Nineteen cases 
(17.3 %) and 18 controls (5.2 %) had a concurrent Ol at the time of inclusion 
(P= 0.015).
These differences between cases and controls are not affected when HIV-
related variables are stratified by gender. Approximately half of male and
female cases (52.9 and 55 % respectively) had previous AIDS diagnoses. The
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median nadir CD4 count for 60 male cases was 130 cell/pl (IQR= 56.5 -  235) 
and 100 cell/[il (IQR= 26 -  156) for the group of 31 female cases with 
information on CD4 count. The median CD4 count at the time of the HL/LA 
event was 220 cell/pl (IQR= 122 -  370) for male cases and 252 cell/pl for 
female cases (IQR= 150 -  300). Both male and female controls had current 
CD4 counts about 400 cell/pl (400 and 389 cell/pml respectively).
6.2.1.2 NRTIs exposure
Cases were much more likely to have been exposed to either d4T or ddl at 
any point in the course of their illnesses than controls. In fact, 92.7 % and 77.3 
% of cases had ever been exposed to d4T and ddl respectively compared to
68.6 % (P <0.001) and 53.6 % of the controls (P <0.001). Exposure to AZT or 
3TC was more frequently seen among controls than cases and such 
differences were also highly significant (P= 0.004 and < 0.001 respectively).
Duration of NRTIs exposure was not significantly different between cases and 
controls except for d4T. Cases were more likely to have been exposed to d4T 
for shorter periods than controls. Fig 6.1 shows the median, IQR and range of 
current d4T duration by study group. The median duration of the current d4T 
exposure for cases (N= 73) was 11.74 months (IQR= 8.62 -  24.47) and 18.42 
months for controls (N= 79) (IQR= 8.32 -  40.33). Such a difference in the 
duration of the current exposure to d4T was not statistically significant (Mann- 
Whitney test P= 0.061), but a clear trend was noticed.
The presence of possible outliers was explored to see if the difference in 
duration of the exposure to d4T was driven by controls exposed to that drug 
for extremely long periods. Unexpectedly outliers with longer duration of 
exposure were identified in the cases rather than inthe controls. Figure 6.1 
shows six observations which lay outside the range expected for the 
distribution and all of them were cases.
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Table 6.5 Surrogate markers of HIV disease severity
Variable Cases Controls
N Median IQR* (Range) N Median IQR* (Range) P
HIV duration (months)** 107 70.07 20.56-132.6 (4.9-218.5) 216 82.24 39.18-130.33(1.1-229.5) 0.175
Nadir CD4 91 120 50 - 200 (2 - 660) 188 180 6 0 -2 8 5 (1  -714) 0.011
Current CD4*** 100 248 136 .5 -365  (3 -8 8 4 ) 212 400 2 20 -551 .5 (1  - 1596) < 0.001
'  IQR= interquartile range 
** Time known as HIV positive 
*** at the time of the event
Table 6.8 Laboratory tests results at the time of the event
Variable Cases Controls
N Median IQR* (Range) N Median IQR* (Range) P
pH 78 7.32 7.25 - 7.40 (6.88 - 7.47) NA**
Lactate (mmol/l) 110 6.75 5 .54 -8 .1  (2 .4 -20 .3 ) 62 1.4 1.1 - 1.88 (0 .6 4 -3 .4 ) NA**
Bicarbonate (mmol/l) 98 18 13.1 -21 .6  (2 .2 -2 9 ) 30 25 2 3 -2 6  (21 -3 1 ) NA**
WCC (x10A12/i) 101 6.7 4.9 - 9.07 (0.4 - 22.7) 192 5.5 4 .5 -7 .0 8 (1 .6 -1 2 .2 ) 0.01
Neutrophils (x10A9/l) 94 3.95 2 .5 -6 .1 9 (0 .1 2 -2 0 ) 190 2.99 2.2 - 4.02 (0.7 - 9.3) < 0.001
Hb (gr/dl) 101 13.2 1 0 .5 -14 .4  (4 -1 7 .8 ) 194 13.5 1 1 .5 -14 .9  (5 .9 -18 .5 ) 0.016
* IQR= interquartile range 
** NA= non applicable
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Three of these subjects had additional factors which may have affected their 
risk of developing HULA. One female patient was an IVDU with HIV/HCV co- 
infection who after many years on d4T/ddl started therapy with Ribavirin and 
Pegylated Interferon a (Peg Inf). She was reluctant to switch ART, and after 2 
months exposure to Rib/Peg Inf she developed a severe and fatal episode of 
LA. The second male patient had been stable on d4T/ddl for a few years. He 
had an episode of acute intoxication, assumed to be due to scopolamine, and 
was found unconscious at his home. Toxicological screening was not 
performed but high alcohol consumption was a possibility considered. The 
patient survived the episode of HULA. The third patient was also a male and 
the only case of HL among these three. He was 70 years old and had a 
diagnosis of Parkinson’s disease on treatment with co-careldopa for over two 
years at the time of the event. Parkinson’s disease has been described as a 
mitochondrial disease. This patient also had Parkinson’s disease-related 
myopathy at the time of the event.
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Excluding these three outliers the difference in current d4T duration between 
cases and controls becomes significant (11.46 months [IQR= 8.42 -  21.28]
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Fig. 6.1 Current d4T duration by study group
versus 18.42 months [IQR= 8.32 -  40.33] Mann-Whitney test P= 0.018) (Fig. 
6.2). Interestingly, as two of these patients were on ddl as well at the time of 
the event, they may also be excluded from the analysis for ddl current 
duration. After excluding these two patients, the median ddl duration for cases 
(N= 62) was 11.56 months (IQR= 8.49 -  21.28) and it was 15.89 months 
(IQR= 7.04 -  34.57) for controls (N= 55) (P= 0.180).
Fig. 6.2 Current d4T duration excluding three outli ers
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Of interest, most of those patients who were receiving d4T-based 
combinations at the time of the event had not had a previous exposure, i.e. 
course of the drug. As shown in Fig. 6.3, only 10 cases (9.1 %) and 12 
controls (5.5 %) of those patients on d4T at the time of being included in the 
study had been previously exposed to d4T and so the duration of their total 
exposure to the drug is longer than the duration of their current exposure.
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Fig. 6.3 Total vs. Current duration of d4T exposure
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Cases were significantly more likely to be receiving d4T or ddl at the time of 
the event whereas controls were more likely to be receiving AZT or 3TC at the 
time of being included in the study (Fig 6.4). The majority of cases who were 
taking d4T at the time of the event were simultaneously receiving ddl (64 %) 
whereas most of controls who were on d4T at the time of being included in the 
study were taking it in combination with 3TC (61 %). Similarly, 73 % of cases 
on ddl at the time of the event were on combination regimens which included 
d4T. Interestingly, almost half (49 %) of controls receiving ddl at the time of 
being selected were taking it in combination with d4T.
Most participants were receiving combination ART at the time of being 
included in the study. Therefore, almost all participants were taking at least 
two NRTIs at the time of their inclusion. Seven cases stopped all ART drugs a 
few days before the diagnosis of the event was made (median= 10.5 days; 
range= 1 -  15). All these seven patients stopped medication because of 
symptoms associated with the event. Therefore, these seven cases were
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included in the study as currently exposed to ART. One case was receiving a 
combination which included only one NRTIs (emtricitabine -FTC-) together 
with efavirenz and atazanavir at the time of the event. Another case was 
receiving a combination of five ART drugs which included d4T, ddl, 3TC and 
ABC. An additional case was exposed to d4T/Efv/Nfv for 8.5 months but 
stopped his d4T seven months before the event (reason not recorded in his 
clinical notes). That patient remained on efavirenz and nelfinavir until the 
event was diagnosed. No AIDS defining conditions were reported at the time 
of the event for that patient. Finally, there was a case who had been off ART 
for over two years by the time of the event. That final male patient had been 
exposed to d4T/3TC/Nfv for 10.2 months before stopping all ART medication 
two years before the event. Patient’s choice was the reason for stopping ART.
Fig. 6.4 Current NRTI exposure
%
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Cases were more likely to be exposed to d4T and ddl simultaneously 
(d4T/ddl) than controls. A total of 47 cases (43 %) were receiving d4T/ddl at 
the time of the event whereas the number of controls receiving such a 
combination was 27 (12.3 %) (P< 0.001). On the contrary, controls were more 
likely of being currently exposed to a combination of AZT and 3TC (29 %) than 
cases (9 %) (P< 0.001). Interestingly, similar proportions of cases and controls 
were taking d4T/3TC at the time of being recruited (17 % and 22 % 
respectively; P= 0.321) (Table 6.6).
P< 0.001 for all four comparisons
0
Current d4T exp Current ddl exp Current AZT exp Current 3TC exp
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Table 6.6 NRTI combinations at the time of inclusion
NRTI Combination Cases Controls P
N % N %
d4T / ddl 47 42.7 27 12.3 < 0.001
d4T / 3TC 19 17.3 48 21.8 0.228
d4T / ABC 7 6.4 4 1.8 0.085
ddl / 3TC 10 9.1 12 5.5 0.202
ddl/AZT 1 0.9 7 3.2 0.174
ddl / ABC 4 3.6 8 3.6 1.00
ddl / TDF 10 9.1 7 3.2 0.011
AZT/3TC 10 9.1 63 28.6 < 0.001
6.2.1.3 Other ART associated adverse events
Cases were also more likely to have previous ART-associated adverse events 
(76.4 % of cases vs. 56.4% of controls; P< 0.001). This was also found for 
those adverse events which are believed to be caused by mitochondrial 
dysfunction (i.e. peripheral neuropathy, myopathy, bone marrow suppression 
and pancreatitis when grouped together) (38.2 vs. 23.6 % in cases and 
controls respectively; P= 0.008) and when analysed alone; previous episodes 
of PN (27.3 % vs. 6.8 %; P< 0.001), pancreatitis (12.7 % vs. 0.9 %; P< 0.001) 
and myopathy (6.4 % vs. 1.4 %; P= 0.018). However, there was no significant 
difference between the proportion of cases (3.7 %) and controls (0.9 %) who 
had previous episodes of bone marrow suppression (P= 0.096). As described 
in chapter 5, for this analysis, all episodes described before the last regular 
appointment with each patient’s regular doctor was considered as previous 
and all episodes diagnosed from that last appointment to the date of the event 
were assumed as current.
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6.2.1.4 Clinical and biochemical presentation of the event
Clinical data were not included in the study case definitions but symptoms at 
the time of diagnosis of the event (HULA) for cases or at the time of being 
included in the study for controls were recorded. Interestingly, 10 cases (9.1 
%) were completely asymptomatic at the time of the event. All 10 cases were 
HL. So, 16.4 % of those individuals with severe hyperlactataemia (N= 61) 
were asymptomatic at the time of diagnosis. The median blood lactate of 
these 10 asymptomatic cases was 5.8 mmol/l (IQR= 5.4 -  6.8) but two of them 
had blood lactate above 7 mmol/l.
Table 6.7 shows the frequency of observed symptoms among both cases and 
controls. There were 107 cases in whom symptoms at the time of diagnosis 
were recorded. Sixty nine out of these 107 cases (64.5 %) had gastro­
intestinal symptoms (i.e. abdominal pain, nausea and/or vomiting). Besides, 
61/107 of the cases (57 %) had constitutional symptoms (i.e. anorexia, 
fatigue, weight loss and/or weakness). Central nervous system (CNS) 
impairment, mostly impairment of consciousness, was reported in five cases 
(4.7 %) but it must be highlighted that all these five cases had LA indicating 
that 10.9 % of those patients included in the study with LA had CNS 
impairment at the time of diagnosis. Similarly, 17 cases had dyspnoea at the 
time of diagnosis and 11 out of these 17 dyspnoeic patients were cases of LA.
The median blood lactate among cases at the time of the event of HL/LA was 
6.75 mmol/l (IQR= 5.54 -  8.1) whereas for the 62 controls in whom that 
parameter was assessed it was 1.4 mmol/l (IQR= 1.1 -  1.88) (Table 6.8). 
Some centres include blood lactate in their routine screening procedures for 
patients in follow-up. Four (6.5%) of the controls had levels higher than 2.2 
mmol/l. The values ranged between 2.5 and 3.4 mmol/l. All four were 
asymptomatic at the time of their inclusion in the study.
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Table 6.7 Symptoms reported at 
the time of the event or inclusion in the study
Cases Controls
N % N %
Nausea 51 47.7 4 1.8
Vomiting 46 43.0 1 0.5
Abdominal pain 43 40.2 4 1.8
Anorexia 31 29.0 0 0.0
Fatigue 37 29.0 7 3.2
Weight loss 30 27.8 9 4.1
Weakness 27 25.2 7 3.2
Dyspnoea 17 15.9 0 0.0
Tachypnoea 9 8.4 1 0.5
CNS impairment 5 4.7 0 0.0
Jaundice 3 2.8 1 0.5
Other 34 31.8 14 6.4
Asymptomatic 10 9.1 182 82.7
Ninety eight cases had blood bicarbonate assessed at the time of the event 
(49 LA and 49 HL). The median blood bicarbonate for this group of cases was 
18 mmol/l (IQR= 13.1 -  21.6). Data on bicarbonate were available from 30 
control patients who all showed normal levels at the time of being included in 
the study. 68 out of the 98 cases (69 %) with blood bicarbonate results 
available had abnormal values (< 20 mmol/l) at the time of the event. 
Interestingly, 8 out of these 68 patients with abnormal bicarbonate (11.8 %) 
had a blood lactate lower than 5 mmol/l. All were acidotic at the time of their 
inclusion. On the other hand, 20 cases of HL (with no abnormal pH by 
definition) had low blood bicarbonate levels at the time of the event ranging 
from 12.2 to 19.7 mmol/l. Arterial blood pH was assessed in 78 cases (49 LA 
and 29 HL). The median blood pH for those cases was 7.32 (IQR= 7.25 -  
7.40).
Cases were more likely to have abnormal haematological laboratory results at 
the time of the event compared with controls (Table 6.8). The median white 
blood cell count (WBCC) for cases (N= 101) was 6.7 cell x 1012/l (IQR= 4.9 -
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9.1) and for controls (N= 192) it was 5.5 cell x 1012/l (IQR= 4.5 -  7.1) (P< 
0.001). Of note, only 24 cases had an abnormal WBCC at the time of the 
event: 17 cases had WBCC > 10 cell x 1012/l (median= 13.4 cell x 1012/!; IQR=
12.3 -  15.8) and seven cases had WBCC < 3 (median= 2.0 cell x 1012/l; IQR=
1.6 -  2.3). The median neutrophil count for cases was 3.95 cell x 109/l (IQR=
2.5 -  6.2) for cases and 2.99 (IQR= 2.2 -  4.0) for controls (P< 0.001). There 
were 25 cases with abnormal neutrophil counts: 13 with neutrophils > 7.5 cell 
x 109/l (median= 10.9 cell x 109/l: IQR= 8 .4 - 1 3 .1 )  and 12 with neutrophils 
count < 2 cell x 109/l (median= 1.3 cell x 109/l; IQR= 1.0 -  1.7). As mentioned 
before, the median CD4 count at the time of the event was 248 cell/pl (IQR=
136.5 -  365) for cases compared to 400 cell/pl (IQR= 220 -  551.5) for controls 
(P< 0.001).
There was a significant amount of missing data on laboratory results, 
particularly among controls. In general, more investigations were performed in 
cases than in controls at the time of being included in the study. That may be 
because most controls were attending regular follow-up visits. However, from 
the available data cases were more likely to have abnormal liver function tests 
(P <0.001), as well as abnormal albumin (P <0.001), amylase (P= 0.034), 
glucose (P <0.001), creatinine (P= 0.021) and urea (P <0.001) at the time of 
the event when compared to controls (Table 6.9). Interestingly, among the 30 
cases with abnormal blood creatinine values at the time of the event 11 had 
levels below the reference normal range for the respective laboratory whereas 
19 of the cases with abnormal creatinine level (19 % of the cases with blood 
creatinine results at the time of the event) had values above the upper limit of 
the respective normal range. Furthermore, the actual level of creatinine 
among these 19 patients ranged between 1.2 and 19.2 times over the upper 
limit of normal range and only two of these cases had levels > 4 times the 
upper normal value. The first of these two patients had creatinine levels above 
7 times higher than the upper limit of normal. It was a male patient who had 
previous diagnosis of diabetes mellitus on treatment with insulin. In addition, 
his blood urea level was more than three times higher than the upper limit of 
normal. He had also developed renal calculi during previous exposure to
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indinavir. The other case with very abnormal creatinine level was a male 
patient with cretainine values 19 times higher than the upper limit of normal. 
That patient was on salvage combination therapy which included ddl in 
combination with TDF plus ABC, 3TC and boosted APV.
Chronic hepatitis B virus (HBV) infection was defined as the presence of a 
positive HBsAg result for longer than six months. A total of eight out of 85 
tested cases (9.4 %) were HBsAg positive whereas 10 out of 159 tested 
controls (6.3 %) were identified as chronically HBV infected (P= 0.644). 
Likewise, 22 out of 80 tested cases (27.5 %) and 26/159 controls (16.4 %) 
were identified as chronically hepatitis C infected (AntiHCV positive) (P= 
0.103).
However, because of the missing data and the matched analysis strategy 
used it was difficult to fit laboratory variables into a regression model. The 
matched analysis implies that a missing value for a control means loosing its 
respective case for the analysis as well. In addition, laboratory markers may 
be considered as factors that are a consequence of the event rather than 
potential risk factors. Therefore, laboratory variables other than those 
assessing HIV disease severity were not included in the further analysis.
Table 6.9 Frequency of abnormal laboratory results
Cases Controls P
Abnormal* Tested** % Abnormal* Tested** %
ALP 52 99 52.5 30 194 15.5 < 0.001
ALT 62 93 66.7 43 183 23.1 < 0.001
AST 45 59 76.3 16 116 13.8 < 0.001
Albumin 24 81 29.6 5 122 4.1 < 0.001
Amylase 24 76 31.6 11 109 10.1 0.034
Glucose 41 86 47.7 12 132 9.1 <0.001
Creatinine 30 102 29.4 31 180 17.2 0.021
Urea 29 79 36.7 7 120 5.8 < 0.001
* Number of patients with abnormal results 
** Number of patients tested
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Abdominal ultrasound scans were performed at study entry in 51 participants 
(34 cases and 17 controls). Sixteen of the cases (47.1 %) had evidence 
suggestive of hepatic steatosis and eight controls (47.1 %) also showed 
similar changes. Five cases (14.7 %) had hepatomegaly with no evidence of 
fatty infiltration or inflammation. Two cases had images suggestive of cirrhosis 
and 11 cases (32.4%) showed normal appearance of their liver. In eight 
controls liver ultrasound scanning was reported as normal. The final control 
had hepatomegaly as the major abnormality found. It is important to mention 
that this may be a biased sub-set as abdominal ultrasound is not a routine test 
in any of the participant centres and therefore it may be performed only in 
those patients with clinical or biochemical abnormalities.
6.2.1.5 Mitochondrial function
Mitochondrial function tests were performed in only three cases. They were all 
males aged 69, 47 and 41 years. Two had mitochondrial studies performed in 
skeletal muscle cells and in PBMC and one in muscle cells but this was the 
only case in whom mitochondrial morphology was assessed by electron 
microscopy. Table 6.10 shows a summary of mitochondrial function tests 
carried out in these three cases. Of note, all three patients had normal 
function of mitochondrial respiratory chain complex II in at least one cell type 
studied. Nevertheless, case 1 had normal complex II activity in muscle cells 
but a mild reduction (73% of the activity measured in healthy controls) in 
PBMC. On the contrary, case 2 had normal complex II activity in PBMC but a 
significant reduction in complex II activity (51 % of controls’ activity) in muscle 
cells. Complexes I and III activities were reduced in the muscle cells of all 
cases. The ratio m t: nDNA was significantly reduced in PBMC of those cases 
in whom PBMC were examined (cases 1 and 2) (Lopez et al. 2002). However, 
case 2 with mtDNA depletion in PBMC had normal mtDNA content in muscle 
cells. Case 2 was receiving treatment with ddl/TDF/Efavirenz at the time of the 
event and had been diagnosed with renal impairment (Creatinine in blood 2.3
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times over the upper limit of the normal at the time of the event). The patient 
with mtDNA depletion in both muscle and peripheral blood mononuclear cells 
(case 1) had previous diagnosis of Parkinson’s disease and concurrent 
diagnosis of myopathy at the time of the event and was on d4T/ddl/TDF. None 
of these two patients were acidotic and their blood lactate level at the time of 
the event were 10.4 and 5.2 mmol/l respectively.
Table 6.10 Mitochondrial function tests
Cases Cl* Cll cm CIV m t: nDNA**
1 Male (69 years old) 
Muscle Reduced Normal Reduced Reduced Reduced
PBMC ND*** Reduced Reduced Reduced Reduced
2 Male (41 years old) 
Muscle Reduced Reduced Reduced Normal Normal
PBMC ND*** Normal Normal Normal Reduced
3 Male (47 years old) 
Muscle Reduced Normal Reduced Reduced Normal
•* CMV= Respiratory chain complexes I to IV 
** m t: nDNA = mitochondrial/nuclear DNA ratio 
*** ND= Not doned
The remaining case (case 3) had significant reduction of all mtDNA encoded 
respiratory chain complexes but normal complex II activity. Surprisingly, the 
patient had normal mtDNA content in muscle cells. However, ultra-structural 
studies showed abnormal mitochondria with giant forms and abnormal matrix 
content. The patient was receiving treatment with AZT/ddl at the time of the 
event of LA (pH= 7.13; bicarbonate= 5.7 mmol/l; lactate= 6.4 mmol/l) (Miller et 
al. 2003).
6.2.2 Risk factors for HL/LA: Univariate analysis
Table 6.11 shows a summary of the univariate analysis performed to identify 
risk factors for HL/LA. Older patients were at higher risk of developing HL/LA 
(odds ratio (OR) 1.03 per year (95% Cl= 1.01 -  1.06) and when age was 
measured as a categorical variable patients older than 40 years (closest entire
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value to the median age for the study population) were 87 % more likely to 
develop HULA (OR= 1.87; 95% Cl= 1 .1 3 -  3.09) than younger patients.
Female patients were about 3 times more likely to develop HULA than male 
participants (OR= 3.27; 95% Cl= 1.78 -  6.03) and as previously described 
cases were more likely to have been infected by heterosexual exposure (OR= 
3.42; 95% Cl= 1 .7 5 -6 .6 9 ).
Although it is likely that only a particular group of patients, such as those with 
symptoms likely to be related to mitochondrial dysfunction would be expected 
to have had previous blood lactate and perhaps amylase measurements, and 
therefore any analysis performed using such variable may be biased, patients 
with previous abnormal lactate and amylase results (at any time before the 
last regular follow-up visit the patient had before the event) were at 
significantly higher risk of developing HULA (OR= 4.74; 95% Cl= 1.98 -  11.30 
and (OR= 5.11; 95% Cl= 1 .9 9 -1 3 .1 0  respectively).
Patients with more advanced HIV disease at the time of being included in the 
study were at significantly higher risk of developing the study outcome. Those 
individuals with concurrent Ol and CD4 < 200 were more than twice and three 
times likely to develop HULA respectively compared to those who did not 
have concurrent Ol at the time of their inclusion in the study (OR= 2.44; 95%  
Cl= 1 .1 9 -  5.03 and OR= 3.63; 95% Cl= 1.94 -  6.82 respectively).
Those patients with concurrent ADR likely to be due to mitochondrial 
dysfunction were at a particularly higher risk of developing HULA when 
compared with those who did not (OR= 5.87; 95% Cl= 3.14 -  10.98). 
Nevertheless, it is impossible to elucidate whether or not the concurrent 
mitochondrial toxicity may be part of the clinical presentation of an episode of 
HULA. In addition, even if the episode of HULA were an independent 
condition that is likely to be the most severe mitochondrial toxicity associated 
with ART and other concurrent (and even recent previous) 
mitochondriopathies may be steps in the pathogenic pathway to extreme
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mitochondrial dysfunction. Therefore, it was considered sensible to exclude 
concurrent mitochondrial dysfunctions from the multivariate analysis. Also 
dates of previous ADR were not recorded and so it was not possible to know 
how close in time previous ADR and the study event were to each other, it 
was therefore decided to exclude previous ADR from the multivariate model.
Patients receiving d4T based ART combinations were more than twice as 
likely to develop HULA compared to those who were taking combinations that 
did not include it. In the same way, patients taking ART combinations which 
included ddl were at much higher risk compared to those who were not 
taking non-ddl containing combinations. On the contrary, in the univariate 
analysis 3TC and AZT exposure were associated with “protective” effects for 
HULA. Patients on 3TC based ART combinations were 73 % less likely to 
have HULA compared to those who were not taking such a drug as part of 
their ART and patients on AZT based ART combinations were 75 % less likely 
to develop HULA than those not taking that.
Patients taking combination ART which include TDF were also at higher risk 
for HULA (OR= 3.16; 95% Cl= 1.17 -  8.50). Ten of the 15 cases (67 %) who 
were taking TDF at the time of the event were doing so in combination with 
ddl. Interestingly, four of those cases taking ddl/TDF were also taking d4T as 
part of their ART combination. In addition, four of the remaining cases on TDF 
at the time of the event were taking that in combination with 3TC and the final 
one was taking TDF in combination with AZT.
Univariate analyses were also performed examining the duration of the 
exposure of each ART drug as the independent variable. From such analyses 
longer exposures to d4T were associated with a “protective effect” for HULA 
(Table 6.12). The OR associated with the duration of current d4T exposure 
was 0.97 (95% Cl= 0.94 - 1.00) per month and the OR associated with current 
d4T exposures longer than 15 months (median of the current d4T duration of 
the entire study population) was 0.27 (95% Cl= 0.11 -  0.68).
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Table 6.11 Univariate analysis : Risk factors for HL/LA
Variable
CASES 
Freq/Total (%)
CONTROLS 
Freq/Total (%) OR 95 % Cl P
Demographics
Age (per year) 1.03 1.01 - 1.06 0.011
Gender
Male 70/110(63.6) 180/220 (81.8) 1 < 0.001
Female 40/110(36.4) 40/220 (18.2) 3.27 1.78 - 6.03
Mode of infection
Homosexual 41/100(41.0) 125/199 (62.8) 1 0.001
Heterosexual 40/100 (40.0) 47/199 (23.6) 3.42 1.75-6 .69
IVDU 14/100(14.0) 23/199(11.6) 2.44 1.04-5 .70
Blood Transfusion 5/100(5.0) 4/199 (2.0) 3.74 0.95-14 .74
HIV history
Previous AIDS diagnosis 59/110(53.6) 82/220 (37.3) 2.08 1.27-3 .40 0.004
Nadir CD4 (< 200) 69/91 (75.8) 101/188(53.7) 4.38 2.08 - 9.22 < 0.001
Previous ART-associated ADR 84/110(76.4) 124/220 (56.4) 3.00 1.67-5 .40 < 0.001
Previous MT adv effects (ART) 42/110(38.2) 52/220 (23.6) 1.95 1.19-3 .19 0.008
Past medical history
Abnormal lactate 24/110(21.8) 17/220 (7.7) 4.74 1.98 -11.30 < 0.001
Abnormal LFT 56/110(50.9) 65/220 (29.6) 3.95 2.11 -7.41 < 0.001
Abnormal amylase 17/110(15.5) 9/220 (4.1) 5.11 1.99-13 .10 0.001
Concurrent medical events
Opportunistic infections 19/110(17.3) 18/220 (5.2) 2.44 1 .19-5 .03 0.015
ART-associated adverse effect 73/110(66.4) 83/220 (37.9) 3.58 2.13-6.01 < 0.001
ART-associated MT adv effect 43/110(39.1) 20/220 (9.1) 5.87 3.14-10 .98 < 0.001
CD4 (< 200) 45/100 (45.0) 49/212(23.1) 3.63 1.94-6 .82 < 0.001
ART exposure
Current d4T exp 73/110(66.4) 79/220 (35.9) 3.67 2 .2 0 -6 .14 < 0.001
Current ddl exp 64/110(58.2) 55/220 (25.0) 5.54 3 .04-10 .10 < 0.001
Curent 3TC exp 40/110(36.4) 144/220 (65.5) 0.27 0 .16 -0 .46 < 0.001
Current AZT exp 11/110(10) 69/220 (31.4) 0.25 0 .12-0 .50 < 0.001
Current TDF exp 15/110(13.6) 15/220 (6.8) 3.16 1 .17-8 .5 0.023
Current Hyd exp 5/110(4.6) 1/220 (0.5) 9.99 1.17-85.59 0.036
Current d4T/ddl exp 47/110(42.7) 27/220(12.3) 8.70 4.05-18 .65 < 0.001
Current AZT/3TC exp 10/110(9.1) 63/220 (28.6) 0.25 0.12-0.51 < 0.001
Current ddl/TDF exp 10/110(9.1) 7/220 (3.2) 4.85 1.29-18.20 0.019
As was described before (see section 6.2.1) there were three cases who may 
be considered as outliers: patients who had received d4T containing regimes 
for periods much longer than the majority of the included cases who had been 
exposed to d4T. If these three cases are excluded from the analysis, the effect
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of d4T duration is some how more evident suggesting that the risk of 
developing HL/LA among those patients exposed to d4T may decrease by 4 
% each month (OR= 0.96; 95% Cl= 0.92 -  0.99) per year. Conversely, 
exclusion of potential outliers from the analysis on duration of ddl exposure 
did not modify the effect of duration of such exposure on the risk of developing 
HL/LA. Nevertheless, it is important to highlight that all OR in that analysis 
were very close to one, even when the significance tests are below the 
previously specified significance level, so they should be interpreted 
cautiously.
Finally, as almost all patients were receiving combination therapy at the time 
of being included in the study and therefore most were taking at least two 
NRTIs simultaneously, univariate analyses were performed to assess the 
effect of the most frequently used NRTIs combinations. As mentioned before, 
most patients were taking at least two NRTIs in combination at the time of 
their inclusion in the study. In addition, NRTIs combinations are not randomly 
allocated and therefore it is difficult to assess the effect of a individual drug as 
that may be prescribed very often with one other specific NRTIs.
As expected, those patients who were receiving d4T/ddl combination therapy 
were about eight times more likely to develop HL/LA (OR= 8.70; 95% Cl= 4.05 
-  18.65) when compared to patients on different combinations. Conversely, 
exposure to AZT/3TC combination at the time of being included in the study 
was a protective factor for the study outcome (OR= 0.25; 95% Cl= 0.12 -  
0.51).
In addition, patients who were receiving combinations which included ddl and 
TDF had more than four times the risk of developing HL/LA than patients who 
were not receiving these two drugs in combination (OR= 4.85; 95% Cl= 1.29 -  
18.20) (Table 6.11).
148
Table 6.12 Univariate analysis : Effect of d4T and ddl duaration
Variable Cases Controls
N Median IQR (Range) N Median IQR* (Range) OR 95% Cl
Current d4T duration 73 11.74 8 .6-24.5  (1 .5-79.1) 79 18.42 8 .3-40.3  (0.5-74.4) 0.97* 0 .9 4 - 1.00
Current d4T duration exc outliers** 70 11.46 8 .4 -2 1 .3 (1 .5 -5 7 .8 ) 79 18.42 8 .3-40.3  (0 .5-74.4) 0.96* 0 .9 2 - 0.99
Current d4T duration > 15 months 47 29 0.27 0.11 - 0.68
Current ddl duration 64 11.68 8 .6 -2 3 .6 (1 .2 -1 1 5 .2 ) 55 15.89 7 .0-34.6 (0 .2-83.4) 0.99* 0 .9 6 - 1.02
Current ddl duration exc outliers** 62 11.56 8 .5 -2 1 .3 (1 .2 -5 4 .3 ) 55 15.89 7 .0-34.6 (0 .2-83.4) 0.96* 0.91 - 1.00
* Per month
** Three patients on d4T and two on ddl
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6.2.3 Risk factors for HL/LA: Multivariate analysis
Table 6.13 shows the multivariate model developed to identify risk factors for 
HL/LA. As was mentioned above, a few variables which were found to be 
significantly associated with the study outcome in the univariate analysis were 
not included in the model. These variables were previous AIDS diagnosis, 
nadir CD4 and laboratory results other than lymphocyte CD4 count at the time 
of inclusion in the study.
After adjusting for other factors, both age and female gender remained 
strongly associated with the study outcome. Older patients were at higher risk 
of developing HL/LA and the risk associated with age increases about 4 % per 
year. In addition, the effect of gender on the likelihood of developing HL/LA 
remained quite strong in the multivariate model. Female patients were more 
than four times more likely to develop the study outcome than male 
participants.
Table 6.13 Multivariate model: Risk factors for HL/LA
Variable Univariate Multivariate
OR P 95 % Cl OR P 95 % Cl
Age (per year) 1.03 0.011 1.01 - 1.06 1.04 0.036 1.00-1.08
Gender (female) 3.27 < 0.001 1.78 - 6.03 4.75 0.001 1.96-11.53
CD4 (< 200) 3.63 < 0.001 1.94 - 6.82 3.44 0.001 1.64-7.22
Current d4T exp 3.67 < 0.001 2 .2 0 -6 .1 4 4.55 < 0.001 2.54-9.18
Current ddl exp 5.54 < 0.001 3 .0 4 - 10.10 4.92 < 0.001 2.30-10.51
Similarly, patients with more advanced HIV-induced immunosuppression were 
also at higher risk of developing HL/LA according to the multivariate model. 
Participants with CD4 count lower than 200 cell/pl at the time of their inclusion 
in the study were more than three times more likely to develop HL/LA than 
those patients with current higher CD4 count.
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Exposures to d4Tand ddl were all strongly associated with the study outcome. 
The risks of developing HL/LA for those currently exposed to d4T or ddl were 
more than four times as high as patients not receiving these drugs. In 
contrast, exposures to either AZT or 3TC, examined individually rather than in 
combination after adjusting for other factors, lost the “protective” effect for 
HL/LA seen in the univariate analysis.
All patients included in the study had been exposed to combination ART, even 
if they were not taking ART at the time of inclusion in the study: one case and 
16 controls were off therapy at the time of inclusion. Therefore, most of the 
study participants were taking at least two NRTIs simultaneously. As 
mentioned before, specific combinations were frequently seen in study 
participants (e.g. d4T/ddl, AZT/3TC, ddl/TDF) and therefore it is difficult to 
assess the effect of specific drugs on the study outcome when they are very 
often used in association with other specific drugs. As a result, it was 
considered appropriate to build up a multivariate model based on drug 
combinations rather than single drug exposures. Table 6.14 shows the 
resulting model.
Table 6.14 Multivariate model based on NRTI combinations
Univariate Multivariate
OR P 95 % Cl OR P 95 % Cl
Age (per year) 1.03 0.011 1.01 - 1.06 1.04 0.015 1.01 -1.08
Gender (female) 3.27 < 0.001 1 .7 8 -6 .0 3 3.57 0.003 1.53-8.35
CD4 (< 200) 3.63 < 0.001 1 .9 4 -6 .8 2 3.64 < 0.001 1.78-7.48
d4T/ddl exp 8.70 < 0.001 4 .0 5 - 18.65 6.42 < 0.001 2.60-15.83
AZT/3TC exp 0.25 <0.001 0 .1 2 -0 .5 1 0.35 0.028 0.14-0.89
ddl/TDF exp 4.85 0.019 1 .2 9 -1 8 .2 0
The model described in table 6.14 shows little difference from the model 
presented earlier which considered individual NRTIs exposures. The effect of 
age, gender and current CD4 count (< 200 cell/pl) remained almost exactly 
the same when adjusted for NRTIs combinations rather than single drug
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exposures. However, the effect of 3TC when combined with AZT remained 
significantly associated with the study outcome. In fact, those patients 
exposed to AZT/3TC based combinations were 65 % less likely to develop 
HL/LA.
As expected, the combination of d4T and ddl showed a strong effect on 
HL/LA. Patients receiving d4T/ddl based combinations were much more likely 
to develop the study outcome (OR= 6.42; 95 % Cl= 2.60 -  15.83). However, 
because of the relatively wide confidence intervals it is difficult to assess the 
actual magnitude of the increased attributable risk.
6.2.4 LA and HL as independent outcomes
As described before, cases of LA and cases of HL were combined in a single 
outcome for the study analysis. Nevertheless, a secondary objective of the 
study was to assess similarities and differences between risk factors 
associated with these two entities. Separate analyses were therefore 
performed considering each outcome individually. Conditional logistic 
regression methods were used to take into consideration matching variables.
Table 6.15 shows the distribution of demographic, HIV-related and ART 
exposure variables by separate outcomes. Considering both together, cases 
of HL and LA were significantly older than controls (see section 6.2.1) 
Similarly, cases of HL were also significantly older than controls, with a 
median age at the time of the event of 44.8 years (IQR= 37.6 -  54.7) whereas 
the median age of controls at the time of being included in the study was 40 
years (IQR= 35.0 -  47.1) (P= 0.001). However, the median age of cases of LA 
(median= 41.1 years; IQR= 35.1 -  48.8) was not significantly different from the 
controls median age (P= 0.806).
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Table 6.15 Cases of LA and HL: descriptive analysis
LA (N= 49*) HL (N=61*)
N° Events % N° Events %
Age
< 40 years 21 42.9 19 13.2
> 40 years 28 57.1 42 68.9
Gender
Male 26 53.1 44 72.1
Female 23 46.9 17 27.9
Ethnicity (N= 36) (N= 50)
White all 21 58.3 29 58.0
Black all 12 33.3 10 20.0
Asian 0 0.0 5 10.0
Hispanic 3 8.3 6 12.0
Other 0 0.0 0 0.0
HIV history
AIDS 30 61.2 29 47.5
Concurrent Ol 8 16.3 11 18.0
Concurrent mt AE 27 55.1 16 26.2
Current NRTI exposure
d4T 28 57.1 45 73.8
ddl 25 51.0 39 63.9
3TC 24 49.0 16 26.2
AZT 5 10.2 6 9.8
TDF 8 16.3 7 11.5
d4T/ddl 15 30.6 32 52.5
AZT/3TC 4 8.2 6 9.8
Outcome
Fatal outcome 16 32.7 3 4.9
* unless a different figure is indicated
The gender distribution was also somewhat different between cases of LA and 
HL. Twenty three cases of LA (46.9 %) were female while among controls only 
40 individuals (18.2 %) were female (P= 0.001). The proportion of female 
cases among those with HL diagnosis (17/61; 27.9 %) was also higher than 
the proportion described among controls (40/220; 18.2 %), but this difference 
did not reach statistical significance (P= 0.087).
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Both patients with LA and HL had CD4 lymphocyte counts significantly lower 
than controls at the time of the event. The median CD4 count of cases with LA 
at the time of the event was 172 cell/pl (IQR= 100 -  360) and the median CD4 
count for cases of HL was 255 cell/pl (IQR= 150 -  390) while the current CD4 
count of controls was 400 cell/pl (IQR= 220 -  551.5). Both differences were 
significant (P< 0.001 and P= 0.002 respectively).
Cases of LA as well as cases of HL were more likely to be exposed to d4T 
(53.1 % and 67.2 % respectively) or ddl (49 % and 60.6 % respectively) at the 
time of the event than controls (35.9 % for d4T and 25 % for ddl) (Table 6.14). 
The proportion of cases of LA and HL when considered as separate outcomes 
who were on d4T at the time of the event were significantly different from the 
same figure among controls (P=0.046 and P= 0.001 respectively) which is 
similar to what was found analysing ddl exposure (P< 0.001 for both 
outcomes).
Patients with both LA and HL diagnoses combined as single outcomes were 
less likely than controls to receive AZT and 3TC at the time of being included 
in the study. Ten percent of the cases of LA and HL were receiving AZT 
compared with 31.4 % of controls who were on AZT at the time of being 
included (P= 0.009 and P= 0.004 respectively). In addition, 49 % of cases of 
LA were on 3TC whereas the proportion of cases of HL on that drug was 26.2 
%. Both figures were significantly different from the 65.5 % of controls who 
were on 3TC at the time of their inclusion (P= 0.043 and P< 0.001 
respectively).
All cases of LA were symptomatic at the time of the event whereas 10 of the 
61 cases of HL (16.4 %) were described as symptom free at the time of 
diagnosis (Table 6.16). Nevertheless, the distribution of symptoms among 
those cases of HL who had clinical manifestations at the time of the event was 
very similar to what was found among cases with LA. The most frequently
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described symptoms such as gastro-intestinal or constitutional symptoms (e.g. 
fatigue, weight loss, etc) were very similar between cases of LA and HL. 
Nonetheless, dyspnoea and tachypnoea were more frequently seen in 
patients with LA (24 % and 13 % respectively) than in cases of HL (10 % and 
5 % respectively). Furthermore, CNS impairment (mostly impairment of 
consciousness) at the time of the event was described in acidotic patients (11 
%) but not in patients with HL.
Table 6.16 Symptoms reported at the time of the 
event by diagnosis
LA (N= 46) HL (N= 61)
N % N %
Nausea 26 56.5 25 40.98
Vomiting 24 52.2 22 36.1
Abdominal pain 19 41.3 24 39.3
Weakness 16 34.8 11 18.0
Anorexia 14 30.4 17 27.9
Fatigue 13 28.3 18 29.5
Weight loss 13 27.7 17 27.9
Dyspnea 11 23.9 6 9.8
Tachypnea 6 13.0 3 4.9
CNS impairment 5 10.9 0 0
Jaundice 2 4.4 1 1.6
Other 18 39.1 16 26.2
Asymptomatic 0 0.0 10 16.4
Table 6.17 shows the univariate conditional logistic regression analysis 
performed for LA and HL as separate outcomes. Of note, even when there are 
apparent differences in the magnitude of the effect of some of the variables 
described before on each of the outcomes, it is important to state that in all 
cases effects were in the same direction and in almost all instances 
confidence intervals overlap. In addition, the study was not powered to assess 
differences between the two components of the outcome and therefore the
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precision of the estimation of the impact of each analysed factor on HL and LA 
is quite poor.
Female patients were at much higher risk of developing LA (OR= 8.88; 95%  
Cl= 2.57 -  30.64) than male participants. Although a trend in the same 
direction was noticed for HL, the effect of female gender did not reach 
statistical significance (OR= 1.94; 95% Cl= 0.91 -  4.15). Similarly other 
factors show stronger impact in one of the outcomes, but as mentioned earlier 
no differences in the direction of any effect were found.
Table 6.17 Univariate analysis: Risk factors for LA and HL
Variable Lactic Acidosis 
OR P 95%  Cl
Severe Hyperlactataemia
OR P 95 % Cl
Demographics
Age 1.004 0.805 0.97- 1.04 1.06 0.002 1.02 - 1.09
Gender (female) 8.88 0.001 2.57 - 30.64 1.94 0.087 0.91 -4.15
Mode of infection
Heterosexual 5.96 0.003 1.80- 19.75 2.39 0.044 1.02 - 5.56
IVDU 3.21 0.123 0.73- 14.09 2.38 0.113 0.81 - 6.98
Blood T ransfusion 6.16 0.164 0.48 - 79.70 2.84 0.215 0.54- 14.85
HIV history
Previous AIDS diagnosis 3.42 0.001 1.65 - 7.07 1.28 0.486 0.64 - 2.53
Previous adverse effects (ART) 2.16 0.053 0.99 - 4.72 4.40 0.002 1.76-10.96
Previous MT adv effects (ART) 1.9 0.073 0.94 - 3.83 2.00 0.049 1.00-3.98
Concurrent medical events
Opportunistic infections 1.57 0.38 0.57 - 4.33 3.87 0.013 1.33 - 11.29
ART-associated adverse effect 4.50 < 0.001 2.08 - 9.74 2.91 0.003 1.44 - 5.88
ART-associated MT adv effect 5.39 < 0.001 2.52- 11.54 6.95 0.001 2.30-21.07
CD4 (< 200) 7.06 < 0.001 2.64- 18.87 1.89 0.139 0.81 - 4.40
ART exposure
Current d4T exp 2.32 0.017 1.16-4.62 6.29 < 0.001 2.75- 14.41
Current ddl exp 5.52 0.001 2.02- 15.08 5.56 < 0.001 2.63 - 11.74
Curent 3TC exp 0.57 0.119 0.28- 1.16 0.11 < 0.001 0.04 - 0.28
Current AZT exp 0.23 0.009 0.08 - 0.70 0.26 0.004 0.11 -0.65
Current TDF exp 10.28 0.031 1.24 - 85.21 1.70 0.398 0.49 - 5.87
Current d4T/ddl exp 3.25 0.020 1.20 - 8.79 25.12 < 0.001 5.97- 105.67
Current AZT/3TC exp 0.18 0.007 0.05 - 0.63 0.30 0.010 0.12-0.75
Current ddl/TDF exp 6.61 0.096 0.72 - 60.86 4.00 0.100 0.77 - 20.87
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6.2.4.1 Additional analysis assessing differences between risk factors
for HL and LA
The presence of interactions between factors identified as significantly 
associated with the combined outcome and its two components (i.e. HL and 
LA) was also assessed. Interaction terms between components of the 
combined study outcome and each factor included in the final multivariate 
model for the combined model were defined and tested.
Three out of the five variables included in the model for the combined 
outcome showed significant interactions with LA. Female gender (OR= 4.58; 
P= 0.040; 95% Cl= 1.07 -  19.57) and current CD4 count lower than 200 cell/pl 
(OR= 3.74; P= 0.046: 95% Cl= 1.02 -  13.64) were shown as positively 
associated with LA in the univariate analysis. On the contrary, age at the time 
of the event was the only factor inversely associated with LA (OR= 0.95; P= 
0.038: 95% Cl= 0.91 -  1.00) although the magnitude of the effect was quite 
weak.
After adjusting for the other variables included in the model, the interaction 
term between female gender and LA was the only one which remained 
significant (OR= 11.51; P= 0.014: 95% Cl= 1.65 -  80.32). Interestingly, the 
inclusion of such an interaction term did not influence the effect of any of the 
variables included in the model other than gender. All the factors included in 
the model remained almost at the same level of impact on the combined study 
outcome with the exception of female gender which lost its significance (OR= 
1.78; P= 0.286: 95% Cl= 0.62 -  5.12) when adjusted by the interaction term 
previously mentioned.
The analysis of the interactions suggests that female gender is strongly 
associated with LA but not necessarily with HL. Interestingly, female patients 
may not only be at higher risk of developing LA but may also be more likely to
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develop severe episodes of HL. The median blood lactate at the time of the 
event was 7.0 mmol/l for the 17 female cases of HL (range= 5.4 -  13.2) 
whereas the same figure for the 44 male cases of HL was 5.8 mmol/l (range=
5.0 -  11.5) (P= 0.075). In addition, 52 % of female cases of HL had blood 
lactate levels equal or higher than 7 mmol/l at the time of the event but only 20 
% of male cases had so (P= 0.011). On the other hand, all female cases of HL 
were symptomatic whereas 23 % of the male cases of HL were asymptomatic 
at the time of the event.
6.3 Outcome of the event
In this study the case fatality rate was 17.3 %, as 19 cases died as 
consequence of the episode. Sixteen of those who died were LA cases, a 
case fatality rate among acidotic patients of 32.7 % (16 deaths among 49 
cases) whereas the case fatality rate among hyperlactataemia cases was 
4.9% (3 deaths among 61 cases)..
Relevant information regarding re-exposure to ART drugs, further ADR and Ol 
was collected from non-fatal cases as recorded in patients’ notes. After the 
event, 33 non-fatal cases of LA were followed-up for a median of 36 months 
(IQR= 1 9 - 5 4 )  whereas the 58 non-fatal cases of HL were followed-up for a 
median of 33 months (IQR= 17 - 48).
6.3.1 Identification of risk factors for case fatality
Of the 19 fatal cases, eight (42.1 %) were women. The median age at the time 
of the event was similar for fatal and non-fatal cases 41.6 years (IQR= 38.1 -  
49.01) and 42.8 years (IQR= 35.9 -  53.6) respectively.
Fatal cases were more likely to have had previous AIDS defining conditions. 
Sixteen out of the 19 fatal cases (84.2 %) had had previous AIDS diagnoses 
compared with 43 of the 91 non-fatal cases (47.3 %) (P= 0.003). However,
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there was no significant difference in the nadir CD4 lymphocyte count 
between fatal and non-fatal cases. Thirteen fatal cases (81.3 %) and 56 
survivors (74.7 %) had nadir CD4 lower than 200 cell/pl (P= 0.577). Fatal 
cases were more likely to have a concurrent Ol at the time of the event (36.8 
%) than non-fatal cases (13.2 %) (P= 0.013) but the proportion of those 
patients who died with a CD4 lymphocyte count lower than 200 cell/pl (55.6 
%) at presentation was not significantly different from that in non-fatal cases 
(42.7 %) (P= 0.320).
Although there were no significant differences between fatal and non-fatal 
cases in the frequency of previous ART-induced ADR likely to be due to 
mitochondrial dysfunction (36.8 % and 38.5 % respectively; P= 0.895), fatal 
cases were more likely to have had previous abnormal blood lactate results 
reported in their clinical notes (47.4 %) compared to non-fatal cases (16.5 %) 
(P= 0.003). In addition, the median blood lactate level in those cases who died 
as a consequence of the episode of HL/LA at the time of their inclusion in the 
study was 8.33 mmol/l (IQR= 7.24 -  13.1), whereas for non-fatal cases it was
6.4 mmol/l (IQR= 5.4 -  7.8) (P< 0.001). Furthermore, 11 non-fatal cases had 
blood lactate levels lower than 5 mmol/l at the time of the event whereas all 
fatal cases had blood lactate levels higher than that figure. In fact 7 of the 19 
of the fatal cases (37%) had blood lactate levels above 10 mmol/l.
Other laboratory abnormalities were also more frequently seen in those 
patients who died as a consequence of the event. All fatal cases had blood 
bicarbonate levels below 20 mmol/l whereas 30 of 79 (38 %) non-fatal cases 
had a normal blood bicarbonate at the time of the event (P= 0.001). 
Additionally, fatal cases were also more likely to have abnormal blood glucose 
11 of 14 (78.6 %) than non-fatal cases 30 of 72 (41.7 %) (P= 0.011). Similarly, 
those patients who died were more likely to have abnormal alkaline 
phosphatase (15/19; 79 %) than survivors (37/80; 46.3 %) (P=0.010) and 
abnormal albumin (14/18; 77.8 % vs. 10/63; 15.9 % respectively; P< 0.001). 
However, there were no significant differences between fatal and non fatal 
cases in transaminases levels.
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There were also no significant differences between fatal and non-fatal cases 
regarding the proportion exposed to different NRTIs other than d4T and 3TC. 
Sixty six non-fatal cases (72.5 %) were taking d4T at the time of the event 
whereas seven of the 19 fatal cases (36.8 %) were doing so (P= 0.003). 
Similarly, differences were found in the proportion of patients who were taking 
3TC at the time of the event as 12/19 fatal cases (63.2 %) were taking 3TC 
whereas 28/91 non-fatal cases (30.8 %) were doing so (P= 0.008). In addition, 
differences were seen on ever exposure to either TDF or HU between fatal 
and non-fatal cases. About 6 of 19 (32 %) of the fatal cases had been 
exposed to TDF or HU at any point in the course of their HIV disease whereas 
only 12 % of non-fatal cases had been exposed to any of these drugs (P= 
0.033). Two of these cases were exposed to both HU and TDF at some point 
in the course of their HIV disease.
In the univariate logistic regression analysis (Tab. 6.18), clinical LA was 
strongly associated with a fatal outcome (OR= 9.37; 95%CI= 2.54 -  34.57) 
and not surprisingly, high blood lactate (> 7 mmol/l, the median lactate level 
for cases in this study) (OR= 8.94; 95%CI= 2.43 -  32.95) and blood 
bicarbonate (OR= 0.83; 95%CI= 0.75 -  0.92) are strongly associated with 
case fatality (Table 6.17). Previous AIDS diagnosis (OR= 5.95; 95%CI= 1.62 -  
21.84) and concurrent Ol (OR= 3.84; 95%CI= 1.26 -  11.68) were also both 
associated with case fatality in the univariate analysis.
Interestingly, the only NRTIs exposure negatively associated with case fatality 
was d4T. In the univariate analysis, those patients who were receiving d4T at 
the time of the event were less likely to die (OR= 0.26; 95%CI= 0.09 -  0.76) 
compared to those who were taking ART combinations not d4T based. On the 
contrary, patients exposed to 3TC at the time of the event were almost four 
times more likely to die.
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Table 6.18 Univariate analysis : Risk factors case fatality
Variable
Fatal (N=19)
N (%)
Non-fatal (N=91) 
N (%) OR P 95 % Cl
Lactic acidosis 16(84.2) 33 (36.3) 9.37 0.001 2.54 - 34.57
Previous AIDS 16(84.2) 43 (47.3) 5.95 0.007 1.62 - 21.85
Previous abnormal lactate 9 (47.4) 15 (16.5) 4.56 0.005 1.58 - 13.13
Current lactate > 7 mmo/l 16(84.2) 34 (37.4) 8.94 0.001 2.43 - 32.95
Concurrent Ol 7 (36.8) 12 (13.2) 3.84 0.018 1.26 - 11.68
Abnormal ALP 15 (79.0) 37 (46.3) 4.36 0.015 1.33-14.29
Abnormal albumin 14(77.8) 10 (15.9) 18.55 < 0.001 5.05-68.10
Abnormal glucose 11 (78.6) 30 (41.7) 5.13 0.018 1.32-20.0
Current d4T exposure 7 (36.8) 66 (72.5) 0.22 0.004 0.08 - 0.62
Current 3TC exposure 12(63.2) 28 (30.8) 3.86 0.010 1.37-10.84
Ever TDF exposure 6 (31.6) 11 (12.1) 3.36 0.040 1.06 - 10.65
Ever HU exposure 6(31.6) 11 (12.1) 3.36 0.040 1.06-10.65
Finally, having a previous abnormal blood lactate result was also found to be 
associated with case fatality. However, blood lactate is not routinely measured 
in all participant centres and therefore, if such a test was performed in a 
particular patient it may suggest the presence of specific medical indication for 
that (e.g. symptoms). Consequently, it was considered inappropriate to 
include previous abnormal blood lactate as a variable in the multivariate 
model. Nevertheless, as described before, previous mitochondriopathies were 
not more frequently seen among fatal cases.
After adjusting for other variables, the multivariate model developed for the 
study shows that those patients more severely ill were at higher risk of dying, 
which is not surprising. Patients with acidosis (OR= 10.1, 95%CI= 2.24 -  
45.52), with blood lactate > 7 mmol/l (OR= 8.35, 95%CI= 1.93 -  36.14) and 
those with concurrent Ol (OR= 7.64, 95%CI= 1.68 -  34.69) were at much 
higher risk of dying (Table 6.19).
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Table 6.19 Multivariate model : Risk factors for case fatality
Univariate Multivariate
OR P 95 % Cl OR P 95 % Cl
Lactic acidosis 9.37 0.001 2.54-- 34.57 10.1 0.003 2.24-■ 45.52
Lactate > 7 mmol/l 8.94 0.001 2.43 -- 32.95 8.35 0.005 1.93 - 36.14
Concurrent Ol 3.84 0.018 1.26 --11.68 7.64 0.008 1.68 - 34.69
It may be relevant to highlight that all asymptomatic cases (N= 10) included in 
this study had at least one of the factors associated with fatality in the 
multivariate model. Two of the asymptomatic cases had blood lactate > 7 
mmol/l at the time of diagnosis. Similarly, five out ten asymptomatic cases had 
had previous abnormal blood lactate results and one of these asymptomatic 
cases had concurrent Ol at the time of the event.
6.3.2 Further follow-up of non-fatal cases
Among the 91 non-fatal cases, 12 (13.2 %) developed further episodes of HL. 
and one further case developed a second episode of LA. The latter was a 
male patient who had previous episodes of pancreatitis and bone marrow 
suppression and was receiving a salvage ART combination which included 
d4T/TDF/enfurvitide (T-20)/delavirdine at the time of his first episode of LA. 
The patient was admitted to hospital but his ART drugs were not stopped. He 
continued on medication until a month later when he developed an episode of 
pancreatitis and all drugs were stopped. Interestingly, the patient was 
restarted on anti-retroviral combination therapy including d4T two months after 
the pancreatitis. He received d4T/T-20/TDF/delavirdine for about seven 
months without any ADR reported in his clinical notes.
Three out of the 12 patients who developed further episodes of HL had 
previous episodes of LA. Two were female (16.7 %) and all 12 of them were 
restarted on ART using combinations which included NRTIs.
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Four out of the 13 patients who developed further episodes of HL/LA (33.3 %) 
were exposed to d4T as part of their re-challenging ART combination, 
whereas 11 patients (14.1 %) of the 78 individuals who did not develop any 
further episode of HL/LA were also exposed to d4T (P= 0.096). Four out the
13 patients who had further episodes were re-exposed to ddl (33.3 %) while
14 (18 %) of the patients who did not have further episodes were also re­
exposed to ddl including combinations (P= 0.215). Similarly, 10 of the patients 
who had further episodes were re-challenged with 3TC containing 
combinations (83.3 %) compared to 43 (55.1 %) of those who did not have 
further episodes (P= 0.065). Finally, 6 patients (50 %) of those who had 
further events were re-treated with AZT based combinations compared to 28 
(35.9 %) patients among those who never had a further episode during the 
study follow-up (P= 0.479).
Of note, six out of the ten asymptomatic cases included in the study 
developed further episodes of HULA. Four of these patients were re­
challenged with ART combinations including d4T, two of them including also 
ddl. The other two patients were treated with ddl but not d4T after their first 
event. Finally, two of the patients re-challenged with ddl were also treated with 
TDF, one of them in a combination with d4T.
Fifty four out of the 91 patients (59.3 %) who survived their episode of HL/LA 
developed further episodes of ART-associated ADR. Of these 20 individuals 
(22 %) developed further mitochondrial toxicities, including peripheral 
neuropathy (N= 16), pancreatitis (N= 3), myopathy (N= 1) and bone marrow 
suppression (N=1).
In a univariate analysis using logistic regression methods, the only factor 
found to be associated with further episodes of HL/LA was inclusion of d4T as 
part of the re-challenging ART combination (OR= 3.81; P= 0.042; 95% Cl=
1.05 -  13.78). However, this calculation included the patient who developed a 
further episode of LA. As mentioned at the beginning of this section, that 
patient was not re-challenged with a d4T containing combination as he had
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not stopped ART at the time of the initial event. If this patient is excluded from 
the analysis, then the previously noted association loses its significance (P= 
0.108) although the extent of the effect remains at the same order of 
magnitude (OR= 3.05; 95% Cl= 0.78 -  11.85).
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CHAPTER 7
Discussion for the case-control study on 
lactic acidosis and severe hyperlactataemia
As described in chapter five, the study has been designed to identify risk 
factors for HULA and therefore, that is the main subject of this discussion. 
However, a few elements regarding clinical and epidemiological 
characteristics of the included cases are also discussed here as well as issues 
concerning the outcome of the event, including factors associated with fatality.
7.1 Factors associated with HL/LA
As has been mentioned before, 110 cases of HL/LA were included in this 
study. Although the number of cases included in the study did not reach the 
target of 135 cases generated from the sample size calculation described in 
Chapter 5, this represents to our knowledge the largest case series and case 
control study of HL or LA carried out to date.
Because of the relative low incidence of LA and the strict case definition for 
HL used in this study, it was difficult to identify eligible patients for the study. In 
fact it took over a year to recruit the study population included in the study and 
it was necessary to include patients diagnosed in 19 centres from three 
different continents. Other factors however have also limited our capacity of 
recruiting a higher number of cases. Firstly, estimates of cases in some 
centres were too optimistic (i.e. over 10 initially proposed eligible cases were 
excluded from the study as they did not meet the study case definitions) and 
secondly, two overseas and three UK centres did not participate for various 
reasons. However, having included more than 80 % of the expected study 
population, it was possible to identify differences between cases and controls 
with a reasonable level of precision.
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Furthermore, the calculation of the sample size required for this study was not 
based on conclusive data previously generated but on assumptions 
engendered from case-series, small studies (mostly retrospective), and the 
systematic review of published cases of LA (see Chapter 4) we performed 
earlier. Therefore, the result of the calculation, as in many other studies, was 
assumed to be more of a frame within which the research should be 
performed rather than an absolute goal which must be reached.
In addition to the issues previously mentioned, an objective of the study was 
to keep similar proportions of HL and LA cases in the study population to allow 
us to compare the two conditions. However, we made the assumption that it 
was likely that HL, as we defined it, was a precursor of LA. In fact, 49 of the 
110 included cases (45 %) met the criteria for LA. As HL has been described 
as a more frequent event than LA (John et al. 2001) the intention to keep 
equivalent numbers of both outcomes in our study population made it even 
more difficult to reach the calculated sample size.
Finally, because of the difficulties and complications mentioned before in the 
process of identifying eligible cases and because of the logistic issues derived 
from the data collection it may have been probably unnecessary to extend the 
study until the calculated sample size was achieved, particularly in the light of 
the results already presented. Although many additional questions may be 
generated from the presented results, it is unlikely that all of these can be 
answered from retrospective data.
7.1.1 Clinical and epidemiological characteristics of cases
It has been suggested that female patients are more likely to develop at least
some ART-related ADR. An observational study published few years ago
shows that gender was independently associated with ART discontinuation
because of toxicity. In that particular study, men were almost 50 % less likely
than women to discontinue ART because of ADR (d'Arminio et al. 2000).
Although the majority of cases included in our study were male, the proportion
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of female patients among cases (36 %) was significantly higher than the 
proportion of female controls included in the study (18 %) (P< 0.001). 
Similarly, slightly more than 50 % of the cases included in the systematic 
review of published cases of LA (see Chapter 4) we performed were women. 
Likewise, Moyle et al. also found that female gender was over-represented 
among the nine cases with either severe HL (defined as blood lactate > 5 
mmol/l) or LA they identified among 108 patients with raised blood lactate 
levels (Moyle et al. 2002). In Moyle’s study, three out of the four cases of 
cases of LA (defined as blood pH < 7.35) and one of the five patients with 
severe HL were women. Furthermore, John et al. described five cases of 
severe HL (blood lactate > 5 mmol/l) in 516 patient-years of follow-up, two of 
whom were women (John et al. 2001). However, two of the male patients with 
severe HL described by John et al. were not receiving any ART drug at the 
time of the event, whereas the authors described the two female cases as the 
only “typical of NRTI-induced lactic acidosis/hepatic steatosis” they managed 
to identify. The last male patient identified by John et al. had a long history of 
alcohol abuse and was diagnosed with severe HL after acute alcohol 
intoxication.
Earlier studies published on the topic have not been able to identify any 
difference in the frequency of HL or LA events between male and female 
patients. For instance, a review on LA published by Megarbane et al. including 
40 cases published between 1991 and 1999 shows a male: female ratio of 
1.18. (Megarbane et al. 1999). Nevertheless, cases included in the previously 
mentioned review were mainly reported from Western European countries or 
North America, where the prevalence of HIV infection is much higher in male 
individuals than in female. Therefore, similarities in the absolute number of 
cases reported in male and female patients may represent a relatively higher 
proportion of affected women. Finally, smaller studies have also failed to 
demonstrate any difference in the frequency of the event between men and 
women. A study on sustained HL (defined as two consecutive lactate readings 
> 2.1 mmol/l) which included only 11 cases, found that about 20 % of both 
cases and controls were female (Hocqueloux et al. 2003).
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Because of three fatal cases of LA which were reported in pregnant women, 
the manufacturer of d4T and ddl produced a ’’dear healthcare provider” letter 
warning that pregnant women and their infants may be at higher risk of 
developing severe LA when exposed to the d4T/ddl combination (Carr 2003). 
The systematic review on LA we performed (see Chapter 4) included also 
three pregnant women who were more than 30 weeks of gestation at the time 
of the event (Arenas-Pinto et al. 2003). In our case control study we found 
only one pregnant woman among the cases and two of them among controls 
and therefore, this study failed to demonstrate any association between 
pregnancy and a higher risk for HL/LA.
It has also been suggested that older patients may be at higher risk of 
developing HL/LA. In our study the median age of cases was significantly 
higher (42.4 years; IQR= 36.1 -  52.5) than the figure calculated for controls 
(40 years; IQR= 35 -  47.1) (P= 0.011). However, conflicting results regarding 
age and its possible association with HL/LA have been reported. Cases of 
severe HL and even LA have been described in neonates exposed to 
prophylactic ART to prevent vertical HIV transmission (Blanche et al. 1999; 
Scalfaro et al. 1998). In addition the range of age among cases included in 
Megarbane’s review on LA was quite wide (0 -  68 years). Not surprisingly, 
age was not found to be associated with sustained but moderate HL in a small 
study which included only 11 cases (Hocqueloux et al. 2003). Nevertheless, in 
a study on peripheral lipoatrophy associated with lactic acidemia and liver 
dysfunction, the authors found that regardless of any other consideration 
and/or association, patients with lactic acidemia (defined as blood lactate >
2.0 mmol/l) were older than people with normal lactate (P= 0.04) (Carr et al.
2000). Furthermore, the Swiss Cohort Study has recently reported that older 
patients may be at higher risk of developing HL (defined as blood lactate > 2.4 
mmol/l) but not necessarily severe HL (blood lactate > 5 mmol/l) (Imhof et al. 
2005).
168
Although cases included in our study were diagnosed and managed in 19 
different centres located in 13 different countries, the majority of the study 
population was white, a category which includes white Europeans, Americans 
and Australians (66 %). However, 42 % of included cases were described as 
non-white (i.e. black African, American or Caribbean, Asian or Hispanic) 
whereas the proportion of included non-white controls was 31 % (P= 0.014). 
As explained in Chapter 5, cases and controls were matched by centre, 
meaning that both were selected from the same population attending the 
centre and therefore were likely to share many characteristics, including ethnic 
background. In fact, a noteworthy ethnic homogeneity was noted in the 
population regularly seen at most participant centres. Therefore, the likelihood 
of randomly selecting a control with the same ethnic background as his or her 
respective case was quite high and consequently, matching by centre may 
imply overmatching by ethnicity as well. Taking these together, the impact of 
ethnicity on LA/HL may be underestimated in this study.
Furthermore, most of the cohort or case-control studies on HL, LA or both 
published to date did not contain information regarding ethnicity of included 
participants but all of them have been performed in centres where population 
homogeneity is also a prominent characteristic (Imhof et al. 2005; John et al. 
2001; Moyle et al. 2002). Nevertheless, a recently presented prospective 
study shows that black Africans may be more likely to develop severe 
hyperlactataemia (defined as blood lactate > 5 mmol/l). In that French study, 
574 patients who started their first line ART combination over the study period 
were followed. Interestingly, about 20 % of the study population was from 
Sub-Saharan countries and more than half of these were black female 
patients. Six out of the 67 black African female participants developed HL over 
the study period and three had severe HL. The authors conclude that black 
women may be at much higher risk of developing severe HL compared to men 
(OR= 18.2; 95% Cl= 3.7 -  88.7). Of interest, two of the three cases of severe 
HL described by Gerard had CD4 counts lower than 50 cell/pl at base-line 
(Gerard etal. 2005).
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Unfortunately, there are no conclusive data on the incidence of HL/LA in 
settings other than predominantly Caucasian populations. There are a few 
large clinical trials currently on going in African countries. In addition, several 
developing countries in Latin America and the Caribbean as well as a few 
South-East Asian countries have national AIDS control programs which 
include ART delivery. Some of these programs have been in place for several 
years now. Clinical trials and observational cohort studies could be used to 
assess the incidence of HULA, as well as other ART-associated ADR, in 
predominantly non-white populations.
It has also been repeatedly suggested that patients with more advanced HIV- 
disease may be at higher risk of developing ART-associated ADR such as 
lipoatrophy (Joly et al. 2002). In this study, 54 % of the included cases had 
been previously diagnosed with at least one AIDS defining illnesses. 
Furthermore, cases were certainly more likely to have more advanced HIV 
disease than controls. Median nadir CD4 lymphocyte count for cases was 
significantly lower than the figure for controls (P< 0.001). As was, the median 
CD4 lymphocytes count at the time of being included in the study (P< 0.001).
A small case-control study on LA (defined as blood lactate > 5 mmol/l and 
arterial pH < 7.38) also found that cases were more likely to have nadir CD4 
lymphocyte count lower than 250 cell/pl than controls (P= 0.03). However, the 
authors did not find any significant difference in the CD4 lymphocyte count 
between cases and controls at the time of the event (P= 0.10) (Bonnet et al. 
2003). Also, a recently published report from the Swiss Cohort Study also 
showed that higher CD4 lymphocyte count may be a protective factor for HL 
(defined as blood lactate > 2.4 mmol/l). However, there was no significant 
difference between cases and controls regarding the level of CD4 lymphocyte 
in peripheral blood at the time of the event (Imhof et al. 2005). In the same 
way, other prospective studies have failed to demonstrate any association 
between CD4 lymphocyte count and the likelihood of developing HL 
(Hocqueloux etal. 2003).
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Differences in the case definition and particularly the number of cases in the 
studies mentioned in the previous paragraph may explain, at least in part, the 
contradictory results with our findings. The study published by Bonnet et al. 
included only nine cases with a median CD4 lymphocyte count of about 200 
cell/pl and a very wide range (31 -  707 cell/pl). In addition, the study 
published by Hocqueloux et al. also included only 11 cases. The case 
definition they used required the confirmation of sustained abnormal blood 
lactate but the cut-off used (2.1 mmol/l) allowed the inclusion of patients with 
very mild episodes of HL. In fact, the baseline blood lactate level of the 11 
cases ranged from 2.2 to 5.8 mmol/l and none of them had LA. Therefore, 
these patients were very different to the group of cases included in our study. 
Both the studies published by Bonnet and Hocqueloux included a very small 
number of cases and therefore, the absence of any association between this 
and any other exposure or potential risk factor and the study outcome may 
reveal just the lack of power of such studies to do so, rather than the lack of 
real associations.
The Swiss Cohort report includes a large population (N= 1,566 participants) 
but only 49 cases of severe HL were identified (blood lactate > 5 mmol/l) in 
there. However differences from our study were that their case definition 
allowed patients with only one blood lactate measurement above the cut-off to 
be included as cases and only four patients developed LA.
Although few case-series, cross-sectional, case-control and cohort studies on 
HL or LA have been published since the late nineties to date, there is still not 
a universally accepted case definition for hyperlactataemic conditions in HIV- 
infected patients on ART. John et al. have proposed to classify lactate 
metabolism abnormalities in this group of patients by dividing them into three 
categories: compensated asymptomatic hyperlactataemia, symptomatic 
hyperlactataemia or hepatic steatosis without lactic acidosis and 
decompensated lactic acidosis or hepatic steatosis (John & Mallal 2002). In 
their review, John et al. suggest that severe hyperlactataemia may have 
different implications when patients are acidotic. However, a more recent
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review suggests the unification of all cases of abnormal blood lactate 
conditions in HIV-infected patients into only one clinical entity “lactic acidemia” 
referred to in chapter 4 (Carr 2003). This approach considers that risk factors 
and therefore predisposing conditions may be the same for developing any 
form of lactate metabolism impairment associated with NRTIs exposure. That 
approach has been supported as well by an International AIDS Society-USA 
Panel (Schambelan et al. 2002).
In any case, both approaches include symptoms associated with elevated 
blood lactate as part of the criteria for grading or classifying the complication. 
However, all case reports, case-series, prospective or retrospective studies 
published to date suggest that symptoms associated with HL/LA are quite 
non-specific and frequently seen in HIV-infected patients not affected by these 
conditions. In our study, as in all other previously published studies, most 
patients had gastrointestinal (65 %) or constitutional symptoms (57 %) 
whereas severe symptoms such as CNS impairment were described in about 
5 % of the included cases. However, all five cases with CNS abnormalities at 
the time of the event were patients with LA.
Of note, 10 out of the 61 included cases of HL (16 %) were apparently 
asymptomatic at the time of being diagnosed with the event. By definition, all 
cases of HL included in our study had confirmed blood lactate levels above 5 
mmol/l. Interestingly, John et al. have pointed out that patients with 
asymptomatic hyperlactataemia usually have mild to moderate blood lactate 
elevations ( 2 - 5  mmol/l) with only occasional or intermittent elevations of 
blood lactate over 5 mmol/l (John & Mallal 2002). This observation was based 
on results of a longitudinal study performed by the same group where all five 
patients with blood lactate > 5 mmol/l were highly symptomatic (John et al.
2001). Furthermore, the management guidelines for lactic acidemia proposed 
by Carr and by the International AIDS Society-USA Panel suggest 
implementing medical interventions in those patients with confirmed blood 
lactate between 5 - 1 0  mmol/l only when symptoms likely to be related with 
the condition are present (Carr 2003; Schambelan et al. 2002).
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Nevertheless, because of the retrospective nature of this study, it is not 
possible to exclude the possibility of mild symptoms not being recorded. Mild 
symptoms may have been ignored by either patients or clinicians and 
therefore not reported in patients’ medical notes. However, it is very unlikely 
that moderate to severe symptoms have been ignored. Similarly, symptoms 
likely to be associated with LA such as CNS impairment or changes in the 
respiratory rate are difficult to be uncared for and therefore even when we can 
not be absolutely sure about the absence of symptoms in this small group of 
patients, we can assume that if something they may have had noting but mild, 
unspecific physical complains.
In addition, the study published by Hocqueloux et al. also found a high 
proportion of asymptomatic patients (7/11) among their cases of HL. 
Noteworthy, the latest study included mainly cases of mild-moderate HL (as 
HL was defined as blood lactate > 2.1 mmol/l). In fact, only one patient had 
blood lactate > 5 mmol/l at the time of being included in that study. Of note, all 
four symptomatic cases described by the authors had blood lactate levels 
lower than 5 mmol/l. Three of these four individuals had symptoms not likely to 
be related to HL. Nevertheless, the fourth patient was a woman who did not 
have any other obvious explanation for her symptoms (fatigue and vomiting) 
at the time of the event and her blood lactate at inclusion was 4.5 mmol/l 
(Hocqueloux etal. 2003).
Taking all together, one could state that even when the presence of severe 
symptoms such as CNS impairment or respiratory rate alteration are usually 
associated with cases of LA, the presence of constitutional symptoms with or 
without gastrointestinal impairment may not be present in all cases of severe 
and sustained HL. In addition, cases of symptomatic mild HL have also been 
described. Even more important, it can be noted from the results presented in 
this study that asymptomatic cases of severe and sustained HL may not be 
considered as less severe than symptomatic cases. Even when none of the 
asymptomatic cases died as consequence of the event in our study (see
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section 7.3), six of them (60 %) had at least one of the factors associated with 
case fatality according to the multivariate analysis shown in section 6.3.1. 
Furthermore, six of the ten asymptomatic cases developed further episodes of 
HL once re-challenged with (or kept on) NRTIs.
The overall median blood lactate level at the time of diagnosis of the episode 
of HL/LA in our study was about 7 mmol/l (IQR= 5.5 -  8.1), but cases with 
blood lactate levels up to 20 mmol/l were included. Nevertheless, such a 
figure is somewhat lower than the median blood lactate observed among 
cases included in our systematic review discussed in Chapter 4 (median= 10.5 
mmol/l; IQR= 7.0 -  17.3). However, a significant proportion of the cases 
included in our review (50 %) were diagnosed during the nineties, when the 
level of awareness of clinicians for this condition was relatively low and 
consequently the diagnosis of LA was likely to be delayed. By contrast, only 
17 (16 %) of the cases included in this study were diagnosed before the year 
2000 and some of them were diagnosed as part of routine blood lactate 
measurements, leading to early diagnosis and prompt interventions. Higher 
blood lactate concentrations have been described in cases of LA severe 
enough to be admitted to intensive care units (median= 20.1 mmol/l; range= 
1 4 - 2 8 )  (Bonnet et al. 2003). There were only 9 cases in the last study, seven 
of whom died, so their sample was biased towards the extreme severity range 
of the condition.
Abnormal laboratory results reflecting several organs involvement have been 
reported consistently in patients with both severe HL and LA. For instance, 
abnormal liver function tests (LFT) have been reported quite often in cases of 
HL/LA. In fact, it has been proposed that the targeted organ for severe HL/LA 
associated with NRTIs exposure is the liver. Several case-series and case 
reports of LA have shown liver involvement. Hepatic steatosis has been 
associated with LA (Freiman et al. 1993; Miller et al. 2000) and with 
symptomatic HL (Gerard et al. 2000). Although, fatal episodes of hepatic 
failure have been described in patients with NRTI-associated LA events (Lai et 
al. 1991; Carr etal. 2001) the commonest pattern of presentation includes just
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mild to moderate elevations in transaminases (Carr 2003; Stenzel & Carpenter 
2000). In this study, even when cases were more likely to have abnormal ALP 
and ALT results than controls (P< 0.001), the median times over the upper 
limit of normal among the 62 cases with abnormal ALT was 1.96 (IQR= 1.5 -  
2.7) which was quite similar to the pattern of ALT elevation seen among the 
43 controls with abnormal ALT at the time of being included in the study 
(median= 1.45; IQR= 1 .2 -2 .0 4 ).
Furthermore, it has been suggested that patients affected by HL/LA are more 
likely to have concurrent chronic viral hepatitis (John & Mallal 2002). However, 
in our study there were no differences in the proportion of cases and controls 
with concurrent chronic hepatitis B or C (OR= 1.29, 95% Cl= 0.44 -  3.76 and 
OR= 1.88, 95% Cl= 0.88 -  4.02 respectively). Similarly, a small case-control 
study on sustained HL (defined as blood lactate > 3.5 mmol/l in at least two 
consecutive occasions) could not find any difference between the proportion 
of cases and controls with concurrent chronic hepatitis B either (Datta et al. 
2003). Also, a study involving patients with LA also failed to demonstrate any 
higher frequency of chronic hepatitis B or C co-infection among cases when 
compared to controls (Bonnet etal. 2003).
Similarities between proposed risk factors of both the proposed “lactic 
acidosis/hepatic steatosis syndrome” and the most frequent cause of 
abnormal LFT in general adult population, which is non-alcoholic fatty lever 
disease (NAFLD) are quite remarkable (Miller et al. 2000; Day 2002). 
Moreover, hepatic steatosis has been reported in many cases of NRTI- 
associated LA (see Chapter 4). In our study we could not find any difference 
between cases and controls in the frequency of hepatic steatosis diagnosed 
by imaging studies. In fact, almost 50 % of the 34 cases in whom abdominal 
ultrasound scanning was performed at the time of the event had images 
suggestive of fatty infiltration. A very similar proportion of the 11 controls in 
whom abdominal ultrasound was performed had the same type of echo- 
pattern. The proportion of abnormal results among control patients is almost 
certainly affected by a selection bias as liver ultrasound was probably carried
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out only in those patients showing evidence of hepatic impairment and 
therefore, the group of patients with imaging study results may not be 
representative of the general population. Furthermore, above 30 % of the 
abdominal ultrasound scans performed in patients with HL/LA at the time of 
the event were reported as normal. Therefore, it is not possible from these 
data to draw any firm conclusions regarding the frequency of fatty liver 
infiltration in patients who develop episodes of HL/LA.
Moreover, factors other than concomitant viral hepatitis or the effect of ART on 
hepatocytes can not be completed excluded. For instance, in this study cases 
were more frequently described in their clinic notes as having had previous 
serious alcohol consumption habits than controls (23 % vs. 11 % respectively; 
P= 0.004), and that may also play a role in the pathogenesis of abnormal LFT 
results seen in cases. However, it is not possible to draw conclusions on 
alcohol consumption and its possible contribution to abnormal LFT results in 
our study as alcohol consumption habits were not universally described in 
patients’ notes and no details of this were recorded in the study proforma. In 
addition, this may be an example of reporting bias, which is one of the 
potential limitations of this study (see section 7.4): i.e. more information with 
respect to past and current medical history is reported in cases than in 
controls.
Cases included in this study were also more likely than controls to have 
abnormal blood glucose and amylase levels. Although there was a significant 
proportion of missing data on these variables, it was possible to notice that the 
differences between cases and controls were statistically significant (P< 0.001 
and P= 0.034 respectively). Patients with HL/LA have been found to have 
higher blood glucose levels than controls in several previous studies (Carr et 
al. 2000; Moyle et al. 2002). Lo et al. have recently proposed that insulin 
resistance may be an additional mechanism leading to abnormal lactate 
values in patients exposed to NRTIs therapy. They found that after adjusting 
for several factors, including duration of NRTIs exposure, insulin resistance 
(measured by homeostasis model assessment -HOMA-IR-) was significantly
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associated with blood lactate levels (Lo et al. 2005). In the same way, another 
prospective study has recently shown that insulin resistance as well as fasting 
hyperinsulinemia in HIV-infected men are related to cumulative NRTIs 
exposure (Brown et al. 2005). About 10 % of cases but less than 1 % of 
controls included in our study had previous diagnosis of diabetes mellitus (P< 
0.001). A significantly higher proportion of cases (13 %) had previous 
episodes of NRTI-associated pancreatitis than controls (1 %) (P< 0.001). 
Therefore, it is also possible that, at least in a sub-set of the included cases, 
hyperglycaemia may precede the episode of HULA. However, as explained 
before, it is not possible to draw any robust conclusion from these data as 
reporting bias may be an issue.
In the study published by Moyle et al. on HULA the authors noted that all four 
cases of LA they described had concurrent bacterial infections (i.e. respiratory 
or urinary tract infections) at the time of the event (Moyle et al. 2002). 
Although it was not recorded in the study proforma, the possibility of 
concurrent bacterial infections in the cases included in this study can not be 
disregarded. About 17 % of the included cases had leukocytosis at the time of 
being included in the study, and almost 80 % of them had neutrophils count 
above the normal range. In addition, almost 12 % of the cases had 
neutropenia, three of them with neutrophil count < 1 cell x 109/l. In addition, 
about 20 % of the non-fatal cases of LA included in this study were treated 
with antibiotics as part of the event management interventions.
7.1.2 Mitochondrial function
Very limited information was recorded on mitochondrial function or 
morphology at the time of the event for this study. In fact only three patients 
out of the 110 included cases had mitochondrial function tests performed.
Two of the included patients had normal mtDNA content in muscle cells, even
when one of them had mtDNA depletion in PBMC at the time of the event. It
has been documented in both clinical and in vitro studies that AZT and
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AZT/3TC or AZT/ddl combinations can lead to mitochondrial dysfunction 
without affecting mtDNA content (Szabados et al. 1999; Miller et al. 2003; 
Setzer et al. 2005). Of note, the patient with normal mtDNA content in muscle 
cells, but with no studies performed on PBMC was receiving AZT/ddl at the 
time of the LA event. However, the patient with normal mtDNA content in 
muscle cells but mtDNA depletion in PBMC was taking ddl/TDF at the time of 
the HL event.
Although it was not possible to collect a great deal of information on 
mitochondrial function in patients with HULA included in this study, the data 
presented on these three cases does illustrate the spectrum of mitochondrial 
dysfunction in this type of patients. Mitochondrial respiratory chain dysfunction 
may be evident in patients with HULA even when mtDNA depletion is not. 
Furthermore, different cell types may express different patterns of 
mitochondrial dysfunction in the same patient at the time of the event, which 
suggest a tissue specificity of NRTI-induced adverse effects (Cherry et al. 
2002; Olano et al. 1995). Finally, patients with HULA can have impairment of 
all respiratory chain complexes, including complex II which is completely 
encoded by nuclear DNA. The two patients who had significant reduction in 
the activity of complex II in at least one cell type were assessed at the same 
centre. Another patient with symptomatic HL who was also evaluated at that 
centre has been reported as having significant reduction in the activity of all 
respiratory chain complexes as well as mtDNA depletion at the time of the 
event. Interestingly, that patient’s mitochondrial parameters all came back to 
normal once therapy was stopped and the patient became asymptomatic 
(Lopez et al. 2002). Similarly, the included patient who had mitochondrial 
studies done only in muscle cells also had a repeated muscle biopsy 14 
months after the event where not only functional tests but also mitochondrial 
morphology was restored to normal (Miller et al. 2003). In this patient at the 
time of the event only minor mtDNA deletions were found but no other 
alterations in mtDNA structural integrity. Nevertheless, major deletions 
(Walker & Venhoff 2001) and different cumulative type mutations, affecting
178
respiratory chain complexes components synthesis have been reported in 
vitro and in vivo (Martin etal. 2003).
7.1.3 Risk factors for lactic acidosis or severe hyperlactataemia
Substantial evidence has been presented over the last 15 years about the 
association between NRTIs exposure and mitochondrial dysfunction. In fact, 
even when several proposed NRTI-induced ADR have been attributed to 
mitochondrial toxicity (see Chapter 2), LA has been considered as the proof of 
the concept for the proposed association (Brinkman 2001).
HL/LA has been described in patients exposed to almost all NRTIs drugs 
currently in use, with the clear exception of ABC and perhaps 3TC. Although 
combination therapy has been the standard of care for more than a decade 
now, it is important to note that ART combinations are not randomly allocated, 
but follow both historical and biological rationale. Therefore, it is very difficult 
to assess the effect of any individual drug on lactate metabolism and therefore 
on mitochondrial function in vivo.
Furthermore, most of the studies performed to date on mitochondrial 
dysfunction associated with NRTIs exposure have focused on the analysis of 
drug exposures at the time of the event, without considering either the length 
of exposure or the implications of previous exposures to different ART drugs 
on the studied outcome. An exception was the study published by Carr et al. 
in which patients with LA received d4T for longer periods than controls (Carr 
et al. 2000). Some studies have also highlighted the possible role of specific 
NRTIs combinations on the likelihood of developing ADR such as HL/LA 
(Imhof etal. 2005; Boubaker etal. 2001).
In our study we assessed NRTIs exposure using three different approaches.
Previous exposures to different NRTIs as well as exposures at the time of the
event were both assessed. In addition, duration of the exposure to all ART
drugs each patient had been on, i.e. those being taken at the time of the event
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and those previously prescribed were both analysed. Finally, as it is difficult to 
separate individual NRTIs effects, the analysis performed using single drug 
exposure as variable was repeated using the most frequent NRTIs 
combinations seen in the study population.
We were unable to identify any association between previous exposure to any 
NRTIs drug and the study outcome. As has been discussed previously (see 
Chapters 4 and 5), evidence suggests that exposure to d4T is a strong 
inducer of mitochondrial dysfunction (Kakuda 2000). It has also been 
proposed that d4T exposure may be considered as a marker of long term 
exposure to NRTIs because a significant proportion of patients on d4T would 
have been previously exposed to AZT. In fact, 36 out of the 73 patients (49 %) 
who were on d4T at the time of the event in our study had been previously 
exposed to AZT. However, as stated before, previous exposure to AZT, even 
among those who were currently receiving d4T was not associated with the 
study outcome. Furthermore, no significant difference was found in the risk of 
developing HL/LA between patients receiving d4T who had or not had 
previous courses of treatment with AZT. Similarly, John et al. reported in a 
study which included 10 cases that the association between d4T exposure 
and HL/LA was not confounded by previous AZT exposure or by longer history 
of NRTIs use (John etal. 2001).
Current exposure to d4T and ddl were strongly associated with the 
development of HL/LA outcome. Of note, d4T was selected as the main 
exposure for our study design based on several previous studies, including 
our systematic review presented in Chapter 4, where d4T use was strongly 
associated with either LA or HL (Arenas-Pinto et al. 2003; Boubaker et al. 
2001; John et al. 2001). Nevertheless, the association between ddl exposure 
with HL/LA has also been highlighted. Moyle et al. have reported that patients 
receiving ddl based ART combinations had twice the risk for HL (defined as 
blood lactate > 2.4 mmol/I) compared with those not exposed to that drug. 
They also found that treatment with ddl was overrepresented among patients 
with severe HL or LA (defined as blood lactate > 5 mmol/l) (Moyle et al. 2002).
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Nevertheless, in a further matched case-control study performed by the same 
group matching by ddl exposure, in the same study population d4T exposure 
became independently associated with HL (defined as blood lactate > 3.5 
mmol/I) (Datta etal. 2003).
Concomitant exposure to both d4T and ddl has been frequently seen in 
patients with HULA. In this study more than 40 % of the cases of HL/LA were 
receiving a combination ART including d4T/ddl at the time of the event 
whereas the proportion in controls was 12 %. Furthermore, in the multivariate 
model exposure to d4T/ddl combination was associated with a six fold 
increase in the risk of developing HULA when compared with those patients 
on ART combinations other than d4T/ddl.
The most recent report from Swiss Cohort Study on the subject highlights that 
the exposure to d4T is associated with the development of severe HL (defined 
as blood lactate > 5 mmol/l) only when it is administered in combination with 
ddl (HR= 6.65; 95% Cl= 2.7 -  16.3). Furthermore, even when the statistical 
significance of the association between ddl without concomitant d4T exposure 
and severe HL was lost in the multivariate model (HR= 2.95; 95% Cl= 0.8 -  
10.4), the univariate analysis showed a significant increase in the risk of 
developing severe HL among those patients exposed to ddl but not to d4T 
(HR= 4.46; 95% Cl= 1.3 -  15.3) (Imhof etal. 2005). In our study, the increase 
in risk attributable to ddl was significant even in the absence of concurrent 
d4T exposure (OR= 4.06; P= 0.017; 95% Cl= 1.29 -  12.80). In the same way, 
patients who were on d4T with no concomitant exposure to ddl appeared also 
at significant higher risk of developing HULA in the univariate analysis (OR= 
2.92; P= 0.015; 95% Cl= 1.23 -  6.93) when compared to patients not on d4T 
containing regimes. It is important to mention that a significant proportion of 
the cases who were on d4T (64 %) were also taking ddl simultaneously 
whereas only 34 % of the controls who were on d4T (N= 27) were taking ddl 
at the same time. In addition, 64 % of the cases who were on ddl were taking 
that in combination with d4T (N=47).
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Nevertheless, the actual proportion of patients exposed to ddl at the time of 
the inclusion in the first study on HL reported from the Swiss cohort was 22 % 
which was not very different from the overall proportion of patients currently 
exposed to ddl in a smaller prospective study on sustained HL (defined as 
blood lactate > 2.1 mmol/l; N= 11 cases) where authors found a significant 
association between ddl exposure and HL. In that study authors suggested 
that the association between ddl exposure and HL is to some extent higher 
than the association between d4T and the same outcome, even when no risk 
analysis was presented (Hocqueloux et al. 2003). In our study the overall 
proportion of current exposure to ddl was 36 %, and certainly the association 
between ddl exposure and HL/LA was consistently found irrespective of the 
approach used to analyse the effect of NRTIs on the likelihood of developing 
HL/LA.
In contrast, the study performed by John et al. did not find any association 
between ddl exposure and HL in the Western Australian Cohort (N= 349) 
(John et al. 2001). However, the actual number of patients exposed to ddl in 
that cohort was very low. Only 44 out of 349 participants (13 %) in the 
previously mentioned study were receiving ddl. However, the proportion of 
people on ddl in the study published by Moyle at al. was fairly similar to that 
figure as it was about 16 % and they did find an association between ddl 
exposure and HL (Moyle etal. 2002).
Although different studies have shown slightly different results on the 
association between d4T, ddl and the combination of these two and HL/LA, it 
has been constantly demonstrated that exposure to these drugs increases the 
risk of developing HL/LA. In addition, in vitro data also support these findings. 
Results presented in chapter 6 show that exposure to both d4T and ddl are 
independently associated with HL/LA. In addition, when exposure to the 
combination of these two drugs (d4T/ddl) is analysed, the magnitude of the 
effect on HL/LA looks even stronger than the effect of any drug considered 
individually, suggesting an additive effect. It looks like exposure to d4T, ddl or 
d4T/ddl is associated with a real rise in the risk of developing HL/LA.
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However, to assess accurately the magnitude of the effect of each drug is 
extremely complicated as drugs are always prescribed in combination and 
therefore, there is not an easy way to control for the effect of other drugs 
included in frequently used combinations.
Conversely, in our study patients exposed to AZT/3TC containing 
combinations were at much lower risk of developing HL/LA. In fact, after 
adjusting by other factors included in the multivariate model, exposure to 
AZT/3TC shows a “protective” effect for HL/LA (OFUO.35; 95% Cl= 0.14 -  
0.89) when compared to those patients receiving different NRTIs 
backgrounds. AZT and d4T are not prescribed together because of the 
interactions described between these two. One would assume therefore that 
being on treatment with AZT containing combinations may protect against 
HL/LA simply because d4T can not be added to AZT containing regimes. Of 
interest, only one case and seven controls were receiving AZT/ddl containing 
combinations at the time of their inclusion in the study.
A few clinical and in vitro studies have suggested that the duration of the 
exposure to NRTIs, and particularly to d4T, may play a significant role in 
mitochondrial dysfunction (ter Hofstede etal. 2000; Walker et al. 2002). Harris 
et al. have found that a longer duration of d4T exposure was associated with a 
moderate (12 % per quarter year) increase in the likelihood of abnormal 
random venous lactate result (Harris et al. 2002). Similarly, a prospective 
study on mitochondrial genetics in HIV-infected patients found that duration of 
NRTIs exposure was the only factor associated with mtDNA depletion 
(McComsey et al. 2005a). Similarly, a few clinical studies have suggested that 
longer exposure to both d4T and ddl may be associated with HULA (Carr et 
al. 2000; Manfredi et al. 2003) in contrast to others who have not found any 
association between duration of the exposure to any NRTIs and the likelihood 
of developing HL (Bonnet etal. 2003).
Interestingly, cases included in our study were more likely to receive d4T for 
shorter time periods than controls. As mentioned in chapter 6, the odds of
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developing HULA in those patients on d4T decline by about 3 % each month. 
Actually, patients exposed to d4T for periods longer than 15 months were at 
significant lower risk of developing HULA (OR= 0.27; 95% Cl= 0.11 -  0.68) 
when compared to patients exposed to d4T for shorter periods of time. 
Furthermore, the median d4T duration for cases immediately before the event 
was about 6 month shorter than the figure calculated for controls (11.74 and 
18.42 months respectively). This could be interpreted as a kind of “survivor 
bias” as those patients exposed to d4T who did not develop any serious ADR 
could keep taking ART combinations including d4T whereas those patients 
who developed a severe d4T-associated ADR (such as severe HL or LA) 
generally are switched away from such a drug. Therefore, the duration of the 
exposure to d4T among controls in this study may be longer than the duration 
of the exposures among cases because the study outcome censors further 
d4T exposure.
Nevertheless, previous studies have suggested that patients with borderline 
mitochondrial function or those with sub-clinical mitochondrial impairment may 
be at higher risk of developing NRTI-induced clinically evident mitochondrial 
dysfunction (Moyle 2000). Therefore, such individuals may be particularly 
susceptible to the effect of any mitochondrial toxic drug, including NRTIs and 
particularly d4T. For instance, a few reports have suggested an association 
between late onset of Leber’s hereditary optic neuropathy and NRTIs 
exposure in HIV-infected patients (Shaikh etal. 2001; Luzhansky et al. 2001).
A recently published study on risk factors for peripheral neuropathy (PN) in 
HIV-infected patients on ART has shown that those patients belonging to 
mitochondrial haplogroup T, a common haplogroup described in European 
populations, are at higher risk of developing PN when compared to people 
showing different haplogoups. The study, which was a sub-study of the ACTG  
trial 384, was limited to white patients. The effect of haplogroup T was 
stronger among those randomised to receive d4T/ddl (Hulgan et al. 2005). 
Similar observations have been made outside of the HIV field in a small study 
on ototoxicity attributed to cisplatin. Patients belonging to the mitochondrial
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haplogroup J, a rare European haplogroup, were overrepresented among 
those with impaired hearing when compared to exposed patients with normal 
hearing (Peters et al. 2003).
Taken all together, one could hypothesise that a particular group of individuals 
may be at much higher risk of developing serious NRT-induced mitochondrial 
dysfunction. They may already have a particular genetic background which 
may or may not lead to sub-clinical mitochondrial dysfunction, but which 
facilitates a deleterious effect of NRTIs on mitochondrial function. If this is the 
rationale, relatively short exposure periods to any mitochondrial toxic drug 
may be enough to induce clinically evident mitochondrial dysfunction in those 
patients with pre-existing inherited conditions.
Furthermore, although the study was not powered to examine the effect of 
ethnicity on the study outcome, there was a suggestion that ethnicity may be a 
risk factor. As mentioned before, Gerard et al. have reported that black African 
women may be at much higher risk of developing severe HL when compared 
with white women (Gerard et al. 2005). Similarly, our data suggest that the 
occurrence of HL/LA may be more frequent in non-white populations.
Nevertheless, the data presented in our study and taking into account those 
from other studies, cannot allow one to reach any definitive conclusion 
regarding the mechanisms for the proposed susceptibility in a particular group 
of individuals. Studies specifically designed to answer that question are 
urgently needed. A better identification of those individuals at significantly 
higher risk of developing serious NRTI-induced mitothondrial dysfunction, 
such as HL/LA, may help clinicians to make more appropriate choices when 
starting a specific patient on ART. This may be particularly relevant in 
resource limited settings where ART options are restricted, laboratory support 
for monitoring therapy is scanty and confidence of people on HIV-control 
programs may be seriously affected by the occurrence of serious ADR 
(Katabira 2005). Proper identification of risk factors for serious ADR, such as 
HL7LA, and particularly elucidation of the proposed inherited predisposition
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may result in a significant step not only in the prevention of morbidity and even 
mortality associated to HIV-infection management, but also in boosting 
community acceptance and support in HIV control programs in developing 
countries.
Advanced HIV disease has also been proposed as an independent risk factor 
for NRTI-induced ADR (Joly et al. 2002). In our study low nadir and CD4 count 
at the time of the event (< 200 cell/pl) were significantly associated with the 
study outcome in the univariate analysis (OR= 4.38, 95% Cl= 2.08 -  9.22 and 
OR= 3.63, 95% Cl= 1.94 -  6.83 respectively). Furthermore, CD4 count at the 
time of the event was independently associated with HL/LA in the multivariate 
analysis. Therefore, one could assume that our study may be comparing a 
group of patients with advanced HIV disease, more likely to develop ADR 
anyway with a group of people with better controlled HIV disease. The latter 
may have started ART earlier and therefore would have better control of viral 
replication and in consequence lower risk of developing ADR. In fact, 76 % of 
the 91 cases with information on nadir CD4 count had less than 200 cell/pl. 
Out of these 91 cases 85 individuals had also current CD4 counts reported in 
their notes. About 40 % of the included cases had both low nadir CD4 and 
low current CD4 count whereas only 18 %  of controls with information 
regarding these values had both nadir and current CD4 counts lower than 200 
cell/|il.
Certainly from the data collected for the study, it is not possible to find out if 
these cases with both low nadir and current CD4 counts just had a poor 
response to ART and remained severely immunosuppressed during their 
exposure to ART drugs or they just had a latter decline in their control of viral 
replication. However, in any case, there is a consistency in the finding of an 
association between advanced HIV disease markers and the likelihood of 
developing NRTI-associated ADR. In the context of the other results 
presented here, it appears that the use of specific drugs, such as d4T and ddl 
in developing countries where patients tend to start ART at advanced stages 
of the HIV disease should be considered as an important issue. Financial
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and public health variables need to be taken into account but also so should 
safety issues.
Another relevant finding in our study is the strong association between female 
gender and the study outcome. Previous studies have suggested that HL/LA 
may be more frequently seen in female patients (Arenas-Pinto et al. 2003). 
Nevertheless, the precise mechanism for that predisposition is not completely 
understood. Female patients exposed to AZT/3TC show a significantly higher 
intracellular concentration (assessed in PBMC) of the respective NRTIs 
triphosphate metabolites, which may induce a higher degree of toxicity 
(Anderson et al. 2003). However, no data on d4T or ddl metabolites have 
been presented. In addition, other factors may also play a significant role. 
Hormonal variations, assessed through estradiol and progesterone infusion in 
a mice model, may lead to liver mitochondrial dysfunction which terminates in 
acute hepatic steatosis (Grimbert et al. 1995). Finally, other chronic conditions 
recently associated with mitochondrial dysfunction, such as Alzheimer’s 
disease, have been found to be more prevalent in women than in men. This 
difference in prevalence between genders has also been suggested to be a 
consequence of greater longevity. However, several epidemiological studies 
have noticed that Alzheimer’s disease is still more frequent among women 
than in men even when other factors are controlled for (Barclay et al. 1985; 
Rocca et al. 1990). Furthermore, an interesting in vitro study with 
teratocarcinoma cells has suggested that mtDNA-related mitochondrial 
dysfunction may play a significant role in cellular degeneration in Alzheimer’s 
disease (Cardoso et al. 2004). Therefore, it is possible that women or a 
specific group of women are at higher risk of developing clinically evident 
mitochondrial dysfunction not only when exposed to mitochondrial toxic drugs, 
but also as consequence of other physiological and pathological processes.
It has also been suggested that women, particularly those from ethnic 
minorities living in developed countries, tend to get access to regular HIV 
medical care late in the course of their HIV disease compared to men 
(Anastos etal. 2005; Clark 2005; Currier etal. 2000). So, it is possible that the
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effect of advanced HIV-induced immunosuppression may be stronger among 
female patients exposed to ART as they may have been started on ART at a 
more advanced stage of their HIV disease. However, in our study male and 
female cases show very similar pictures of HIV disease progression both at 
base-line (nadir CD4 < 200 cell/pl was noted in 70 % of male cases and 87 % 
of female cases) and at the time of the event (CD4 200 cell/pl seen in 47 % of 
male and 40 % of female cases).
Therefore, even though the exact mechanism for most of the factors 
associated with HL/LA is not well understood, it does looks clear that female 
patients with advanced HIV disease when exposed to d4T and also to ddl are 
at much higher risk of developing HL/LA. In addition, it is also possible that 
those individuals who are non-white may be at even greater risk for this 
complication. A genetic mechanism for this mitochondrial dysfunction should 
be investigated as a matter of urgency.
7.2 Comparison between risk factors for HL and LA
As mentioned before, a few experts in the field have suggested unifying all 
diagnoses previously used to describe abnormalities in blood lactate 
metabolism into a single entity: lactic acidemia (Carr 2003; Schambelan et al. 
2002). Although there is a clear biological plausibility for this a few issues 
should be considered when this approach is taken. Firstly, even when several 
authors have suggested that LA is the final outcome of a progressive 
mechanism of rising levels of blood lactate induced by NRTIs (Moyle et al. 
2002; Powderly 2002), such a progression through increasing hyperlactatemic 
stages to LA has not been properly demonstrated.
In addition, even when attributable symptoms are almost always present in
patients with LA, our study shows that some symptom free patients can have
sustained and severe HL (10/110; 9% of our cases) and conversely, other
smaller reports have established that patients with mild-moderate HL may
have symptoms attributable to that condition (Hocqueloux et al. 2003).
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Therefore, those patients with severe but asymptomatic HL can only be 
diagnosed through routine or random screening of blood lactate levels which 
is not a regular practice in most centres.
It has been proposed that mild to moderate episodes of HL can be transient 
and may not imply any further risk for developing serious complications (Moyle 
et al. 2002). Nevertheless, this proposal was made in reference to patients 
with blood lactate usually in the range of 2.5 to 5 mmol/l not in the context of 
patients with sustained blood lactate levels above 5 mmol/l. Six out of the 10 
asymptomatic cases of HL included in our study developed further episodes of 
HL while continuing or after being re-challenged with combination ART 
including either d4T, ddl or both (d4T/ddl). This observation may suggest that 
those patients who develop episodes of asymptomatic severe HL are at higher 
risk of developing this complication at any time if they are exposed to further 
dideoxynucleoside analogues. None of the asymptomatic cases had a fatal 
outcome in our study but some of them presented characteristics associated 
with fatality such as current blood lactate concentration higher than 7 mmol/l 
(see section 7.3). Consequently, although it is difficult to speculate on the 
long-term implications of asymptomatic episodes of HL, given the results of 
our study, it may not be easy either to assume that such episodes are benign 
and transient elevations of blood lactate levels.
The results from our study and all previously published reports support the 
association between exposure to NRTIs, particularly d4T, ddl and the 
combination of these two, and both HL and LA. However, from table 6.13 one 
could assume that not all variables identified as risk factors for the combined 
outcome (HL/LA) behave in the same way for each outcome when considered 
separately. Few variables such as female gender appears strongly associated 
with LA (OR= 8.88; 95% Cl= 2.57 -  30.64) but not necessarily with HL (OR= 
1.94; 95% Cl= 0.91 -  4.15). However, as with all other variables in the table 
6.13, even when the effect of gender on HL does not reach statistical 
significance the direction of the effect is in the same direction for HL as that for 
LA. Therefore, considering that the study was not powered to assess
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differences between each outcome considered in isolation, it is at least not 
possible to draw any firm conclusion on this issue.
Nevertheless, not only from the data presented in table 6.13, but also from the 
analysis of interactions performed (see chapter 6, section 6.2.4) it is clear that 
even after adjusting for all other variables, the interaction term between 
female gender and LA remains significant suggesting that the association 
between female gender and LA is quite strong. Furthermore, after adding the 
interaction term between female gender and LA to the multivariate model 
developed for the combined outcome, only the effect of female gender is 
affected, leading that to lose its significance while the effect of all other factors 
included in the model remained practically the same. This additional analysis 
also supports the impression of female patients being at significantly higher 
risk for LA but not necessarily for HL.
Nonetheless, if progression from HL to LA is part of a continuum in the natural 
history of the complication and if female patients are at particular higher risk of 
developing LA compared to male patients, one could hypothesise that 
episodes of HL may be somehow more severe in female patients when 
compared to male. Indeed, all female cases of HL included in this study were 
symptomatic. In addition to that, women tended to have higher blood lactate 
levels at the time of the event (median lactate=7.0 mmol/l; IQR= 6.01 -  7.5) 
than men (median lactate= 5.8 mmol/l; IQR= 5.42 -  7.35) although that 
difference was not statistically significant (P= 0.075). Furthermore, 52 % of 
the female cases of HL had blood lactate higher than 7 mmol/l at the time of 
diagnosis whereas only 20 % of male cases had levels that high (P= 0.001). 
Therefore, from the clinical and the biochemical points of view female cases of 
HL were in some way more severe than the episodes presented in male 
patients included in this study.
Data coming from a clinical trial published few years ago, shows that female 
patients randomised to receive either ddl monotherapy or the combination of 
AZT/ddl were significantly more likely to discontinue ART or to reduce dose
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because of ADR than male participants (Currier et al. 2000). Interestingly 
women were also more likely to be black or Hispanic.
In conclusion, in addition to an as yet unexplained underlying special 
susceptibility which may be ethnicity patients with advanced HIV-induced 
immunosupression who are exposed to d4T, ddl or the combination of these 
two NRTIs are at higher risk of developing HL/LA. Furthermore, as aging may 
also be associated with mitochondrial dysfunction, older patients exposed to 
all previously listed factors may be even at higher risk of developing such a 
combined outcome. Also, based on the results presented in our study, one 
could assume that a particular group of individuals, namely HIV-infected 
women when exposed to the previously mentioned factors may be at higher 
risk of developing LA. Furthermore, the fact that female patients are more 
likely to developed more severe episodes of sustained HL than male may also 
support the concept of progression from HL to LA.
7.3 Analysis of the outcome of the event
A few issues regarding the outcome of the event have been already 
discussed. However, it is important to emphasize some important issues 
which may have implications in the management of this complication.
7.3.1 Risk factors for mortality associated with HL/LA
Since the first cases of LA in HIV infection were published a high case fatality 
rate attributable to that complication was recognised. However, only one study 
published to date has explored factors associated with a fatal outcome. In the 
paper published by Falco et al 12 cases were presented (Falco et al. 2002). 
The calculated case fatality rate for that series was 33 %, which is appreciably 
different from the rate calculated for our study (17.3 %). Nevertheless, the 
figure calculated by Falco et al. does not differ at all from the case fatality rate 
we calculated in this study when only cases of LA are considered (32.7 %).
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The case fatality rate calculated from the systematic review of published 
cases of LA we performed earlier (see chapter 4) was rather higher (47 %).
However, in our systematic review there were 90 cases of LA included, 50 %  
of whom were diagnosed between 1991 and 1999. The other 45 cases were 
diagnosed between 2000 and 2001. Interestingly, the case fatality rate among 
the first half of cases included in such review was 64 %, whereas the same 
figure calculated for the most recently diagnosed cases was 33 % (Arenas- 
Pinto et al. 2003). Similarly, the case fatality rate calculated by Megarbane et 
al. for the review of published cases of LA, which included cases diagnosed 
during the 90’s, was 60 % (Megarbane et al. 1999). The differences here are 
probably due to an increasing level of awareness of this complication amongst 
clinicians which has led to earlier diagnosis and intervention over time. 
Nevertheless, LA is still associated with a high mortality rate.
In contrast, it is important to mention that the case fatality rate among patients 
with severe and sustained HL was significantly lower than the figures 
presented in the previous paragraph. Only about 5 % of HL cases died as a 
consequence of the event. Of note, few data have been published on mortality 
associated with HL. For instance, in a small cohort study eight patients were 
diagnosed with HL (defined as 2 consecutive blood lactate > 2.1 mmol/l) and 
only one of them died as consequence of the event. Interestingly, the fatal 
case presented by Hocqueloux et al. went onto an episode of LA. So the 
authors suggested that the long-term outcome of patients with HL may not be 
poorer than controls (Hocqueloux et al. 2003). In addition, in a review on the 
long-term complications associated with ART, although no evidence was 
presented to support the statement, Powderly suggests that progression of 
untreated HL may lead to acidosis, which is associated with high rates of 
fatality (Powderly 2002). Therefore, there is not evidence of HL leading to fatal 
outcome unless acidosis is developed.
In this study, LA itself was identified as the strongest independent risk factor 
for case fatality: acidotic patients were 10 times more likely to die as
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consequence of the episode when compared with non-acidotic individuals. In 
addition, those patients with blood lactate levels above 7 mmol/l were also at 
significantly higher risk of dying when compared to those with lower levels of 
blood lactate. Similarly, Falco et al. also found that having a blood lactate level 
higher than 10 mmol/l was the only factor independently associated with 
fatality in their study (Falco et al. 2002). In our study the cut-off was set at 7 
mmol/l as that value was the median calculated for the cases of HL/LA.
As mentioned before, it is not surprising that more severely ill patients are at 
higher risk of dying. However, it is important to mention that most of the 
previously proposed classifications for blood lactate disorders in HIV-infected 
patients have used a threshold of 10 mmol/l of blood lactate to either make a 
diagnosis of severe HL (John & Mallal 2002) or to classify a case of “lactic 
acidemia” regardless of the presence of symptoms (Carr 2003; Schambelan et 
al. 2002). However, in the light of results presented in our study, it may be 
pertinent to consider a different threshold value, as patients with blood lactate 
levels substantially lower than 10 mmol/l are at significantly higher risk of 
dying.
In addition, it is important to highlight in our study that 14 % (7/49) of the LA 
cases had blood lactate levels lower than 5 mmol/l at the time of diagnosis. 
Therefore, they would not meet the criteria as cases of lactic acidemia, 
according to the proposed classification. None of the seven acidotic cases 
who had lactate levels lower than 5 mmol/l died as consequence of the event 
but all of them were clearly symptomatic.
7.3.2 Further follow-up of non-fatal cases
It has been previously proposed that patients who have a history of episodes
of ADR, particularly those attributable to NRTI-induced mitochondrial
dysfunction, may be at higher risk of developing HULA (ter Hofstede et al.
2000; Gerard et al. 2000). In our study, previous ART-associated ADR and
particularly those believed to be due to mitochondrial dysfunction were
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significantly associated with the study outcome in the univariate analysis (OR= 
3.58, 95% Cl= 2.13 -  6.01 and OR= 5.87, 95% Cl= 3.14 -  10.98 respectively). 
However, these variables were excluded from the multivariate model as it was 
not possible to assess the length of time between them and the current 
episode of HULA. This was because dates for such previous ADR were not 
collected in the study proforma. Therefore, it was not possible to exclude the 
possibility of the events being somehow associated with each other, i.e. they 
were all part of the same episode.
Nevertheless, 13 (14 %) of these 91 cases who survived their episode of 
HULA developed further episodes of HL. Interestingly, all these 13 
subsequent episodes were HL and all were associated with re-exposure (or 
continuation of the exposure) to ART. In addition, 20 of those 91 non-fatal 
cases (22 %) developed other forms of mitochondrial ADR after the episode of 
HULA. So, in all, about a third of the non-fatal cases developed some form of 
clinically apparent mitochondrial dysfunction after being re-exposed to ART.
As the study was not powered to assess the recurrence of ADR in non-fatal 
cases, we cannot speculate any further on potential risk factors for 
subsequent episodes of HL or any other mitochondrial toxicity after a 
successfully managed episode of HULA. Nevertheless, a trend was noticed 
towards an increased risk for further episodes when patients were re­
challenged with a d4T-containing ART combination. In the absence of any 
conclusive data on this issue, it may be sensible to avoid, whenever possible, 
to re-expose patients who have developed episodes of HULA to drugs likely 
to induce HULA (i.e. d4T and ddl).
7.4 Limitations of the study
Like any other retrospective study, the case-control study presented here has
important limitations. Firstly, this retrospective, multi-centre study included
cases diagnosed and managed in centres with different policies in the
monitoring and management of patients. A few clinics included in this study
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incorporate blood lactate in the set of tests routinely performed to patients. 
Therefore, in some but not all participant centres, it was possible to identify 
asymptomatic cases of severe and sustained HL. Furthermore, policies have 
changed in a few centres during the study period in this regard, and therefore 
the likelihood of identifying cases of HL has also varied over time.
In addition, even when a standardised proforma was used to collect data from 
both cases and controls and when most of the study proformas were either 
completed or audited by the principal investigator, a certain degree of 
reporting bias can not be excluded. The level of description of current and 
previous medical information in cases tended to be rather higher in some 
centres when compared with the available information about controls. 
Nevertheless, all patients’ notes were searched backwards until the earliest 
available documented consultation and therefore, all the available information 
was recorded in the study proformas.
Besides, reasons for switching ART combinations were not recorded and 
therefore, it is not possible to assess whether or not exposure to any specific 
drugs was preceded by virological or immunological failure or was 
consequence of any ADR. Therefore, we cannot exclude the impact of high 
viral load or low CD4 on the effect of a given regimen. Similarly, even when 
previous ADR were recorded, the dates for these episodes were not. 
Consequently, it is difficult to analyse the occurrence of these previous ADR in 
the context of concurrent exposure to ART and impossible to assess how 
close in time these previous ADR were to the event of HL/LA.
As in many other retrospective studies, significant amounts of missing values 
were identified. This missing data was particularly relevant during the process 
of developing the multivariate model for risk factors associated with HL/LA 
because of the conditional analysis used. Of note, data on variables such as 
laboratory results and past medical history were less frequently available 
among controls than in cases. Therefore, because of the conditional 
(matched) analysis performed, when a specific variable was not reported in a
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control patient its respective case was also lost for the analysis of that 
particular variable.
As has been mentioned before, given the lack of ethnic variability observed in 
the study population and because of the level of ethnic homogeneity found in 
most participant clinics’ population, matching by centre may be an 
overmatching by ethnicity. Therefore, results presented in chapter 6 are likely 
to underestimate the association between ethnic background and HULA.
In addition, among all limitations classically attributed to case-control studies, 
information or recall bias is perhaps the less relevant to this particular one. All 
data were collected from clinical notes which were completed at the time of 
the event or at the time of the index consultation for cases, and therefore are 
not likely to be affected by what either clinicians or patients may recall months 
or even years after the event. Nevertheless, it is not possible either to exclude 
the possibility of cases to be a group more frequently affected by HIV- 
associated complications than controls. Therefore, it is possible that more 
clinical and laboratory data are collected in cases than in controls simply 
because cases were seen in clinic more often or required more attention from 
their doctors.
The fact that duration of d4T exposure is shorter on average among cases 
than the controls probably indicates that the risk of HULA decreases over time 
as has been mentioned before. Although a sort of “survivor bias” could be 
argued as an explanation for that, matching by calendar time results in the 
same effect on both cases and controls. Therefore, the reduction on the risk 
for the study outcome over time may be real. That is certainly a very important 
finding which should be investigated further.
The study population included in this case-control study represent also the 
largest case series of HULA compiled to date. Therefore, a detailed 
descriptive analysis of the cases included is presented. Demographic, 
epidemiological and clinical variables were assessed in an attempt of
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producing a comprehensive picture of the group of cases included. However, 
it is well known that multiple comparisons certainly can generate false positive 
associations (Type I error). Therefore, for the study of risk factors for HL/LA, 
not all the variables collected were assessed in the logistic regression model. 
As described in chapter 5, the analysis strategy was designed before the data 
collection phase and was based mainly on the findings of the systematic 
review (chapter 4) and other previous studies available. Factors such as age, 
gender, severity of HIV-induced immunosuppression (both at baseline and at 
the time of the event), previous and concurrent ADR and detailed history of 
exposure to NRTI were assessed in the model developed. Other factors, 
although described in the previous section, were not entered in the model. 
However, specific statistical tests for type I errors were not performed.
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CHAPTER 8
Concluding discussion
After about two decades of experience in the therapeutic management of HIV 
infection and after having achieved significant progress in controlling viral 
replication, NRTIs remain as the backbone of most ART combinations 
prescribed worldwide. Furthermore, NRTIs and particularly thymidine 
analogues (i.e. AZT and d4T) are the cornerstone of first line combination 
options suggested by the WHO for developing countries (World Health 
Organization 2003).
Therefore, most of those patients who are taking ART at the moment and the 
several million people more in the developing world that will start in coming 
years are going to be exposed to NRTIs. Of note most of the patients who are 
going to initiate ART in the near future are going to receive thymidine 
analogue based combinations. Consequently, it remains critically important to 
identify not only the risk factors associated with NRTI-induced ADR but also to 
quantify risk and to produce evidence based guidelines for the use of 
thymidine analogues. In addition, it is also critically important to identify an 
efficient approach in the management of associated complications. It will also 
be essential to develop and evaluate appropriate and cost-effective safety 
monitoring strategies considering the limited access to laboratory support in 
many countries of the developing world.
8.1 Effect of dideoxynucleosides on mitochondrial function
As mentioned in chapter 2, most of the NRTIs currently in clinical use, and 
particularly dideoxynucleosides have been shown to affect mitochondrial 
structure and function. Such deleterious effects on mitochondria have also 
been suggested as a mechanism for most NRTI-associated ADR.
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8.1.1 Dideoxynucleosides as risk factor for HL/LA and PN
Both in-vitro and clinical studies have demonstrated that NRTIs can induce 
mitochondrial dysfunction and such mitochondrial impairment may or may not 
include mtDNA depletion (see chapter 2). Furthermore, most of ADR 
attributed to NRTIs have been explained as a consequence of mitochondrial 
dysfunction. In that context, both PN and HL/LA have been described as 
major ADR associated with d4T and ddl. Interestingly, even when ddC has 
also been described as a potent PN inducer (Yarchoan et al. 1988), not a 
single case of HL/LA associated with ddC has been published. However, ddC 
has not been prescribed to the same extent as other licensed NRTIs and 
therefore, a significantly smaller number of patients have been exposed to it 
than to other NRTIs. The last observation could be important as uncommon 
ADR, to be identified, require a large number of exposed individuals (Bisson et 
al. 2003). Interestingly, a few patients who were previously exposed to ddC 
have developed HL/LA when exposed to other NRTIs but not ddC. In fact, 19 
out of the 110 cases included in the case-control study presented in chapters
5 to 7 had previous exposure to ddC as so did at least 7 of the cases included 
in the systematic review presented in chapter 4 (data not shown).
On the other hand, ddC exposure has been consistently associated with PN 
(Bisson et al. 2003; Fichtenbaum et al. 1995). In the sub-analysis of Delta 
presented in chapter 3 it was obvious that those patients exposed to AZT/ddC 
combination showed a higher incidence rate of PN when compared to patients 
receiving either AZT monotherapy or AZT/ddl combination. It has been 
mentioned before that NRTI-induced mitochondrial dysfunction may be drug 
and tissue specific (Vittecoq et al. 2002; Cherry & Wesselingh 2003). 
Therefore, one could assume that the capacity of a given dideoxynucleoside 
to induce clinically evident complications may depend not only on its ability of 
inducing mitochondrial dysfunction but also on other variables, which may 
include not only pharmacokinetic factors but also pre-existing mitochondrial 
dysfunctions and the effect of the HIV itself (Cherry & Wesselingh 2003; Max
6  Sherer 2000).
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It has been proposed that HIV itself can affect the likelihood of developing 
mitochondrial toxicities, suggesting that those patients with more advanced 
HIV disease are at higher risk of developing at least some NRTI-associated 
ADR (Joly etal. 2002; Moyle 2005b). In chapter 3 some evidence is presented 
suggesting that patients exposed to ddC in combination with AZT in the Delta 
trial had a poorer clinical response to ART than those exposed to AZT/ddl 
combination. Therefore, the higher incidence of PN among those patients 
exposed to ddC may be explained not only because of the strong effect of 
ddC on mitochondrial function but also the effect of HIV itself or the 
inflammatory response to it in peripheral nerves (Keswani et al. 2002; Luciano 
et al. 2003). A few studies have shown that HIV-infected individuals who have 
never been exposed to any ART drug have a significantly lower level of 
mtDNA in their PBMC when compared to healthy volunteers (Cote et al. 2002; 
Shikuma et al. 2001). Interestingly, after a year of exposure to ART 
combinations those patients with baseline mtDNA depletion show a significant 
recovery of their mtDNA content and this was seen even among those 
receiving dideoxynucleoside based combinations (Gallant et al. 2002; Miura et 
al. 2003). The study published by Miura et al. has also found an association 
between mtDNA content and HIV disease progression which has not been 
confirmed by others yet.
Furthermore, not only mtDNA depletion but also significant reduction in 
respiratory chain complex activity has been demonstrated in treatment naive 
HIV-infected individuals when compared with healthy volunteers (Miro et al. 
2004a; Morgello et al. 1995). Interestingly, Miro et al. have found significant 
reduction in the activity of all respiratory chain complexes, including complex 
II, which is entirely encoded by nDNA. Therefore, HIV-induced mtDNA 
depletion may be interpreted as a marker of generalised mitochondrial 
damage rather than any direct effect of the virus on mtDNA replication. 
Interestingly, two of the cases included in the case-control study presented in 
chapters 5 to 7 in whom mitochondrial function tests were performed also
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showed significant reduction in respiratory chain complex II in at least one cell 
type. These two cases were taking NRTIs at the time of the event.
In addition, several HIV proteins (e.g. TAT, vpr and HIV protease) have been 
proposed as capable of affecting mitochondrial function through different 
mechanisms (Raidel et al. 2002; Jacotot et al. 2000; Roumier et al. 2002; Nie 
et al. 2002). Furthermore, inflammation mediators and cytokines released in 
response to HIV infection or its complications (e.g. tumour necrosis factor-a or 
interferon-y) have been associated with functional and morphological 
impairment of mitochondria in neurons and smooth muscle cells (Polla et al. 
1996; Li et al. 2001; Geng et al. 1992). Therefore, it may be possible for HIV 
to affect mitochondrial function and structure either directly or indirectly and if 
that is the case, one could assume that the magnitude of the viral burden in a 
given patient may influence the likelihood of developing serious mitochondrial 
dysfunctions.
In summary, one could assume that HIV disease may at least modulate the 
effect of NRTIs and particularly dideoxynucleosides on mitochondria. Not 
surprisingly then, current CD4 count lower than 200 cell/pl was identified as an 
independent risk factor for HL/LA in the case-control study presented in 
chapters 5 to 7.
Nevertheless, it has been clearly demonstrated that NRTIs can affect 
mitochondrial function even in the absence of HIV infection. This has been 
demonstrated not only in vitro (Yamaguchi et al. 2002) but also in vivo. In a 
small study, twenty healthy male adults were exposed to either AZT/3TC or 
d4T/3TC for six weeks. After only two weeks of exposure these healthy 
individuals showed a significant reduction of mitochondrial gene expression in 
adipocytes and in monocytes at week six (Mallon et al. 2005). Interestingly 
Mallon et al. did not find any evidence of mtDNA depletion in that group of 
individuals.
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However, given the fact that combination ART is the standard of care and 
because combinations in clinical use are not randomly allocated, it is difficult 
to analyse the effect of specific drugs on ADR and therefore, almost all NRTIs 
currently in clinical use have been associated with mitochondrial toxicities.
However, d4T has been consistently reported as independently associated 
with clinically evident mitochondrial dysfunction, particularly with HL/LA 
(Brinkman et al. 1999; Caron et al. 2004; Walker et al. 2001). The data 
presented in this thesis also support that association. However, when 
exposure to NRTIs is analysed considering the combination backbone rather 
than single drug exposure, the effect of d4T was found to be significant only 
when it was prescribed in combination with ddl. In addition, ddl was also found 
to be associated with HULA when assessed as single drug exposure (see 
chapter 6). The effect of ddl with or without d4T concomitant exposure should 
be assessed carefully, particularly because ddl has been included as a 
second line option for HIV treatment in developing countries by the WHO  
(World Health Organization 2003). Therefore, many patients who may have 
developed therapeutic failure or significant toxicity with first line NRTIs may be 
at high risk for HULA.
ABC has not been associated with any mitochondrial toxicity and that may be 
consequence of its unique phosphorylation pathway (Kakuda 2000). In 
addition, it has been shown that switching patients from d4T to ABC may 
reverse the mtDNA depletion seen at baseline not only in PBMC but also in 
muscle and adipose tissue as well. Furthermore, such a switching strategy 
can also improve the activity of respiratory chain complex I after 48 weeks 
(McComsey et al. 2005b). Although AZT has been associated with a number 
of ADR attributable to mitochondrial dysfunction (i.e. bone marrow 
suppression and LA) switching patients from d4T to AZT has also been shown 
to be beneficial for patients with lipodistrophy syndrome and even persistent 
HL (Lonergan etal. 2004).
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On the other hand, 3TC has been shown to be a very weak inducer of 
mitochondrial dysfunction in vitro (Kakuda 2000) and is considered in clinical 
practice as a relatively safe drug. Interestingly, in the case-control study 
presented in chapters 5 to 7, exposure to ABC or 3TC was not associated with 
HULA as expected. Furthermore, when ART exposure is assessed using 
NRTIs combinations rather than single drug exposure, current treatment with 
AZT/3TC based combinations was found to be negatively associated with 
HULA. One could assume that being exposed to AZT may avert the study 
outcome by preventing patients being treated with d4T, so patients on AZT 
may be at lower risk of developing HULA because they were not taking d4T.
If 3TC is not capable of inducing significant mitochondrial dysfunction, one 
would expect it to have a very safe profile, at least on mitochondrial 
dysfunction associated ADR. Data from a large observational study have 
highlighted the beneficial effect of 3TC on HL. In the paper published by the 
Swiss Cohort in 2001 both 3TC (OR= 0.4; 95% Cl= 0.2 -  0.6) and AZT 
exposure (OR= 0.4; 95% Cl= 0.2 - 0.7) showed a protective effect for HL in 
the univariate analysis but they did not find any significant effect of 3TC or 
AZT after adjusting for other factors in the multivariate model, so the apparent 
beneficial effect of these drugs on protecting against mitochondrial dysfunction 
may be confounded by other factors (Boubaker et al. 2001). However, Moyle 
et al. have shown that patients exposed to some combinations including 3TC, 
such as 3TC/ABC or even 3TC/d4T have a significant lower risk of developing 
HL (defined as blood lactate > 2.5 mmol/l) than those individuals exposed to 
d4T/ddl (RH= 0.2; 95% Cl= 0.05 -  0.85 and RH= 0.39; 95% Cl= 0.23 -  0.66 
respectively) (Moyle et al. 2002). In the case-control study presented in this 
thesis, 17.3 % of cases were receiving d4T/3TC based combinations at the 
time of the event while the proportion of controls on d4T/3TC was 21.8 %  (P= 
0.231). The study failed to identify any difference between cases and controls 
in terms of their exposure to the combination of d4T with 3TC. Although the 
study was powered to identify significant differences between cases and 
controls with regards to their exposure to d4T, the calculation was done
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considering d4T as a single drug exposure and it did not take into 
consideration other NRTIs used in combination with d4T.
At the moment the WHO recommendations includes d4T/3TC as the preferred 
backbone for ART combinations to be used in resource limited settings (World 
Health Organization 2003). Recently presented studies in small numbers of 
patients have shown that reduced doses of d4T are associated with less ADR 
without loosing potency when administered in combination with at least two 
other ART drugs (Milinkovic et al. 2005; Wolf et al. 2004; Siangphoe et al.
2004). Therefore, given the relevance of serious ADR for the long-term 
success of HIV/AIDS control programs, assessing the safety profile of 
dideoxynucleosides at reduced doses may be critically important for 
developing countries.
Cote has proposed a combined multi-factorial mechanism to explain 
mitochondrial dysfunction in HIV-infected patients exposed to NRTIs. 
According to the author, long-term exposure to ART may result in 
mitochondrial dysfunction as consequence of a triple hit mechanism where the 
effect of HIV and the NRTIs on mitochondrial function increases production of 
ROS, which completes the vicious circle amplifying the deleterious net effect 
on mitochondrial function (Cote 2005). Nevertheless, other possible, as yet 
unidentified mechanisms for NRTI-induced mitochondrial impairment may 
exist and therefore, more research is needed to fully clarify the underlying 
mechanisms for this toxicity. Unfortunately, different studies performed to date 
on mitochondrial function in HIV-infected individuals have used different 
assays and approaches making difficult if not impossible to compare results 
form these studies. In addition, such studies have generally involved small 
numbers of patients. Therefore, it is important to perform large longitudinal 
studies using standardised assays to produce robust information on ADR 
associated with mitochondrial dysfunction (Cossarizza 2003).
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8.1.2 Special susceptibility
It has been suggested that environmental factors may affect the likelihood of 
developing any specific ADR, even in the presence of specific genetic 
polymorphisms shown to be clearly associated with such a complication. 
Factors such as co-morbidities, treatment adherence and drug-drug 
interactions can all affect the likelihood of developing any ADR in the 
presence of a specific genetic predisposition (Quirk etal. 2004).
Pharmacogenomic studies may generate information leading to the 
identification of specific genetic polymorphisms which may predispose to a 
particular ADR. As an example, in the HIV medicine field screening for HLA 
B5701 has been recently implemented in some centres as regular practice as 
it was demonstrated that people with that specific haplotype were at much 
higher risk for ABC-induced hypersensitivity reaction (Mallal et al. 2002). In 
addition, pre-prescription testing for HLA B5701 has been shown as a cost- 
effective intervention for prevention of ABC-induced hypersensitivity (Hughes 
etal. 2004).
Little is known about genetic predisposition to NRTI-associated mitochondrial 
toxic effects (Lewis 2005). However, as mentioned before, a recent study has 
highlighted a possible association between mitochondrial haplogroup T and an 
increased risk for PN in HIV-infected individuals exposed to 
dideoxynucleosides (Hulgan et al. 2005). Some additional evidence suggests 
that genetic polymorphisms may play a significant role in NRTI-induced 
mitochondrial dysfunction. Similarities between toxic mitochondrial dysfunction 
and inherited mitochondrial diseases and the recently published association 
between specific mtDNA haplogroups and PN in HIV-infected patients 
illustrate this point (White 2001; Hulgan et al. 2005). Nevertheless, assessing 
the impact of mtDNA variations on multifactorial diseases has been shown to 
be difficult. Even when initial reports may have shown promising results it has 
been almost always impossible to replicate original results (Samuels et al. 
2006). Because the distribution of different mtDNA haplogroups is not uniform,
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the low frequency of some haplogroups tends to increase the statistical 
significance of specific analyses generating false-positive results (Roff & 
Bentzen 1989). Therefore, proper study designs where appropriate statistical 
methods are used to deal with the described type I error tendency are needed 
to properly assess the impact of mtDNA haplogroups on the likelihood of 
developing NRTI-induced mitochondrial dysfunction (Samuels et al. 2006).
In addition, as the distribution of human genetic polymorphisms is not 
homogeneously distributed and significant differences, particularly in the case 
of mitochondrial genetics, have been found between different ethnic groups it 
is essential to perform pharmacogentic studies including populations large 
enough to achieve robust results where different ethnic backgrounds are well 
represented.
Even when not powered to look at ethnicity, and despite the possible 
overmatching discussed in chapter 7, the case-control study presented in this 
thesis suggests that non-white populations may be more likely to develop 
HULA than white people. Similarly, Gerard et al. have shown that black 
women may be at higher risk of developing HL compared to white women 
when exposed to d4T containing combinations (Gerard etal. 2005).
In chapters 3 and 7 the effect of advanced HIV disease on the likelihood of 
developing PN and HULA was also discussed. Patients with low CD4 count 
appear to be at high risk for these complications. Therefore, one could 
assume that the magnitude of the problem associated with NRTI-induced 
mitochondrial dysfunction in the developing world could be much higher than 
thought, not only because d4T-based combinations are used much more often 
but also because among the target population the other important identified 
risk factors for HULA are over-represented (i.e. female gender and advanced 
HIV disease).
In addition, one can assume that a high level of suspicion among clinicians 
and close monitoring of patients on ART may help to identify cases at an early
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stage (Stenzel & Carpenter 2000). Not surprisingly then, the calculated case 
fatality rate for the cases of LA presented in chapter 4 was significantly higher 
among cases diagnosed before the year 2000 compared to more recent cases 
(Arenas-Pinto et al. 2003). However, even when an early diagnosis is made, 
and even when some studies have shown improvement in mtDNA content in 
patients switched away from d4T (Boyd et al. 2004), stopping 
dideoxynucleoside exposure may not lead to an immediate recovery of 
mtDNA content. A small study has shown that previously d4T or AZT exposed 
patients randomised to switch therapy to ABC did not show any recovery in 
the content of mtDNA in PBMC at week 24 from randomisation (Hoy et al.
2004). In fact, patients may need at least six months after stopping ART 
exposure to show any significant rise in the content of mtDNA in CD8 T 
lymphocytes (Mussini et al. 2005). Interestingly, the study published by 
Mussini et al. also showed that the content of mtDNA in CD4 T lymphocytes 
remained unchanged one year after stopping any exposure to ART. The last 
observation may reflect the effect of HIV itself on the mitochondrial genome of 
CD4 lymphocytes.
In any case, patients exposed to dideoxynucleosides may remain susceptible 
to express clinical manifestations of mitochondrial dysfunction even after 
stopping the exposure to such drugs if mtDNA is a good marker of 
mitochondrial function. For instance, a fatal case of liver failure following an 
acute episode of LA has been published (Carr et al. 2001). Interestingly, the 
patient reported by Carr et al. died a few months after stopping ART.
8.2 Impact of safety issues on HIV/AIDS control programs
It has been mentioned before that the benefits of HAART combinations in the 
management of chronic HIV disease are endangered in the long-term by ADR 
(Carr 2002). Fortunately, only a few ART-associated ADR can be life 
threatening (e.g. LA) but even mild to moderate complications such as 
vomiting or diarrhoea may affect adherence to ART, which has been
demonstrated to be associated with resistance (Taylor-Castillo et al. 2005).
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Therefore, beyond the implications of ADR in clinical practice, toxicities may 
have a considerable impact on HIV control programs by affecting mortality, 
morbidity and resistance.
8.2.1 ART delivery as a public health intervention
According to UNAIDS estimates, there were just over 40,000,000 people living 
with HIV world-wide by the end of 2005. However, as has been highlighted 
almost since the beginning of the epidemic, the vast majority of those infected 
by HIV are living in developing countries. In fact, over 90 % of the infected 
population live in the developing world and almost 26 million (64 % of the 
entire HIV-infected population) live in Sub-Saharan countries (UNAIDS 2006).
Although the introduction of HAART combinations has had a tremendous 
impact in reducing mortality and morbidity associated with HIV disease in 
North America and Western Europe (Palella, Jr. et al. 1998; Mocroft et al. 
1998), the benefits of this therapeutic approach at a population level have 
been very small in most developing countries. In fact, almost all (98 %) of 
those patients who may have died in 2005 because of HIV-related causes did 
so in developing countries according to UNAIDS estimates (UNAIDS 2006). 
Therefore, it may be obvious that access to ART drugs should be the first 
priority of any program addressed to control the HIV/AIDS epidemic. This is 
why the WHO has launched a scaling-up initiative aimed to increase 
significantly the number of patients on ART in developing countries. That 
initiative has been defined and conceived as a public health intervention and it 
is aimed to reduce as much as possible mortality attributable to HIV/AIDS in 
the developing world (World Health Organization 2003).
Interestingly, the effectiveness of HAART in resource limited settings has
been shown to be not significantly different from what has been achieved in
developed countries. In Thailand a “cohort” of HIV-infected patients has
shown equivalent response to ART to what it may be expected in developed
countries (Duncombe et al. 2005). However, this Thai cohort is in fact a
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compilation of clinical trial participants which may not reflect the situation in 
real life conditions. Nevertheless, similar findings have been communicated by 
Medecins Sans Frontieres (MSF) in an observational study on clinical 
outcomes of their HIV/AIDS programs in 21 resource-limited countries. The 
study published by Calmy et al. (N= 6861) shows an estimate survival of 0.82 
(95 % Cl= 0.81 -  0.84) at 12 months after starting a d4T/3TC/Nvp fixed drug 
combination therapy (intent-to-treat analysis missing equal death) (Calmy et 
al. 2006). In addition, a meta-analysis analysing data from 10 studies 
performed in developing countries (mainly in Africa) has shown that based on 
surrogate markers, efficacy of ART in resource-limited settings may be 
comparable to efficacy rates reported for developed countries (Ivers et al.
2005).
A small study performed in Venezuela (N= 96) has shown that naive patients 
receiving ART as part of the national HIV/AIDS control program have 
achieved a significant level of response to therapy: 50 of the 67 patients 
tested for HIV viral load were undetectable (< 400 copies) at week 48 (Garcia
2005). However, a comparative study analysing cohorts of HIV-infected 
patients from both developed and developing countries has recently shown 
that patients starting first line HAART combinations in developing countries 
show a higher mortality rate than what is seen among similar patients in 
developed countries over the first year of therapy. Interestingly, the mortality 
rate fell substantially over the first months and by the second half of the first 
year on HAART the mortality rate in developing countries was similar to what 
has been recorded for developed countries (Braitstein et al. 2006). Similarly, 
the mortality rate reported by Calmy et al. (14.2/100 person-years; 95% Cl= 
13.8 -  14.5) was noted not to be constant over the follow-up period. The 
likelihood of dieing in the MSF cohort was significantly higher during the first 
three months of HAART (Calmy et al. 2006). Several factors may contribute to 
increase mortality rate in developing countries during the first months of 
HAART. Co-morbidities such as tuberculosis (TB) or malaria among others 
and of course advanced HIV disease at base line, may all affect negatively the 
outcome of HAART. However, it looks like that HAART-induced HIV
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replication control can overcome these factors and offer long lasting benefits 
to patients in developing countries.
Little is known about safety issues related to ART in developing countries. 
Most studies on ART in these settings have been focussed on the delivery 
question as well as on efficacy of the intervention. However, growing concerns 
on ART-associated ADR and its possible impact on adherence and ultimately 
on resistance have been recently expressed. The Forum for Collaborative HIV 
Research has recently organised a workshop called Long-Term Monitoring of 
Treatment Related Adverse Events in the Resource Limited Setting where key 
issues on methodological and logistic questions were addressed (Miller & 
Powderly 2005). During that meeting, issues such as reduction of patients’ 
confidence on ART due to real and assumed ADR and the implications for 
adherence and therapeutic failure as a result of resistance were highlighted as 
major problems for HIV/AIDS control programs (Katabira 2005).
8.2.2 An opportunity for pharmacoepidemiological studies
A number of reports have been recently presented showing data on
monitoring ADR in developing countries both in the context of clinical trials
and surveillance as a component of national HIV/AIDS control programs. The
clinical trial cohort in Thailand has recently shown that grade 11 I/I V laboratory
abnormalities (mostly abnormal LFT, hyperlipidemia, anaemia and
thrombocytopenia) are frequently seen among their study population (Nuesch
et al. 2006). Interestingly, even though AZT, ddl and d4T were part of the
therapeutic options in use, blood lactate levels were not reported in the last
study. On the other hand, centres involved in ART delivery as part of the
South African HIV/AIDS control program have reported a rate of switching
patients away from d4T of 15 per 1000 person-years because of HULA and
17 per 1000 person-years because of PN (Boulle et al. 2006). Similarly, data
from a Ugandan study have shown that 21 % of over a thousand patients who
started their first line ART combination were switched to a different
combination because of toxicity. Of those Ugandan patients with ADR 82 %
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were switched away from d4T (Foma et al. 2006). Likewise, it has been 
showed that in DART, one of the largest clinical trials in Sub-Saharan Africa, 
the incidence of grade IV anaemia is significantly greater than what has been 
reported in developed countries (Ssali et al. 2005). However, it was also noted 
in DART that the vast majority of patients showed a significant rise in their 
haemoglobin levels by week 24 of treatment. Base-line low haemoglobin level, 
due to nutritional factors, helminth infections and even malaria, may explain 
the findings in DART. On the contrary, the reported rate for NRTI-associated 
ADR in the MSF study was rather lower. In the safety sub-study reported by 
Calmy et al. (N= 655) 30 out of 52 patients followed for 12 months had to 
discontinue ART because of severe toxicity (grade III or IV). Interestingly, only 
nine of the 30 severe episodes of ADR reported by MSF in their cohort were 
attributable to d4T (i.e. PN and Lipodystrophy) (Calmy etal. 2006).
According to WHO/UNAIDS data, by December 2005 there were more than 
one million people receiving ART regularly in the developing world (Estimated 
number of individuals on ART = 1,330,000). 61 % of those patients were 
being treated in Sub-Saharan Africa whereas 24 % were in Latin America and 
the Caribbean (WHO/UNAIDS 2006). Most of the control programs including 
ART delivery in Sub-Saharan African countries have been implemented over 
the past few years while several programs in Latin American and Caribbean 
countries have been in place for over a decade now. In any case, it is obvious 
that the expansion of accessibility to ART in the developing world is giving us 
the opportunity to offer ART to many more people than ever before. 
Furthermore, because of the epidemiological characteristics of the HIV/AIDS 
epidemic in resource limited settings, we are now treating many more women 
and children. Because women and children are usually excluded from clinical 
trials and because the HIV-infected population in western developed countries 
included mainly men, the information we have produced through clinical trials 
and post-marketing surveillance over the past years on safety issues do not 
provide sufficient information in these populations groups.
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Taken all together, one could easily assume that information becoming 
available from the developing world would be critically important in expanding 
our understanding of ART-associated ADR. Nevertheless, given the limited 
availability in most developing countries for regular follow-up of patients on 
ART and laboratory support, specifically designed studies in these settings 
may be needed to generate relevant information not likely to be obtained from 
regular monitoring. Furthermore, as surveillance systems in developing 
countries have been traditionally weak and in most cases inconsistently 
applied, relaying on such traditional surveillance approaches for safety issues 
associated with ART may not be the most appropriate approach. Here is 
where pharmacoepidemiological studies may have a critical role in generating 
clean and reliable data. Such studies range in a hierarchy from spontaneous 
case reports through case-control studies and observational cohort studies 
and clinical trials. All can generate valid and useful information. Nevertheless, 
novel approaches such as sentinel surveillance systems may be more 
appropriate options. The pharmacovigilance program in South Africa 
combines a novel electronic spontaneous reporting system which is 
complemented with a sentinel surveillance scheme to investigate signals 
generated in the reporting system (Banoo 2005).
Given the sustained growth in the number of individuals on ART in developing 
countries and because of the lack of laboratory support strong enough for 
monitoring patients on ART in the same way that is done in developed 
countries, generating robust information for a more efficient diagnosis and 
management of ART-associated ADR may be a major challenge. ADR have 
been shown as major contributors for intentional non-adherence to ART both 
in developed and developing countries (Bonolo et al. 2005; Mocroft et al. 
2001) and adherence is certainly the most important strategy to avoid 
resistance. In the context of limited options for ART in the developing world, 
resistance is a major threat for HIV/AIDS control programs. Dealing with a 
rapid requirement for second line options will make programs too expensive 
for countries with very limited funds (Katabira 2005; Kent etal. 2003).
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Finally, because of the limited number of drugs developing countries can 
afford to include in their programs, a better understanding of factors 
associated with ADR attributable to NRTIs, particularly AZT, d4T and even 
ddl, is essential to protect such programs.
8.3 Retrospective and observational data: valid sources of information
Randomised clinical trials are likely to produce clean data but their results are 
usually “artificial” as generally only highly selected individuals are allowed to 
take part in these studies. Patients with more advanced or complicated 
disease, those with co-morbidities, patients exposed to other therapeutic 
interventions and very often women and children are generally excluded from 
clinical trials. Therefore, beyond other disadvantages such as duration of 
follow-up, logistic issues and costs, most clinical trials are not likely to produce 
sufficient information on safety questions (loannidis & Lau 2001; Strom 2000).
On the other hand, observational studies can offer the opportunity to compile 
robust information on specific groups such as women or intravenous drug 
users as well as other populations generally not included in clinical trials. In 
addition, the effect of duration of the exposure to any ART drug can also be 
evaluated in prospective data generated through cohort studies (Bisson et al. 
2003). In addition, nested case-control studies have been performed to 
assess many questions from behavioural issues to genetic susceptibility to 
HIV infection (Shrestha et al. 2006; Todd et al. 2006). Therefore, such an 
approach may be also valid to assess specific questions on ADR.
Nevertheless, to be regularly recorded any medical condition must be 
previously defined and included in the template used for data capture in any 
established cohort (Bisson et al. 2003). However, one of the major problems 
in studying ADR is the lack of universally accepted definitions for some of 
them (Carr 2002). Discrepancies in definition of ADR have been suggested to 
be even more notorious for complex conditions such as lipodystrophy
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syndrome or metabolic complications, but even ADR known for longer such as 
PN may be difficult to define and classify (Moore et al. 2000).
In the case-control study on LA/HL presented in this thesis (chapters 5 - 7 )  it 
was demonstrated that patients with sustained and severe HL may be 
asymptomatic and therefore they would not be considered as cases of lactic 
acidemia if the classification system proposed by the USA-IAS panel was 
used (Schambelan et al. 2002). Similarly, cases of LA were found to have 
blood lactate levels lower than 5 mmol/l and consequently following the same 
classification system, they would not be diagnosed either with lactic acidemia 
as arterial pH is not included in the diagnosis criteria (see chapter 7, section 
7.1.1). Therefore, retrospective data can help in retrieving information which 
may help in properly defining ADR and such definitions may be used to 
generate prospective data subsequently.
8.3.1 Limitations of retrospective studies in the current 
environment in the UK
Many disadvantages of retrospective studies have been already discussed in 
this thesis (see chapters 5, section 5.1 and 7, section 7.4). Nevertheless other 
factors may be relevant in the process of generating valid data from 
retrospective studies.
In the UK the Data Protection Act 1998 has been conceived to protect
confidentiality and ethics committees have been very active in protecting
patients’ rights. For instance, it was agreed for the case-control study
presented in chapters 5 to 7, all study participants had to be recruited and
consented by their regular doctor. This is apparently a common practice in
many epidemiological research projects. Ward et al. in an educational debate
published in the BMJ recently have questioned the implications of such a
practice. For a national case-control study on Creutzfeldt-Jakob disease the
authors tried to consent 2,804 controls through their general practitioners but
only 37 % of them actually replied to the invitation. At the end, the overall
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response rate for controls was 16 % (Ward et al. 2004). It is clear that such an 
extremely low control recruitment rate seriously compromises the validity of 
any analysis to be performed and therefore limits the possibility of conducting 
valid community based epidemiological research in this country.
For the case-control study presented in this thesis we recruited most of the 
controls we planned to because HIV-infected patients are a “captive” 
population. Patients are seen regularly by their doctor in order to get not only 
their treatment but also the essential monitoring all patients know is needed. 
Therefore, even when the recruitment rate through the initial letter system was 
relatively low (see chapter 5, section 5.5.4), it was possible to approach all 
selected controls during their regular appointments. Nevertheless, even 
though it was possible to consent most of the originally selected controls for 
the study, the process took much longer than we anticipated, generating extra 
costs and delaying the start of the study.
Centres in the UK were not the only ones requested to seek written consent 
from every participant in the case-control study on HL/LA. However, the 
system used in the UK was certainly the most complicated. On the other hand, 
centres from countries where generic consent for retrospective research is in 
place (e.g. the US, Switzerland, Spain, and the Netherlands) managed to 
complete the data collection exercise in a shorter period of time and at a lower 
cost.
Protecting patients’ rights is certainly important. Nevertheless, patients are or 
at least should be the ultimate beneficiaries of medical research and therefore, 
any obstacle in the process of performing pertinent and valid research can 
ultimately affect the rights of patients. Some evidence suggests that patients 
affected by chronic diseases such as cancer, may be more motivated than the 
general population to support research in that particular field. For instance a 
large cross-sectional survey performed to assess patients’ views on the use of 
personal identifiable medical data for research found that over 80 % of the
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2,955 interviewed patients did not consider the confidential use of personal 
information as an invasion of privacy (Barrett etal. 2006).
Alternative approaches for retrospective epidemiological research, where no 
direct contact between researchers and patients is needed and where only 
information already generated and recorded in medical notes are going to be 
used, may be designed without affecting significantly either patients’ 
confidentiality nor patients’ privacy. Generic consent is for instance a strategy 
which has been used successfully in other countries. In addition, assessing 
the views of HIV-infected community on this issue may be helpful in 
generating acceptable procedures for inclusion of patients in epidemiological 
research projects.
8.4 Recommendations
Because most of the patients currently exposed or likely to be exposed in the 
near future to NRTIs traditionally associated with mitochondrial toxicity are 
from developing countries, pharmacoepidemiological studies in such settings 
are urgently needed. As has been mentioned before, there is limited 
information regarding the nature, frequency and predictors of ADR in HIV- 
infected populations from resource limited countries (Kent et al. 2003). 
Furthermore, because of the epidemiological patterns of the HIV epidemic in 
the developed world there is little experience in management of ADR in 
female patients and children which represent a significant proportion of the 
HIV-infected population from the developing world. Therefore, studies on 
safety issues related to ART should preferentially assess specific questions 
related to these particular groups.
Relying on regular surveillance systems in developing countries may not be 
the most appropriate strategy to identify cases of ART-induced ADR. Active 
monitoring strategies for ADR may be a more suitable intervention in such 
settings. In fact, sentinel surveillance systems may generate accurate and 
clean data on specific issues such as ADR.
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Therefore, case-control studies nested on well designed sentinel surveillance 
systems, which in fact will constitute cohorts of HIV-infected individuals, may 
offer the most appropriate source of information regarding specific questions 
on ART safety.
In addition, it may be worth assessing genetic predisposition for NRTI- 
associated ADR since these complications can have serious consequences 
not only for individual patients exposed to such drugs but also on the 
effectiveness and stability of HIV/AIDS control programs in the developing 
world. Therefore, pharmacogenomic studies, particularly assessing 
mitochondrial genetic polymorphisms may offer important information to guide 
a better ART selection in specific population groups to avoid certain ADR. This 
approach may be pertinent also because of the lack of laboratory support in 
most developing countries for monitoring patients during ART.
Finally, in the light of the results presented in this thesis, the definition of lactic 
acidemia may need to be reviewed. Producing clear and unambiguous case 
definitions for known ADR related to ART is critically important for them to be 
recorded systematically. Universally accepted case definitions are essential 
for comparative analysis between patients seen in different settings. Both 
prospective and retrospective data may be useful in assembling more 
appropriate case definitions for ADR.
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Appendix 1
Proforma and patient information sheets used for the
Case-control study on HL/LA
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CASE-CONTROL STUDY ON 
LACTIC ACIDOSIS and SEVERE HYPERLACTATAEMIA 
IN HIV-INFECTED PATIENTS
ID  N u m b e r...............................................................................| | | [~~| | | | | (id)
First fields: Clinic code Central field: 0. Case 1-2. controls
D a te  o f LA  o r H L  D ia g n o s is  [ | | | | | | | I (datedx)
Date of the episode or outpatient control appointment 
11/11/17. NA
D ate  o f a d m is s io n  j | | | | | | | | (datead)
11/11/17. NA 11/11/19. Nl
Diagnosis of admission | I \ (dxadm)
1. LA 2. HL 3. Sepsis
4. Cancer 5. Other AE 6. Other____________
7. NA
Clinic or HIV unit caring for patient  J I I ( c l i n i c )
01. MMC 02. KSC 03. NMS
04. BRI 05. PET 06. CH&W
07. SM 08. MAN 09. ARG
10. SYD 11. PER 12. VAN
13. BAR 14. ZUR 15. AMS
16. SL 17.0ther UK 18. Other OS
Hospital where the patient was admitted____________________________  (hospital)
Date of birth J I I I I I I I I (datebirt)
Sex ........................................................................................  I I (sex)
0. Female I.M ale 9. Nl *— '
Pregnancy ............................................................................ Q] (pregn)
0. No 1. Yes 7. NA
Menopause............................................................................ [ [ [ ]  (menop)
0. No 1. Yes 7. NA
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Country of origin □  (country)
1. UK 2. Other EU 3. US/Canada
4. Europe non-EU 5. Africa Sub-Sahara 6. Africa other
7. Autralia 8. Other_____________________________
9. Nl
Ethnic group  Q ]  (race)
1. White European 2. White American 3. Black Caribbean
4. Black African 5. Black American 6. Asian
7. Hispanic 8._Other________________ 9. Nl
Date of first HIV positive result   | | | /  | | | /  | | | (datehiv)
11/11/19. Nl
Mode of HIV infection acquisition........................................................................  Q  (mode)
1. Homosexual 2. Heterosexual
3. IDU 4. Vertical
5. Transfusion or needle accident 9. Nl
AIDS diagnosis......................
0. No
Criteria: cdc class c
1. Yes
I I (aids)
Previous AIDS defining illness
01. Oesoph/bronch candidiasis
03. Cryptoccocosis ..................
05. C M V ......................................
07. Herpes virus infection........
09. Isosporiasis.........................
11. Lymphoma........................
13. T B .........................................
15. P M L......................................
17. Cerebral Toxoplasmosis .... 
19. Recurrent Pneumonia........
02. Coccidiodomycosis ....
04. Cryptosporidiosis........
06. Encephalopathy HIV ...
08. Histoplasmosis............
10. Kaposi’s sarcoma.......
12. M.avium or M.kansasii
14. P C P ..............................
“  “ 16. Recurrent Salmonella . --------
' 18. Wasting Syndrome..... ---
97. N A .................................
Variable: aidsdef# 0. No 1. Yes
Nadir CD4 count..
999. Nl
Peak Viral Load........
9999999. Nl
(nadcd4)
(peakvl)
(both nadir CD4 count and peak viral load, prior to therapy)
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Previous medical history
Metabolic
11.D M..........................
12. Glycogen storage.. 
disease
Hepatic —
21. Chronic viral hep B..—
22. Chronic viral hep C___
23. Biliary disease ....
24. Other hepatic dis.
Drug use
31. Ethanol..................... .....
32. IV .............................. _
33. Biguanides...............
(Metformin)
34. Salicylates................. _
35. Carbamazepine......... _
36. Isoniazid...................
37. Fructose...................
38. Sorbitol.....................
39. Other______________Q
Neurological
41. Seizures | |
Mvooathies:
61. Myopathy | I
Negative 
97. NA .. 
99. Nl ..
Variables: medhist# 0. No
Malignancies:
51. Cancer (non-HIV related) | |
Other
71. Specify. □
1. Yes
ART history (starting for the regimen at the LA event time)
Regimen Drugs Start date Stop date
1
2
3
4
5
6
7
01. Abacavir (abc)
04. Stavudine (d4T)
07. Delavirdine (dvn)
10. Amprenavir (apv)
13. Ritonavir (rtv)
16. Tenofovir (tfv)
97. NA
Variables:
02. Didanosine (ddl)
05. Zalcitabine (ddC)
08. Efavirenz (efv)
11. Indinavir (idv)
14. Saquinavir (sqv)
17. Hydroxyurea (hyd) 
99. Nl
Start date: drugsta
03. Lamivudine (3tc) 
06. Zidovudine (zdv) 
09. Nevirapine (nvp) 
12. Nelfinavir (nfv) 
15. Lopinavir (Ipv) 
18. Other
Stop date: drugsto
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Previous Adverse effects related to ART
I. Peripheral neuropathy..........
3. Pancreatitis............................
5. Body shape changes.............
7. Severe hypercholesterolemia 
9. Severe hypertrigliceridemia ..
I I .  Hepatopathy........................
13. Other:
Variables: preadv# 0. No 
Criteria: Hypercholesterolaemia: 
Hypertriglyceridaemia
2. Myopathy.............................
4. Myelosuppresion.................
6. Mild-mod hypercholesteroler
8. Mild-mod hypertrigliceridemi;
10. Diabetes..............................
12. Osteopenia/osteoporosis..
97. None reported...................
1. Yes
mild-mod <6.5 mmol/1 
mild-mod < 5 mmol/l
severe > 6.5 mmol/l 
severe > 5 mmol/l
Previous laboratory abnormalities
01. Lactate 02. LFT 03. Amylase
04. Glucose 05. pH 06. Anion gap
07. CK 08. TC 09. TG’s
10. Albumin 11. Non 12. Other
Variables: prevlab# 0. No 1. Over normal 2 Under normal
Normal Weight
(weighnor)
Current Weight
(weighcur)
Height
(height)
Normal BMI
(bminor)
Current BMI
(bmicur)
Normal Weight: at the last asymptomatic control 
Current Weight: at the time of the LA or inclusion
Weight problems at the time of the inclusion
1. Overweight (BMI > 25 Kg/m2)
3. Normal weight (BM118.5 -  24.9 Kg/m2)
Clinical symptoms at the LA event time
01. Abdominal pain .... H
03. Vomiting...............
05. Jaundice................“
07. Weight loss........... “
09. Dyspnoea..............—
11. Weakness.............““
13. Other___________“
Variables: symp# 0. No
97. NA 99.Nl
I | (weight)
2. Underweight (BMI < 18.5 Kg/m2)
9. Nl
02. Nausea............
04. Anorexia..........
06. Fatigue............
08. CNS impairment
10. Tachypnoea.....
12. None................
97. NA ....................
1. Yes
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Other investigations/imaging
(abultras) 
(abctscan) 
(dexa) 
(liverbx) 
(musclebx) 
(otherbx) 
(olherim)
0. Normal 1. Abnormal 2. Not done
Results of laboratory tests
Abdominal ultrasound 
Abdominal CT Scan ...
DEXA..........................
Liver biopsy ..............
Muscle biopsy............
Other biopsy..............
Other Imaging............
Varib. Test Admission Peak or nadir Normal values
(lact) Lactate
(ph) ^ pH
(hco3) H C 03
(agap) Anion-gap
(pco2) PC 02
(po2) P 0 2
(wbcc) WBCC
(neutro) Neutrophils
(hb) Hb
(cd4) CD4
(vl) VL
All variables: Admission: variablead Peak or nadir value: variablepeak
99999: Nl VL: 49: Undetect
Varib. Test Result Normal Values Abnormal Times 
over NV 
(varout)
Peak or 
Nadir
(alkphos) Alka. Phosphat
(alt) ALT
(ast) AST
(lip) Lipase
(amyl) Amylase
(ck) CK
(glue) Glucose
(cholest) Total cholesterol
(trigly) Triglycerides
(alb) Albumin
(creat) Creatinine
(bun) Urea
Abnormal = Is the result in the normal values range (variable name)
0. No 1. Yes 9. Nl
Times over of the normal values range 97. NA
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Markers of hepatic infections
Marker Status Date Result
HBsAg
(hbsag)
HBeAg
(hbeag)
Anti-HBc
(antihbc)
Anti-HBs
(antihbc)
Anti-HBe
(antihbe)
Anti-HCV
(antihcv)
HCV-RNA
(hcvarn)
Status: variables 0. Neg 1. Pos 2. Not done 9. Nl
Result: variabler
Results of the other studies
Study Description Conclusion
Liver ultrasound
(livultr)
CT scan
(ctscan)
Dexa
(dexa)
Other imaging
(otherim)
Liver biopsy
(livbx)
Muscle biopsy
(mucbx)
Autopsy
(autop)
Other histology
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Liver biopsy: predominant feature
01. Microvesicular steatosis 
03. Focal steatosis
05. Inflammation 
07. Fibrosis 
09. Normal
(livbxla)
02. Macrovesicular steat 
04. Mixed steatosis pattern 
06. Necrosis 
08. Cholestasis 
97. NA
Liver ultrasound: predominant feature   Q ]  (livusia)
1. Hepatomegaly 2. Fatty infiltration
3. Cholestasis 4. Other___________________
5. Normal 7. NA
Liver CT Scan: predominant feature............................................ Q  (Hvctia)
1. Hepatomegaly 2. Fatty infiltration
3. Cholestasis 4. Other____________________
5. Normal 7. NA
Tissue used for mitochondrial studies
0. PBMC 1. Muscle
3. Other 7. NA
2. Liver
| | (mitused)
Mitochondrial dysfunction evidence
1. Enlargement............ 2. Shape alteration...................
3. Density increased ... 4. Respiratory chain dysfunctior
5. Reduction of mtDNA 6. MtDNA Deletion...................
7. None......................... — 8. Other
97.N A ............................ —
Variables: mitab# 0. No 1. Ves 2. Not done
Mitochondrial studies
Study Status Result % of control
MRC Complex I
(compi)
MRC Complex II
(compii)
MRC Complex III
(compiii)
MRC Complex IV
(compiv)
MRC Complex V
(compv)
mtDNA/nDNA ratio
(dnarat)
Variables: Status: namest 0. Not done 1. Done
Result: namers 0. Normal 1. Low 2. High 7. NA
% Control: namepor
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Concurrent 01 or malignancy
01. Oesoph/bronch candidiasis
03. Cryptoccocosis..................
05. C M V .....................................
07. Herpes virus infection.......
09. Isosporiasis.........................
11. Lymphoma..........................
13. T B .........................................
15. P M L ......................................
17. Cerebral Toxoplasmosis ... 
19. Recurrent Pneum onia........
Variable: oi# 0. No
02. Coccidiodomycosis ....
04. Cryptosporidiosis......
06. Encephalopathy HIV ...
08. Histoplasmosis...........
10. Kaposi’s sarcoma......
12. M.avium or M.kansasii
14. P C P ..............................
16. Recurrent Salmonella .
18. Wasting Syndrome...
97. N A ...................................
1. Yes
Other important drugs taken at the LA event time
Drug StaT date Stop date
01. TMP/SMZ (tmpsmz) 02.
04. Ketoconazole (ketocon) 05.
07. Pyrimethamine (pyrimeth) 08.
10. Foscarnet (foscar) 11.
13. Vinbalstine (bleomyc) 14.
16. Liposomal Daunorubidn (lipdau) 17. 
19. Thalidomide (thali) 20.
22. Other drug_____________________
Fluconazole (flucon) 
Isoniazid (inh)
Acyclovir (acydov) 
Steroids (steroids) 
Doxorubicin (doxor) 
Vincristine (vincri)
Other cytotoxic (cytotox) 
___________ (otherdrl)
03. Itraconazole (itracon)
06. Rifampicin (rifamp)
09. Gancydovir (gancyclo)
12. Bleomycin (bleomy)
15. Lipo. Doxorub. (lipodox)
18. Interferon a  (inf)
21. Contraceptive pill (aco) 
97. NA
Variables: Sart: drugsta Stop: drugsto
Concurrent Adverse events at the time of LA event
I .  Peripheral neuropathy...........
3. Pancreatitis...............................
5. Body shape changes..............
7. Severe hypercholesterolemia 
9. Severe hypertrigliceridemia ..
I I .  Hepatopathy...........................
13. Other:
2. Myopathy................................
4. Myelosuppresion...................
6. Mild-mod hypercholesteroler
8. Mild-mod hypertrigliceridemi.
10. Diabetes.................................
12. Osteopenia/osteoporosis ..
97. None reported......................
Variables: preadv# 0. No 1. Yes
Criteria: Hypercholesterolaemia: mild-mod < 6.5 mmol/l severe > 6.5 mmd/1
Hypertriglyceridaemia mild-mod < 5 mmol/l severe > 5 mmd/1
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ART was stopped at LA event time (as a medical indication) I I (stoparv)
0. No 1. Yes 7. NA
Fatal outcome..................................................................................  I I (death)
0. No 1. Yes 7. NA
Date of death...................................................... J I I J I I J I I (timede)
11/11/17. NA
Date of ICU admission.......................................J | | \  | | \  | | (icudate)
11/11/17. NA
1. Riboflavin.....................
—
2. IV bicarbonate...........
3. IVAB s............................
—
4. Ent/parenteral feeding 
6. Ventilation...................5. Dialysis........................ —
7. Thiam ine...................... — 8. Other
9. N o n e ............................. 97. N A ...............................
Variables: manag# 0. No 1. Yes 7. NA
ART was restarted after LA event.......................................................................  I I (restart)
0. No 1. Yes 7. NA 9. Nl 1— 1
ART regimen restarted.................................................................  I I (drrestar)
1. Inducing NRTI 2. Not induding NRTI
7. NA 9. Nl
ART regimen started after LA event
Regimen Drugs Start date Stop date
1
2
3
4
01. Abacavir (abc)
04. Stavudine (d4T)
07. Delavirdine (dvn)
10. Amprenavir (apv)
13. Ritonavir (rtv)
16. Tenofovir (tfv)
99. Nl
Variables:
02. Didanosine (ddl)
05. Zalcitabine (ddC)
08. Efavirenz (efv)
11. Indinavir (idv)
14. Saquinavir (sqv)
17. Other
Start date: ndrugsta
03. Lamivudine (3tc)
06. Zidovudine (zdv)
09. Nevirapine (nvp)
12. Nelfinavir (nfv)
15. Hydroxyurea (hyd) 
97. NA
Stop date: ndrugsto
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HIV markers after the event
First Control Last Control
Result Date Result Date
CD4
VL
Variables: CD4= cdfirstime / cdlastime / cdfirdate / cdlasdate / 997: NA
VL= vlfirstime / vllastime / vlfirdate / vllasdate / 999997:NA
Time of follow-up after LA event.................................................. I I | (survival)
1-24. months 99. Nl 97. NA
Further LA event..................................................................................  I I (furthia)
0. No 1. LA 2. HL 1— 1
7. NA 9. Nl
Other Adverse event after ART restarted
I .  Peripheral neuropathy..........
3. Pancreatitis............................  .......
5. Body shape changes ..| |
7. Severe hypercholesterolemia.
9. Severe hypertrigliceridemia .
I I .  Other:
2. M yopathy..............................
4. Myelosuppresion................
6. Mild-mod hypercholesterolenr
8. Mild-mod hypertrigliceridemic
10. Diabetes..............................
97. None reported.....................
Variables: furthadv# 0. No 
Criteria: Hypercholesterolaemia: 
Hypertriglyceridaem ia
1. Yes
mild-mod < 6.5 mmol/l 
mild-mod < 5 mmol/l
severe >6.5  mmol/l 
severe > 5 mmol/l
Further AIDS defining illness
01. Oesoph/bronch candidiasis
03. Cryptoccocosis....................
05. C M V .......................................
07. Herpes virus infection.......
09. Isosporiasis..........................
11. Lym phom a...........................
13. T B ...........................................
15. P M L ........................................
17. Cerebral Toxoplasmosis ....
19. Recurrent Pneum onia.......
Variable: furoi# 0. No
02. Coccidiodomycosis ....
04. Cryptosporidiosis
06. Encephalopathy HIV ..
08. Histoplasmosis..........
10. Kaposi’s sarcom a......
12. M.avium  or M.kansasii
14. P C P ..............................
16. Recurrent Salmonella
18. Wasting Syndrome .... 
97. N A ...................................
1. Yes
Form completed by:____________________ Date:
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Severe Hyperlactataemia and Lactic Acidosis in 
patients taking anti-retroviral therapy
Patient-information sheet
You are being invited to take part in a research st udy. Before you 
decide it is important for you to understand why the research is 
being done and what it will involve. Please take t ime to read the 
following information carefully and discuss it with others if you 
wish. Ask us if there is anything that is not clea r or if you would 
like more information. Take time to decide whether or not you 
wish to take part.
Thank you for reading this.
•  What is the purpose of the study?
The build up of lactic acid in the blood causing the blood to be more acid 
(lactic acidosis) is an uncommon side effect of antiretroviral therapy (ART) but 
it can be fatal. However, a build up of lactic acid, which is not sufficient to 
make the blood more acid (severe hyperlactataemia) is believed to occur 
before patients develop lactic acidosis. If treatment is stopped early enough 
in patients who have hyperlactataemia, then usually they do not progress to 
severe lactic acidosis.
Because these two conditions are uncommon, information about the factors 
that might put patients at risk of them is lacking. The main aim of the study is 
to identify things that might increase the risk of developing both these 
conditions. W e are also interested in the things that also might make some 
patients develop a fatal illness.
One way of achieving these aims is to compare people who have had these 
complications (cases) with people who have not but have received 
antiretroviral ART in the same way (controls).
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Because the conditions are uncommon this study is going to be carried out in 
a large number of centres in the United Kingdom and also in other countries in 
Europe, the Americas and Australia.
• Why have I been chosen?
According to your regular doctor or the clinic database, you have either had 
an episode of lactic acidosis or considerably raised lactate level in the blood 
(hyperlactataemia) in the past. W e are interested in collecting information 
about you and your condition.
• What type of information are we interested in?
W e are planning to collect information about your HIV medical history, 
including the date of your first HIV positive test, how you acquired HIV, the 
type of treatment that you have been given, other illnesses that you might 
have suffered and other treatments for other medical conditions. W e would 
also like to know whether you have had other side effects from ART and any 
previous abnormal laboratory tests.
In addition, we would like to collect information about any HIV related 
symptoms that you have and laboratory tests and other investigations such as 
the CD4 count and level of virus and any medical care during the episode of 
the lactic acidosis or hyperlactaemia.
Finally, some general information such as your date of birth, gender, and 
country of origin or ethnic group would also be collected.
Many of these factors might be important in determining whether people 
develop lactic acidosis or hyperlactataemia.
•  What will happen to me if I take part?
The study will only use information extracted from your clinical records. No 
direct contact will occur between you and the researchers. This is what is 
called a retrospective case controlled study'. Again, we are planning to 
collect information from patients who have suffered from these complications 
(cases) and compare them with randomly selected patients who have never 
had these complications (controls).
There are no risks of taking part in this study.
• Will my taking part in this study be confidential?
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All information obtained from the clinical reports will be strictly 
confidential. The proforma or record on which the information is to be 
put will not have your nam e on it but it will be linked with your clinic or 
hospital identification number. The custodian of this confidential linking 
information will be a physician at your clinic. Researchers other than  
your regular doctor will not have access to this linking information.
No personal information leading to identification of any individual taking 
part in the study will be included in any scientific publication.
•  W hat will happen to the results of the research study?
Results will be published and fed back to every participant centre.
•  W ho is organising and funding the research?
The research team  includes members of the Royal Free and University 
College Medical School staff and also personnel from the Clinical Trials 
Unit of the Medical Research Council and from the London School of 
Hygiene and Tropical Medicine. The principal researcher is Dr. 
Alejandro Arenas-Pinto who is a PhD student and this case-control 
study will form part of his PhD.
•  W ho has reviewed the study?
The London Multi-Centre Research Ethics Comm ittee has approved this 
research.
•  Contact for further information:
Dr.  
Camden Primary Care Trust.
The Mortimer Market Centre.
Mortimer Market 
off Capper Street 
London W C1E6AU
Telephone number:  
E-mail: 
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